The potential of the PARP-1 inhibitor, AGO14699, in human cancers defective in homologous recombination DNA repair by Drew, Yvette Claire
i 
 
 
The potential of the PARP-1 inhibitor, AG014699, 
in human cancers defective in Homologous 
Recombination DNA repair 
 
Yvette Drew 
 
Thesis submitted in part requirement for the degree of Doctor of Philosophy 
Newcastle University 
 
 
 
 
 
 
 
 
 
 
 
Northern Institute for Cancer Research 
November 2011 
  
 
ii 
 
Declaration 
The work presented in this thesis was carried out at the Northern Institute for Cancer 
Research, Newcastle University and the Northern Centre for Cancer Treatment, 
Newcastle General Hospital between December 2006 and September 2010. These 
studies represent my own original work except where acknowledged by name or 
reference. 
No part of this work is being, or has been submitted for another degree or other 
qualification in this or any other university 
  
iii 
 
Abstract 
The aims of this study were to undertake the first comprehensive in vitro, in vivo and 
clinical investigation into the effects of the PARP-1 inhibitor, AG014699, in human 
cancers defective in homologous recombination (HR) DNA double strand break (DSB) 
repair. 
HR deficient cells were 9-fold more sensitive to AG014699 than HR proficient cells 
(mean LC50 = 3.26 µM vs. 29.68; P < 0.0001), confirming the theory of synthetic 
lethality. BRCA1 methylated UACC3199 breast cancer cells were also sensitive to 
AG014699 with mean LC50 significantly lower than the HR proficient cells (7.6 M vs. 
29.68; P = 0.002). AG014699 inhibited PARP activity by > 95% and induced DNA DSBs in 
all 11 cell lines studied. Evidence of HR (by Rad51 foci) was observed only in cells with 
functional BRCA1/2. 
A prolonged schedule of AG014699 (10 mg/kg daily for five days of a seven-day cycle 
for six cycles) more effectively delayed the growth of BRCA2 mutated xenografts than 
a ten day AG014699 schedule (tumour growth delay (TGD) = 27.5 vs. 12.5 days; P = 
0.02). AG014699 significantly delayed UACC3199 tumour growth compared to 
untreated controls (mean time to relative tumour volume 5 = 35.8 vs. 25.2 days; P = 
0.05); confirming in vitro findings that BRCA1 methylated cancer cells are sensitive to 
PARP inhibition.  
Clinical trial data from 38 patients demonstrated that AG014699 is non-toxic and 
efficacious with a clinical benefit rate of 34%. Higher baseline PARP-1 activity was 
associated with response to AG014699.   
The major findings of these studies are: the confirmation of the selective cytotoxicity 
of PARP inhibitors in BRCA mutated cancers; the results in UACC3199 cells which 
suggest that cancers with other HR defects could benefit from single agent PARP 
inhibitors, and finally the concept that length of exposure to (not just degree of) PARP 
inhibition is important for single agent anti-tumour activity. Furthermore, these data 
have formed the basis for a major amendment to the clinical trial; the result of which is 
eagerly awaited. 
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Chapter One 
 
1. Introduction 
1.1 Introducing the cancer, PARP and BRCA story 
More than one in three of us will develop cancer at some point in our lives and despite 
advances in treatment over the last twenty years, cancer remains the most common 
single cause of mortality in the UK (www.cancerresearch.org/cancerstats). The major 
shortcomings of existing anti-cancer agents are that their efficacy is limited by toxicity, 
specificity and the development of drug resistance. The search for new targeted, less 
toxic treatments and methods to improve the specificity and effect of existing 
therapies is a major focus of cancer research.  
Many current chemotherapy agents work by damaging a cell’s ability to repair or 
replicate its DNA. These include: alkylators, topoisomerase I and II inhibitors and DNA 
cross-linking agents (DeVita et al., 2008). Cancer cells, by definition, are characterised 
by genomic instability, recently described as an ‘enabling characteristic’ in the 
‘Hallmarks of Cancer’ update (Hanahan and Weinberg, 2011). That is to say they have 
developed ways to adapt pre-existing DNA damage signalling and repair pathways to 
enable them to survive DNA damage and evade cell death. One novel approach then, 
in the treatment of cancer, is to potentiate the DNA damaging effect of chemotherapy 
agents by also targeting the mechanisms by which this DNA damage is repaired. To put 
it simply: to combine a DNA damaging agent with a DNA repair inhibitor.  
One such novel target is the nuclear enzyme Poly(ADP-ribose)polymerase-1(PARP-1). 
PARP-1 is essential to the repair of single strand DNA breaks (SSBs) via the base 
excision repair/single strand break repair (BER/SSBR) pathway (Schreiber et al., 2006). 
Inhibiting PARP-1 has been shown to potentiate the cytotoxic effects of ionising 
radiation and DNA damaging chemotherapy agents such as the alkylators and 
topoisomerase inhibitors (Calabrese et al., 2004; Delaney et al., 2000).  The first PARP 
inhibitor to enter anti-cancer clinical trials was AG014699 (Pfizer, Global Research 
Development).  
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At this time there was no data to support single agent use; and so AG014699 was 
combined in a phase I study with the oral monofunctional alkylating agent 
temozolomide (Plummer et al., 2008).   
In 2005, two Nature papers reported that cells deficient in the Breast Cancer 
Susceptibility (BRCA) genes 1 and 2 were exquisitely sensitive to single agent PARP 
inhibition; being 100-1000 -fold more sensitive than BRCA heterozygote or wild type 
cell lines (Bryant et al., 2005; Farmer et al., 2005). This observation, made 
independently by two laboratories using different BRCA1/2 deficient models and 
different chemical classes of PARP inhibitors suggested that the sensitivity of these 
cells was due to PARP inhibition. Mutations in either BRCA1 or 2 result in defective 
DNA double strand break (DSB) repair by Homologous Recombination (HR) and are 
associated with a high lifetime risk of breast and ovarian cancer (Gudmundsdottir et 
al., 2006). It is hypothesized that PARP inhibitors can induce ‘synthetic lethality’ in cells 
with BRCA1/2 mutations, which are defective in HR DNA repair by inactivating the 
BER/SSBR pathway. ‘Synthetic Lethality’ is the process by which cancer cells are 
selectively targeted by the inactivation of two genes or pathways when inactivation of 
either gene or pathway alone is non-lethal (Kaelin, 2005). The term was first used in 
the 1940s by geneticists but the suggestion that ‘synthetic lethality’ could be a useful 
strategy in anti-cancer treatment did not arise until the late 1990s (Friend and Oliff, 
1998). 
 Clinical trials of single agent PARP inhibitors in BRCA mutation carriers with advanced 
ovarian or breast cancer began in 2005, with results of the olaparib phase I and II 
studies now reported (Fong et al., 2009; Audeh et al., 2010; Tutt et al., 2010). These 
‘proof of principle’ early phase studies demonstrated that the PARP inhibitor, olaparib, 
is active and well tolerated in selected BRCA mutation carrier populations. Results of 
other classes of single agent PARP inhibitor studies are awaited. 
There is now evidence that cells lacking other components of the HR repair pathway or 
where the BRCA genes have been silenced by epigenetic changes are sensitive to PARP 
inhibitors (Ashworth, 2008). Given that a substantial proportion of sporadic cancers 
may harbor such defects, a phenotype known as ‘BRCAness’ or HR deficiency (HRD), a 
wider therapeutic use for PARP inhibitors is emerging. Clinical trials in selected 
populations are already underway (www.clinicaltrials.gov).  
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Chapter one of this thesis sets out to provide the background information and 
scientific rationale for this body of work investigating the role of the potent, selective 
PARP-1 inhibitor, AG014699, in the treatment of cancers defective in HR DNA repair. 
1.2 DNA damage and repair mechanisms 
The accurate and efficient repair of DNA damage is essential for normal cellular 
function and the maintenance of genomic stability (Hoeijmakers, 2001). In humans 
acquired or inherited defects in DNA repair can result in an increased lifetime risk of 
cancer (Hoeijmakers, 2009). The integrity of DNA faces continual threat from a variety 
of agents. These can be classified into two groups. Firstly, endogenous sources which 
occur as the by-products of normal cellular metabolism. For example, reactive oxygen 
and nitrogen species, oestrogen and cholesterol metabolites and reactive carbonyl 
species are all generated by normal cellular activity and can damage DNA (De Bont et 
al., 2004). Spontaneous reactions within the DNA micro-environment such as 
hydrolysis can also result in damage to bases such as deaminations (Lindahl et al., 
1993).  Secondly, DNA can be damaged by exogenous physical and chemical stressors 
such as ultra-violet (UV) light, cigarette smoke and chemotherapy agents.  
 In humans over 130 genes have been identified that are associated with DNA repair 
and these genes can be sub-grouped, by function, into five distinct DNA repair 
pathways (Christmann et al., 2003). They are the excision repair mechanisms: Base 
excision repair (BER), Nucleotide excision repair (NER) which consists of two branches: 
global genome and transcription coupled NER; Mismatch repair (MMR) and finally the 
double strand DNA break repair mechanisms: Non-homologous end joining (NHEJ) and 
Homologous recombination (HR). Each pathway, shown in figure 1.1, has evolved to 
deal with a specific type of DNA damage, although there is some overlap in their 
functions (Hoeijmakers, 2001).  
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Figure 1.1: DNA damage and repair mechanisms in man (adapted from JHJ Hoeijmakers, 2001). 
MMC = mitomycin C, Cis-Pt = cisplatin, UV = ultra-violet light. 
 
1.2.1 Base excision repair/ Single strand break repair 
Base excision repair or single strand break repair, as it is otherwise known, is the main 
mechanism by which damaged bases and SSBs are repaired (Bernstein et al., 2002). 
The main function of the BER/SSBR pathway is to protect cells from endogenous DNA 
damage caused by hydrolysis, reactive oxygen species and other by-products of normal 
cellular metabolism that modify base structure. Such internal DNA damage occurs at 
high frequency with > 104 depurinations per cell per day (Lindahl et al., 1999). 
BER/SSBR also repairs damage induced by external agents such as cigarette smoke, 
alkylating chemotherapy agents and ionising radiation.  It consists of two sub-
pathways; short patch repair which replaces single nucleotides and long patch repair 
which replaces 2-15 nucleotides. The key steps are summarised in the following 
section and illustrated in figure 1.2 
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1.2.1.1 Recognition, base removal and incision (steps I-II) 
BER/SSBR can be initiated by the recognition of the damaged base by one of at least 11 
known DNA glycosylases. The glycosylases are divided into type I and II, distinguished 
by function. Glycosylase I enzymes remove modified bases out of the helix creating an 
apurinic/apyrimidinic (AP) site. This occurs by the action of the Apel AP endonuclease - 
Ref -1 which makes a 5’ nick in the DNA backbone leaving a 5’deoxyribose-5-
phosphate (5’dRP) and 3’OH. The type II glycosylases also remove bases but in addition 
cleave the AP site via endogenous 3’ endonuclease activity resulting in a SSB.  
1.2.1.2 The role of PARP in BER (step III onwards) 
The nuclear enzyme PARP-1 detects DNA strand breaks via its two zinc fingers. PARP-1 
binds with high affinity to and is in turn activated by the DNA SSB. Once PARP-1 is 
activated it catalyses the successive transfer of ADP-ribose units from the substrate 
nicotinamide adenine dinucleotide (NAD+) to a variety of acceptor nuclear proteins 
including itself as shown in figure 1.3 . This produces linear and/or branched polymers 
of poly ADP-ribose (PAR). The reaction requires the catalysis of the glycosylic bond 
between the C-1’ atom of ribose and the nicotinamide of the NAD+ and the formation 
of a new glycosylic bond with the nucleophilic acceptor. Residues of glutamic acid, 
aspartic acid and lysine act as receptors for poly(ADP-ribosyl)ation on the target 
proteins (Schreiber et al., 2006). This ‘poly(ADP-ribosyl)ation’ creates a negatively 
charged target at the SSB which attracts the other DNA damage repair enzymes to the 
site forming the BER multi-protein complex. This complex is made up of PARP-1, the 
scaffold protein XRCC1 (x-ray repair cross-complementing 1), DNA ligase III and the 
DNA polymerase pol β. Following ADP-ribosylation PARP-1 has reduced affinity for 
DNA and is released, opening up the chromatin and allowing access to the damaged 
site to the other repair complex proteins. This process involving PARP-1 is required for 
both short and long patch repair. The PAR polymers are subsequently degraded by the 
poly(ADP-ribose)glycohydrolase (PARG). The structure of PARP-1 and its other DNA 
repair functions are discussed later in this chapter in section 1.4. 
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Figure 1.2: The BER/SSBR pathway (adapted from JHJ Hoeijmakers, 2001) showing the role of 
PARP-1 in both short and long patch repair. XRCC1 (X-ray repair cross-complementing 1), PARP 
(poly(ADP-ribose) polymerase), APE-1 (Apel endonuclease- Ref -1), PCNA (Proliferating cell 
nuclear antigen), FEN1 (Flap endonuclease 1). Further figure explanations are provided in the 
main text under the corresponding Roman numerals. 
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1.2.1.3 Short patch repair (steps IV-VI) 
In mammals short patch BER/SSBR is the dominant pathway. As shown in figure 1.2, 
the DNA pol β replaces the missing nucleotide using the complimentary strand as a 
template and removes the 5’-terminal baseless sugar residue via its lyase activity. The 
XRCC1-DNA ligase 3 complex then seals the nick with XRCC1 acting as a scaffold 
protein.  
1.2.1.4 Long patch repair (steps VII-IX) 
In long patch repair the process is more complex with the synthesis of more than one 
nucleotide required for repair. This synthesis  is achieved by DNA pol β, pol δ/ε and the 
proliferating cell nuclear antigen (PCNA). Flap endonuclease 1 (FEN1) acts to remove 
the DNA flap and DNA ligase 1 is responsible for sealing.  
 
 
Figure 1.3: The role of PARP-1 in SSB repair pathway (Drew and Calvert, 2007).             
Following DNA damage PARP-1 is activated and binds to the exposed single strand break (SSB). 
Once bound it catalyses the successive transfer of ADP-ribose units from the substrate 
nicotinamide adenine dinucleotide (NAD+) to a variety of acceptor nuclear proteins. This 
creates multiple linear or branched polymers of poly(ADP-ribose). This ‘poly(ADP-ribosyl)ation’ 
creates a negative charge at the SSB which recruits the other enzymes required for successful 
long or short patch SSB repair: XRCC1 (X-ray repair cross-complementing 1), DNA ligase III and 
the DNA polymerase pol B (shown).  
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1.2.1.5 Human disorders of BER/SSBR 
There are no known human disorders associated with inherited BER/SSBR deficiencies. 
In fact, inactivation of BER/SSBR core proteins in mouse models results in embryonic 
lethality (Schreiber et al., 2002) emphasising the importance of this pathway in 
genomic maintenance and cell survival.  
However, polymorphisms in the BER/SSBR genes do exist and are linked with increased 
cancer risk and response to chemotherapy. For example, polymorphisms in the PARP-1 
encoding gene - ADPRT (adenosine diphosphate ribosyl transferase) and the XRCC1 
gene are linked with an increased risk of lung adenocarcinoma in smokers (Zhang et 
al., 2005). In addition; XRCC1 polymorphisms have been shown to predict the response 
to oxaliplatin- based chemotherapy in patients with advanced colon cancer 
(Stoehlmacher et al., 2001). 
1.2.2 Double strand DNA break (DSB) response 
DSBs are regarded as the most lethal of the DNA lesions and if left un-repaired can 
result in genomic instability, carcinogenesis and ultimately cell death (Hoeijmakers et 
al., 2001). They occur as a result of direct damage to both strands of DNA from 
exogenous agents like ionising radiation or chemotherapy (e.g. the topoisomerase 
inhibitors) (Helleday et al., 2008) or as part of normal physiology e.g. to permit genetic 
recombination during meiosis (Neale et al., 2006) and the rearrangements needed for 
the development of immunoglobulin genes during V(D)J (variable, diversity and 
joining) recombination (Leavy., 2010). It is now known that a significant number of 
DSBs arise during DNA replication when a replication fork encounters an un-repaired 
SSB; and that the HR pathway and PARP-1 have a vital role in repairing such collapsed 
replication forks (Bryant et al., 2009; Helleday et al., 2007). 
The two major proteins involved in DSB detection are the ataxia-telangiectasia 
mutated (ATM) and ATM Rad53 related (ATR) proteins, both members of the 
phosphadtidylinositol 3-kinase-like family (Bakkenist et al., 2004). ATM and ATR sense 
the DSB and trigger the activation of multiple genes involved in either HR or NHEJ 
repair, cell cycle arrest, and in some circumstances apoptosis. Substrates for ATM 
phosphorylation include: BRCA1, p53, the check-point kinases CHK1 and CHK2, 
Fancona anaemia protein FANCD2, the histone H2AX and the Mre-11-Rad50-NBS1 
(Nijmegen breakage syndrome) (MRN) complex. ATR is known to phosphorylate CHK1, 
  Chapter One - Introduction 
9 
 
BRCA1 and the DNA helicase BLM1 (Lord et al., 2006).  It was originally thought that 
ATM and ATR acted independently in their response to DNA damage. With ATM 
activated in response to DSB arising from ionising radiation (IR), and ATR 
phosphorylating its substrates following DNA damage induced by stalled replication 
forks or insults such as UV light and DNA damaging chemotherapy agents. However, 
recent evidence suggests that ATM and ATR work together; with reports of both ATM 
and ATR required for ionising radiation-induced CHK1 phosphorylation and ATM 
regulating the activity of ATR in response to DSBs (Jazayeri et al., 2006). 
The role of both ATM and ATR in halting cell cycle progression prior to DSB repair is 
essential to avoid the passage of deleterious genetic mutations through to daughter 
cells at mitosis. This cell cycle arrest is facilitated by the activation of CHK1 and CHK2, 
which results in cell cycle arrest at the G2/M and S phase check-points. If the DNA 
damage is considered too severe for effective repair then apoptotic cell death can 
ensue. This apoptosis is triggered by CHK2 via the phosphorylation of E2F1, PML and 
p53 (Zhou et al., 2004).  
The two primary DSB repair mechanisms in humans are NHEJ and HR. These two 
pathways operate independently but do share some common proteins. Which 
pathway is used to repair the DNA damage depends principally on the origin of the 
DSB and the stage in the cell cycle in which the DSB occurs (Takata et al., 1998). HR is 
an error-free pathway which is dependent on the proximity of the sister chromatid and 
so only takes place in late S and the G2 phases of the cell cycle (O’Driscoll et al., 2006). 
NHEJ, as the name suggests, simply joins together two ends of broken DNA and 
therefore does not require the synthesis of a complementary template and so can 
occur at any stage in the cell cycle. However, its main action occurs prior to replication 
in G0 and G1 (Chu et al., 1997). 
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 1.2.3 DNA DSB repair: Non-homologous end joining 
Non-homologous end joining is the main mechanism in mammalian cells by which 
DSBs are repaired (Chu et al., 1997). It is an error-prone pathway and may result in the 
deletion or insertion of base pairs. The core protein components of NHEJ (shown in 
figure 1.4) are DNA-PK (DNA - protein kinase), DNA ligase IV, X-ray cross 
complementation group 4 (XRCC4) and the nuclease Artemis (Collis et al., 2005). DNA-
PK, the main NHEJ player, is a nuclear serine/threonine protein kinase that consists of 
a catalytic subunit (cs) (DNA-PKcs) and a DNA binding/regulatory subunit (Ku). 
Following a DSB, NHEJ is thought to be initiated by the heterodimer of Ku (Ku70 + 
Ku80) which binds to both DNA ends (Bernstein et al., 2002). The Ku heterodimer then 
recruits DNA-PKcs, which is in turn activated. The complex of Ku + DNA-PKcs now 
becomes the active protein kinase – DNA-PK. This brings together the ends of the DSB 
for processing prior to re-ligation. This processing is thought to be carried out by a 
number of proteins. For example, the MRN complex has exo/endonuclease and 
helicase activity to remove the excess DNA at the 3’ flaps. Whilst FEN1 is recruited to 
remove the 5’ overhangs, the protein Artemis is recruited and, acting in a complex 
with DNA-PK, primes the site of damage via its endo/exonuclease activity, resecting 
DNA at both the 3’ and 5’ flaps.  New DNA ends are synthesised by a DNA polymerase 
thought to be pol µ and finally, ligation is achieved by the actions of XRCC4 and DNA 
ligase 4 (Christmann et al., 2003) 
DNA-PK has been a target for anti-cancer drug developers for some years. NU7441, a 
2-N morholino-8-dibenzothiophenyl-chromen 4, is a potent and selective DNA-PK 
inhibitor developed at Newcastle University in collaboration with KuDOS 
pharmaceuticals (now owned by Astrazeneca) (Zhao et al., 2006). Inhibition of DNA-PK 
by NU7441 has been shown to enhance the cytotoxicity of ionising radiation and 
doxorubicin in DNA-PK proficient but not deficient hamster and human cancer cell 
lines (Tavecchio et al., 2011). Interestingly, Tavecchio et al demonstrated that 
inhibiting DNA-PK with NU7441 resulted in reduced HR activity, as represented by 
reduced Rad51 foci formation, suggestive of DNA-PK activity within the HR repair 
process. NU7441 is still in pre-clinical drug development but it is envisaged that DNA-
PK inhibitors will enter early phase clinical trials in the next few years.  
  Chapter One - Introduction 
11 
 
1.2.4 DNA DSB repair: Homologous recombination 
Homologous recombination plays a major role in repairing DSBs that arise as a result of 
replication fork stalling following un-repaired SSBs (Helleday et al., 2007). HR can be 
subdivided into two pathways; Gene Conversion (GC), illustrated in figure 1.4, and 
Single Strand Annealing (SSA). GC is the predominant pathway but they share common 
beginnings. It was always proposed that HR is initiated by the MRN complex (Falck et 
al., 2005) which recruits ATM to the site of DNA damage but the precise mechanism 
behind this was unknown. However, it was recently discovered that the MRN complex, 
in processing the DSB end, creates multiple short single strand (ss) DNA 
oligonucleotides which in turn stimulate ATM (Jazayeri et al., 2008). Once activated, 
ATM phosphorylates a number of proteins including: BRCA1, the histone H2AX, CHK1 
and 2 and the MRN complex itself. Following this phosphorylation, the MRN complex 
resects, via its exo/endonuclease activity, the sequence of DNA damage exposing 
single strand overhangs of DNA at the 3’ ends on either side of the DSB. This process is 
thought to also involve BRCA1 (Zhong et al., 1999). Next, Rad51, one of the major 
players in HR, facilitates the assembly of a helical nucleoprotein filament known as the 
pre-synaptic filament (shown in figure 1.4 II). This is thought to also involve the Rad51 
related proteins (XRCC2, XRCC3, Rad51B, C and D). Paradoxically, this process is made 
more difficult by another component of HR, the replication protein A (RPA). RPA, an 
abundant ssDNA-binding protein, competes to bind to the sites of exposed ssDNA 
(Sung et al., 2006). Biochemical and chromatin immunoprecipitation experiments have 
shown that the Rad52 protein and the heterodimeric Rad55-Rad57 complex help to 
overcome the inhibitory effects of RPA on the filament formation (Sung et al., 1997).  
In addition recent data has shown that BRCA2 facilitates Rad51 in displacing RPA from 
the exposed ssDNA (Jensen et al., 2010). Rad51 localises to the site of DSB with the 
help of BRCA2 which binds directly to Rad51 via its eight conserved BRC repeat zones 
transporting it into the nucleus. It is proposed that this BRCA2-Rad51 complex binds to 
the exposed single stranded DNA and this binding then enables the loading of Rad51 
onto the break and the formation of the pre-synaptic filament (Yang et al., 2002).  
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Figure 1.4: DNA DSB repair pathways (adapted from JHJ Hoeijmakers, 2001). Homologous 
recombination (Gene Conversion): (I) Following DSB DNA excised by the MRN complex and 
Rad51 localises to DSB via BRCA2. (II) Rad51 and related proteins assemble the pre -synaptic 
filament. (III) Rad51 and Rad54 identify homologous sequence of DNA and facilitate invasion 
into break site and new sequence of DNA is synthesised. (IV) Exchanged ends, (Holliday 
junctions), are rejoined by resolvases. Non-Homologous end joining (NHEJ): (V) Heterodimer of 
Ku (Ku70 + Ku80) binds to exposed DNA initiating NHEJ. (VI) The active protein kinase – DNA-
PK (Ku + DNA-PKcs) brings the ends of DSB for processing prior to re-ligation. (VII) MRN 
complex, FEN1 and Artemis remove excess DNA ends. New DNA synthesised by a DNA 
polymerase and ligation occurs via XRCC4 and DNA ligase 4. DSB = double strand break, MRN = 
Mre-11-Rad50-NBS, XRCC2/3/4 = X-ray cross complementation group 2/3/4, V(D)J = Variable, 
diversity and joining, BRCA1/2 = breast cancer susceptibility 1/2. 
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Rad51 with the help of Rad54 identifies a homologous sequence of intact DNA and 
facilitates its invasion into the site of break. This then acts as a template for a new 
identical sequence of DNA to be synthesised. Finally the exchanged ends, known as 
Holliday junctions, are rejoined by resolvases (Constantinou et al., 2001). Recent work 
has also suggested that BRCA2 also has a role in regulating the DNA-binding activity of 
Rad51 holding it in an inactive state when it is not needed (Davies et al., 2001; Esashi 
et al., 2007). 
If the DSB occurs within matching sequences of DNA it can be repaired by the process 
of SSA. A much less complex pathway; it involves the matching of homologous 
sequences on either side of the DSB followed by the deletion of the intermediate non-
complementary sequence. The process is facilitated by RPA and Rad52 and is 
dependent on functioning BRCA1. However, it does not require the full repertoire of 
HR genes in particular it is Rad51- independent. SSA is likely to generate errors and 
considered only an alternative pathway in the absence of functioning Rad51 mediated 
HR (Helleday et al., 2007). 
It is clear that the BRCA1 and BRCA2 proteins play major roles in the HR repair process. 
Therefore it would be logical to hypothesise that deficiencies within either BRCA1 or 2 
genes could result in defective HR. There are a number of human syndromes 
associated with mutations within genes involved in the HR process. These are shown in 
table 1.1.  The most common and best described is the Hereditary Breast Ovarian 
Cancer syndrome (HBOCS). This occurs mainly as a result of inheriting a mutation 
within either the BRCA1 or 2 genes and is associated with a high risk of developing 
breast and ovarian cancer.  
Mutations within other genes have been identified which are associated with an 
increased lifetime risk of breast and/or ovarian cancer. These include CHEK2 (CHEK2 
Breast Cancer Case –Control Consortium., 2004), PTEN (Lynch et al., 1997) and most 
recently Rad51D (Loveday et al., 2011).  
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Human syndrome 
 
Gene 
 
  
Chromosome  
  
Cancer  risk 
 
Reference 
 
HBOC 
 
BRCA1 
BRCA2/FANCD1 
  
17q21 
13q12 
 
Breast  
Ovary 
Prostate 
Fallopian Tube 
Primary peritoneal 
Pancreas 
 
 
King et al., 2003 
 
Fanconi anaemia 
 
 
Other FANC 
genes 
(A,C,D2,E,F,G,) 
 
 
 
  
16q24.3 
9q22.3 
3p25.3 
6p21-22 
9p13 
 
 
Acute myeloid leukaemia 
Head and neck cancers 
Squamous cell carcinoma 
 
Kennedy et al., 2006 
Nijmegen breakage syndrome NBS1  8q21 Lymphomas Demuth et al., 2007 
Bloom syndrome BLM   15q26 Leukaemia’s 
NHL 
Breast 
 
Hickson, 2003 
Rothmund-Thomson syndrome RECQL4   8q24.3 Osteosarcoma 
 
Hickson, 2003  
 
Table 1.1: Human syndromes with mutations within genes associated with Homologous recombination and increased risk of cancer. BRCA = bre ast cancer 
susceptibility, HBOC = hereditary breast and ovarian cancer syndrome, FANC = Fanconi, NBS1 = Nijmegen breakage syndrome, BLM = Bloom, NHL= non-hodgkins 
lymphoma.
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1.3 The BRCA1 and 2 tumour suppressor genes 
The BRCA1 gene was first identified in 1990 by Mary King’s group working at Berkeley, 
California, USA. The name BRCA was originally chosen to stand for Berkeley California 
but was later changed to represent Breast cancer susceptibility (Hall et al., 1990). The 
gene was subsequently cloned in 1994 by Myriad Genetics (Miki et al., 1994). Around 
the same time in 1994, the BRCA2 gene was discovered by Stratton and Wooster 
working at the Institute of Cancer Research, London, UK (Wooster et al., 1994). The 
identification of these genes was a significant breakthrough in the management of 
breast and ovarian cancer families. It enabled the introduction of risk assessment, 
genetic counselling and BRCA mutational analysis.  
The BRCA1 gene, located on chromosome 17q21, encodes a large, predominantly 
nuclear protein (1863 amino-acid) with an estimated molecular weight of 220kDa 
(Venkitaraman et al., 2002). It consists of multiple functional domains including an N-
terminal RING, 2 nuclear localisation signals (NLSs) and 2 C-terminal BRCA1 carboxyl 
terminal (BRCT) domains of ~ 110 residues.  The BRCA2 gene, located on chromosome 
13q12.3, and later identified to also be the Fanconi Anaemia gene FANCD1, encodes a 
larger 3418 amino acid protein with an estimated molecular weight of 384kDa 
(Venkitaraman, 2002). An important feature of the BRCA2 protein is the eight copies of 
the 30-80 amino acid repeats – BRC, known to be the main binding sites for Rad51 
(Bertwistle et al., 1998).   
The structures of both proteins are shown in figure 1.5. Although the BRCA1 and 
BRCA2 proteins have different functions involving multiple cellular pathways, both 
share important regulatory roles in co-ordinating the response and repair of DNA 
damage. Consequently loss of these functions can result in genomic instability and 
increased risk of carcinogenesis, as observed in carriers of germline BRCA mutations 
carriers (Venkitaraman, 2009). To understand why inheriting defective BRCA1 and 2 
genes can confer such a devastating risk of cancer on an individual it is important to 
review in detail the roles of these proteins play in normal cellular life in particular in 
DNA repair. 
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Figure 1.5: Schematic representation of the BRCA1 and BRCA2 proteins. NLS = nuclear 
localisation signal, BRCT = BRCA1 carboxyl terminal. 
 
1.3.1 Functions of BRCA1 
BRCA1 is predominantly a nuclear protein but it is able to shuttle freely between the 
cytoplasm and nucleus in order to carry out its variety of cellular functions which 
include: DNA damage signalling response and repair, transcriptional regulation and cell 
cycle check-point control. 
1.3.1.1 BRCA1 and DNA damage response and repair 
One of the earliest observations to suggest a role in DNA repair for BRCA1 was its co-
localisation with Rad51 in the nuclear foci of mitotic and meiotic cells (Scully et al., 
1997). Since then studies have shown that not only does BRCA1 play a vital role in the 
repair of DNA DSBs but also in the initial detection of the DNA damage. The BRCA1 
protein acts as part of a large complex known as the BRCA1- associated genome 
surveillance complex (BASC). BASC is thought to act as a sensor for DNA damage and 
includes: the MRN complex, mismatch repair proteins (MSH2, MSH6 and MLH1), BLM 
syndrome helicase and ATM (Gudmundsdottir et al., 2006). Once DNA DSB damage has 
been sensed the BRCA1 protein plays a vital role in its repair via HR, as discussed in 
section 1.2.4. However, there is evidence that BRCA1 plays a role in the other 
mechanisms of DNA repair in particular NER and NHEJ. BRCA1 has been shown to 
  Chapter One - Introduction 
17 
 
regulate the global genomic repair (GCR) sub-pathway of NER. The proposed 
mechanism is via direct transcriptional control of the NER genes : XPC, DDB2 and 
GADD45 (Hartman et al., 2002). There is also a growing body of evidence suggesting 
that BRCA1 may regulate a component of NHEJ. NHEJ is an error-prone pathway but 
more recently the existence of an additional potentially more mutagenic sub-pathway 
has been proposed (Durant et al., 2005). This sub-pathway is thought to operate 
independently of DNA-PK and is strongly dependent on Mre11 and Rad50. It rejoins 
chromosomal DNA ends with imperfect micro-homology creating non-random 
deletions of up to 300 base pairs. This process, which could be highly mutagenic, has 
been named micro-homology-mediated end joining (MMEJ). Studies have shown that 
BRCA1 can suppress MMEJ by inhibiting Mre11 activity (Zhuang et al., 2006). This 
proposal is supported by the observation that BRCA1 deficient cells demonstrate an 
increased tendency to generate large deletions during NHEJ repair.  
1.3.1.2 BRCA1 and cell cycle control 
The ability to control the timing and sequence of cell cycle events following DNA 
damage is essential for maintaining genomic stability. This function is governed by a 
family of cyclin-dependent kinases and their endogenous inhibitors acting at cell cycle 
check-points. BRCA1 is rapidly phosphorylated after DNA damage and plays a key role 
in this cell cycle regulation. Firstly, BRCA1 has been shown, via a number of p53 
dependent and independent pathways, to stimulate the transcription of the 
p21WAF1/CIP1 promoter of the p21 gene leading to G1/S cycle arrest (Chai et al., 1999). 
This activation of p21WAF1/CIP1 transcription is dependent on the phosphorylation status 
of BRCA1. Secondly, BRCA1 is thought to be involved in intra-S phase checkpoint 
activation. Following damage by IR, activation of the intra-S phase checkpoint requires 
the phosphorylation of BRCA1 by ATR (Tibbetts et al., 2000). BRCA1 has also been 
shown to up-regulate the expression of the cyclin-dependent kinase inhibitor p27KIP1, 
which results in intra-S phase arrest (Williamson et al., 2002). 
The CHK1 and CHK2 kinases acting downstream of ATM and ATR are responsible for 
maintaining the G2-M check-point. In response to IR BRCA1 is phosphorylated by CHK2 
and subsequently BRCA1 deficient cell lines have been reported to be unable to 
activate G2/M arrest in response to IR (Aprelikova et al., 2001).  Finally, BRCA1 is 
known to be a transcriptional regulator of several genes involved in the regulation of 
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the G2/M check-point. The strongest evidence for this comes from its regulation of 
GADD45, which activates the checkpoint by inhibiting the activity of cyclin B-cdc2 
complex (Mullan et al., 2001). 
1.3.1.3 BRCA1 and transcriptional regulation 
BRCA1 can regulate transcription by its direct interaction with the core component of 
transcription; RNA polymerase II and its co-activation or co-repression of a number of 
known transcription factors (Irminger-Finger et al., 1999). Two such transcription 
factors are the oestrogen receptor-alpha (ERα) and the tumour suppressor protein 
p53.  
Given the fact that carriers of BRCA1 mutations have a high lifetime risk of developing 
breast and ovarian cancer, both oestrogen responsive tissues, the relationship of 
BRCA1 to ERα is the focus of much research (Gorski et al., 2009). Studies have shown 
that BRCA1 is able to induce ERα mRNA expression and negatively regulate ERα 
signalling pathways (Fan et al., 1999). BRCA1 has also been reported to inhibit the 
induction of over 90% of the known oestrogen-inducible genes (Xu et al., 2005). One 
such gene is vascular endothelial growth factor (VEGF), which is important for the 
angiogenesis required to sustain cancer cells. Confirming this is the observation that 
VEGF is severely impaired in the presence of exogenous, wild type BRCA1 and not 
mutated BRCA1 (Kawai et al., 2002).  
In response to cellular stress p53, known as the ‘guardian of the genome’, is activated 
to induce target genes involved in DNA repair, cell-cycle arrest and apoptosis. BRCA1 
has been shown to interact with the C-terminus of p53. This interaction results in a re-
direction from the activation of pro-apoptotic target genes to those involved in cell-
cycle arrest and DNA repair (Chai et al., 1999). Interestingly, mutations in p53 are 
common in BRCA-mutated cancers and that this loss of p53 function may be important 
to mediate tumourigenesis (Parant et al., 2003).  
1.3.2 Functions of BRCA2 
The main function of BRCA2 is its role in HR mediated DNA DSB repair through its 
direct interaction with Rad51 (discussed earlier in this chapter in section 1.2.4). Loss of 
BRCA2 can result in the repair of DSBs via error-prone pathways and subsequent 
genomic instability (Tutt et al., 2001). Furthermore, cells deficient in BRCA2 have 
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impaired formation of Rad51 foci following exposure to DNA damage (Yuan et al., 
1999; Drew et al., 2011b). 
In addition to its role in DNA DSB repair, BRCA2 may have a role as a regulator of cell 
cycle progression at the mitotic check-point. BRCA2 associates with the DNA binding 
protein BRAF35 and both proteins co-localise on mitotic chromosomes. Injections of 
antibodies which block either BRCA2 or BRAF35 into cells were shown to block 
progression through mitosis (Marmorstein et al., 2001).  
In summary the BRCA1 and 2 proteins are essential to the mechanism of HR DSB repair 
and major players in the maintenance of genomic stability. It is therefore not 
surprising that carriers of mutations within the BRCA genes have a high lifetime risk of 
developing cancer. 
1.3.3 BRCA1/2 mutations and the risk of cancer 
Inheriting a mutation in either of the BRCA1 or 2 genes confers a high lifetime risk of 
developing breast and/or ovarian cancer. The lifetime risk of breast cancer in female 
BRCA1 mutation carriers has been reported to be as high as 84% and between 60-80% 
in BRCA2 mutation carriers (King et al., 2003). In men, breast cancer is rare, accounting 
for < 1% of all cases, but in BRCA mutation carriers the lifetime risk is estimated to be 
between 58 and 100 times that of the general male population (Brose et al., 2002; 
Liede et al., 2004). The life-time risk of developing ovarian cancer is lower and 
estimated at 40-50% and 10-20% for BRCA1 and BRCA2 mutation carriers respectively 
(Ford et al., 1994).  
The frequency of carrying a germline BRCA1 or 2 mutation in the general population is 
thought to be between 0.1 – 0.8% (Risch et al., 2006). However in patients with breast 
and/or ovarian cancer it is estimated that between 10-15% will be associated with 
carrying a BRCA1 or 2 germ-line mutation (Stratton et al., 1997; Venkitaraman et al., 
2002).  
Carriers of the mutations are not limited to a particular population but specific groups 
with high prevalence have been identified, such as women of Ashkenazi Jewish 
descent (Stuewing et al., 1997). The autosomal dominant mode of genetic 
transmission means that both the male and female children of a carrier have a 50% 
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chance of inheriting the mutation in their germline. One defective allele is sufficient to 
predispose to cancer, but the somatic loss of function of the second allele is required 
in cancer cells confirming the classic Knudson two hit hypothesis for tumour 
suppressor genes (Knudson, 1971).  
Breast and ovarian cancer are the most commonly observed but an increased risk of 
other cancers including: prostate, pancreatic, fallopian tube and primary peritoneal 
carcinoma has been documented (Brose et al., 2002, The Breast Cancer Linkage 
Consortium (BCLC)., 1999). Primary peritoneal carcinoma (PPC) can arise from an 
occult ovarian cancer focus or de novo in the peritoneal mesothelium. In one study 
follow-up of women who had undergone prophylactic bilateral oophrectomies 
reported a frequency of PPC of 2-4%; occurring more often in BRCA1 than BRCA2 
carriers (Casey et al., 2005). Primary fallopian tube carcinoma is unusual in the general 
population but life-time risk in BRCA1/2 carriers is reported to be more common at 3% 
(Brose et al., 2002). In male BRCA 1 mutation carriers, the prostate is the commonest 
cancer site. In a study by the BCLC an elevated risk of prostate cancer was observed in 
carriers < 65 years old but not in those > 65yrs (Thompson et al., 2002). This is 
probable explained by the fact that prostate cancer risk increases with age in all men. 
Pancreatic cancer is more common in BRCA2 carriers. They have a younger than 
average age of disease onset and the estimated lifetime risk is thought to be as high as 
5% (BCLC, 1999). Pancreatic cancer risk in BRCA1 carriers is less well established.  
The risk of childhood cancer is not increased in BRCA mutation carriers except in the 
uncommon situation where an individual inherits mutated BRCA2 genes from both 
parents resulting in Fanconi anaemia (Kennedy et al., 2006).  
1.3.4 Tissue specificity of BRCA-related cancers 
Why BRCA1/2 gene mutation carriers are so highly predisposed to cancers of the 
breast and ovary is not fully understood. However several theories exist attempting to 
part-explain this phenomenon. Firstly, these cancers arise in oestrogen-dependent 
epithelial tissues. BRCA1 is known to regulate transcription (see section 1.3.3) and 
inhibit oestrogen receptor signalling; loss of this function could result in un-controlled 
cell proliferation in these tissues and ultimately cancer (Fan et al., 1999). Another 
proposal is that BRCA function somehow protects cells from the local effects of 
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mutagenic oestrogen metabolites thus preventing genomic instability. For example, in 
vivo studies in Brca1 and Brca2 heterozygous mice report alterations in the mammary 
gland and ovarian tissue architecture following exposure to the highly oestrogenic 
compound diethylstilbestrol (Bennett et al., 2000).  
It is often hypothesised that breast and ovarian tissues are highly proliferative and that 
it is this cell-turnover that increases the chances of mutation and subsequent 
tumourigenesis. This theory however is questionable as cancers of the highly 
proliferative gastrointestinal tract and lymphoid tissue are not commonly seen in BRCA 
mutation carriers.   
Elledge and Amon propose an alternative reason for this tissue specificity which they 
coined the ‘suppressor hypothesis’. This suppressor hypothesis suggests that BRCA-
mutated cancers do not arise in other tissues because they cannot tolerate the loss of 
BRCA heterozygosity required for cancer development and that breast and ovarian 
tissues can. They suggest a variety of reasons for this including a protective anti -
apoptotic effect of oestrogen (Elledge and Amon, 2002). 
Another proposal is that there must be something specific about breast and ovarian 
tissues that makes them more dependent on the function of BRCA1 and 2 than other 
tissues or that loss of another essential gene product co-exists within these tissues 
resulting in the high risk of cancer. One such gene is the tumour suppressor gene p53. 
Studies have shown that the additional loss of p53 in mice already deficient in Brca1 
accelerates the formation of tumours (Xu et al., 1999). p53 is mutated in almost 100% 
of all high grade serous ovarian cancers (Ahmed et al., 2010) and it may be that in the 
presence of a germ-line BRCA mutation this may be enough to promote cancer. 
In summary it is likely that the tissue specificity of BRCA mutated cancers is due to 
multiple genetic and environmental factors. 
1.3.5 Management options for BRCA1/2 mutation carriers 
Over the past ten years the main focus for those identified as BRCA mutation carriers 
has been cancer prevention through prophylactic surgery and early cancer detection 
through screening.  
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1.3.5.1 Prophylactic surgery 
Prophylactic bilateral salpingo-oophorectomy (BSO) reduces the risk of ovarian cancer 
by up to 95% and in pre-menopausal women the risk of breast cancer by around 50%. 
Prophylactic bilateral mastectomy (BM) reduces the risk of breast cancer by 90% 
(Domchek et al., 2006b). National guidelines in the UK recommend that women 
undergo prophylactic BSO by age 40-45 and support various strategies for reducing 
breast cancer risk including BM (National Comprehensive Cancer Network, 
www.nccn.org). BRCA mutation carriers face difficult decisions in terms of whether and 
when to opt for prophylactic surgery and the support of a multi-disciplinary team 
including clinical psychologists should be offered to all patients. As surgery does not 
totally eliminate cancer risk these patients also require long-term follow-up including 
the management of BSO- induced premature menopause.  
1.3.5.2 Screening 
The purpose of any cancer screening programme is to detect cancer early enough to 
enable interventions that will have an impact on patients survival. Any such 
programme also has to be acceptable in terms of financial and patient costs. The 
National Breast Screening Programme (NBSP) invites women in the UK to attend for a 
mammogram every three years between the ages of 47 and 73 
(www.cancerscreening.nhs.uk). The NBSP is considered to be worthwhile with a recent 
report that between 5.7 and 8.8 breast cancer deaths are prevented for every 1000 
women screened and between 2 and 2.5 lives saved per every over-diagnosed patient, 
that is someone treated for a cancer that might never have revealed itself in their life-
time (Duffy et al., 2010). However, the questions for BRCA mutation carriers are; how 
early to start screening and with what modality? Women with BRCA mutations 
develop cancer at an earlier age than the national screening programme would pick up 
and at a time when X-ray mammography is less sensitive due to denser breast tissue. 
Following the results of a large multi-centre cohort study (the MARIBS trial) which 
demonstrated the superiority of it magnetic resonance imaging (MRI) over 
mammography in detecting breast cancer in 649 women aged between 35 and 49; it is 
now recommended that screening should start at age 30 and consist of a combination 
of annual MRI and mammogram (Leach et al., 2005).  
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There is no evidence that screening for ovarian cancer using trans -vaginal ultrasound 
(TVU) scanning and blood monitoring of the tumour marker CA125 (cancer antigen 
125) saves lives and as a result there is no UK national screening programme for 
ovarian cancer. However, within the UK, women are currently being offered screening 
as part of a national trial known as the UK Familial Ovarian Cancer Screening Study 
(UKFOCSS). UKFOCSS offers women annual TVS and four monthly CA125 
measurements. The study is now closed to recruitment and results are expected in 
2013. If this shows a benefit then surveillance may be offered on a national level. But 
until then the main option to prevent ovarian and fallopian tube cancer for BRCA 
mutation carriers remains surgery. 
1.3.5.3 Chemoprevention 
The use of the oral contraceptive pill (OCP) as chemoprevention, to reduce the risk of 
ovarian cancer and delay the need for BSO in younger women wishing to have families 
has been explored in this population. In 1998 one study involving 207 BRCA1/2 
mutation carriers with ovarian cancer and 161 of their sisters, acting as case-controls, 
reported a 60% reduction in the risk of ovarian cancer with the use of the OCP for at 
least six years (Narod et al., 1998). One major concern with this preventative strategy 
is the associated increased risk of breast cancer with the prolonged use (> 4 years) of 
the OCP (Brohet et al., 2007). In addition, chemoprevention has not been shown to be 
as effective as BSO in preventing ovarian cancer and therefore the use of OCP outside 
of a clinical trial is not recommended in the UK. The potential use of PARP inhibitors as 
chemoprevention will be discussed later in this chapter.  
1.3.6 Medical treatments of BRCA mutated cancers 
Surveillance and surgery will not prevent all BRCA1/2 carriers developing cancer and 
many will already have cancer at the time their mutation status is diagnosed. The 
current management of BRCA mutation associated cancer is identical to the treatment 
of the non-hereditary forms of the same staged-matched cancer. However, data are 
emerging to suggest that they should be treated as a distinct disease entity.  For 
example, it is clear that BRCA mutated cancers show increased sensitivity to some 
chemotherapy regimens. Several in vitro studies have demonstrated that BRCA1 and 2 
deficient cells are more sensitive than their wild type controls to the platinum 
analogue cisplatin and less sensitive to anti-microtubule agents such as the taxanes 
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(Bhattacharyya et al., 2000; Tan et al., 2008; Tassone et al., 2003).  Preliminary patient 
data are now emerging to support this theory. A retrospective study of 102 BRCA1 
mutation carriers receiving neoadjuvant chemotherapy for breast cancer showed an 
increased complete pathological response rate to cisplatin compared to the more 
standard regimens of CMF (cyclophosphamide, methotrexate and 5-fluorouracil) and 
AT (doxorubicin and docetaxel) (Byrski et al., 2009). A small study by Tan et al. also 
demonstrated higher complete response rates (81.8% vs. 43.2%; P = 0.004) and 
improved overall survival to first line platinum based chemotherapy in 22 ovarian 
cancer patients with germline BRCA1/2 mutations over a matched non-hereditary 
control group. Improved responses were also seen in the BRCA mutation carriers who 
received second and third line chemotherapies (Tan et al., 2008). Interestingly, an 
improved response to platinum has also been reported in ovarian cancers with 
reduced BRCA1 mRNA expression (Quinn et al., 2007). This retrospective study 
analysed BRCA1 mRNA levels in 70 sporadic ovarian cancers. The results showed that 
women with low to intermediate levels had a significantly increased median survival 
following treatment with platinum based chemotherapy than those with high BRCA1 
mRNA expression (57.2 vs. 18.2 months; P = 0.0017). Of note, the BRCA1 mutation 
status of patients in this study was unknown; thus the reduced levels of BRCA1 
expression observed could be attributed to BRCA1 germline mutations but additionally 
somatic mutations or gene promoter methylations.   
These data suggest that BRCA mutation carriers have a better outcome following 
treatment for cancer and that it is associated with an increased response to the 
platinum chemotherapy agents. This question of increased platinum sensitivity in 
BRCA-related breast cancer will hopefully be answered by a current randomised 
clinical trial. This randomised phase II trial, conducted by the Breakthrough Breast 
Cancer Research Centre in conjunction with Cancer Research UK (CRUK) 
(www.brcatrial.org) is randomising patients with a known BRCA1/2 mutation at first 
presentation of metastatic/advanced disease to six cycles of the platinum- carboplatin 
or standard treatment with the anti-microtubule agent-docetaxel. 
Recently a novel strategy for treating these germline BRCA mutated cancers has 
emerged; to use small molecule inhibitors that target the nuclear enzyme Poly(ADP-
ribose polymerase-1 (PARP-1). This is discussed in detail in section 1.5.3. 
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1.4 PARP-1 and the PARP family 
The discovery of the first poly(ADP-ribose) polymerase (PARP) began over forty years 
ago when in 1963 researchers in Paul Mandel’s laboratory observed the synthesis of a 
new polyadenylic acid after adding nicotinamide mononucleotide to rat liver extracts 
(Chambon et al., 1963). Shortly after this discovery independent research groups 
demonstrated that this new polymer, named poly(ADP-ribose), was made up of two 
ribose moieties and two phosphate units (Chambon et al., 1966; Nishizuka et al., 1967; 
Sugimura et al., 1967). The enzyme that could generate large amounts of this 
poly(ADP-ribose) was later purified and designated the name ADP-ribosyl transferase 
(ADPRT) (Okayama et al., 1977).   By 1980 it was discovered that ADPRT was activated 
by single and double strand DNA breaks (Benjamin and Gill., 1980) and seminal work 
by Sydney Shall’s group demonstrated that it was not only involved in DNA repair but 
inhibiting it with 3-aminobenzamide (3-AB) enhanced the cytotoxic effects of 
methylating agents in leukaemic mice cells (Durkacz et al., 1980). Durkacz et al. were 
the first to suggest that inhibitors of ADPRT could act as chemosensitizers. ADPRT was 
later renamed PARP (De Murcia and Menissier de Murcia., 1994) and there are now 17 
members of the PARP super-family (Rouleau et al., 2010). A true PARP is defined as an 
enzyme that is able to transfer ADP-ribose units from NAD+ (nicotinamide adenine 
dinucleotide) to acceptor proteins, including itself, resulting in the formation of 
multiple branched and linear poly(ADP-ribose) (PAR) chains. A process known as 
‘poly(ADP-ribosyl)ation’ and shown in figure 1.3 (Schreiber et al., 2006).  Using this 
definition only PARP-1, 2, 3, 4, 5 and 5a would be true PARPs. PARP-1, 2 and 3 are the 
only members known to be activated by DNA damage with PARP-1 playing the 
dominant role in DNA repair (Ame et al., 1999; Ame et al., 2004) and the main focus of 
this thesis.  
1.4.1 Structure of PARP-1 
The PARP-1 gene is located on chromosome 1, position q41-42, and encodes the 1014 
amino acid, 113KDa, PARP-1 protein (Auer et al., 1989). PARP-1 is an abundant nuclear 
enzyme that is expressed in all nucleated human cells except neutrophils (Oei et al., 
1994). It is reported to be over-expressed in some cancers (Alderson, 1990). PARP-1, as 
shown in figure 1.6, consists of three principle domains.  
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Figure 1.6: Schematic representation of the PARP-1 protein showing the three domains.       
ZnF = zinc fingers, NLS = nuclear localisation zone, BRCT = BRCA1 carboxyl terminal  
 
Firstly, at the amino-terminal region, is the DNA binding domain, which consists of two 
zinc fingers and a nuclear localisation signal (NLS). These zinc fingers are essential to 
the sensing and binding of PARP-1 to DNA single and double strand breaks (De Murcia 
and Menissier de Murcia., 1994). A third PARP-1 zinc finger (not shown) has recently 
been identified using spectroscopic and crystallographic analysis; its role is not 
proposed in DNA binding but in the coupling of the activities of the DNA binding and 
the catalytic domains (Langelier et al., 2008). The second domain of PARP-1 is the 
auto-modification zone which is located centrally within the enzyme (Tao et al., 2009). 
It contains 15 glutamate residues which enable the enzyme to poly(ADP-ribosyl)ate 
itself. Interestingly, this domain also contains a BRCT motif which is a protein-protein 
interaction zone that is found in other DNA repair pathways. The third and final 
domain is the catalytic domain which is located at the C-terminus. It is the most 
conserved region between species and is aptly referred to as the PARP ‘signature’ (De 
Murcia and Menissier de Murcia, 1994). This region acts to bind the substrates of 
PARP-1 (Kurosaki et al., 1987). ADP-ribose tranferase activity is limited to a 40 KDa 
region at the far C terminus of the enzyme and loss of this 45-amino acid section 
results in total absence of enzyme activity (Simonin et al., 1990). 
1.4.2 Functions of PARP-1 
One of the main roles of PARP-1 is in the repair of DNA SSBs via the BER/SSBR 
pathway, as discussed in section 1.2.1. Its other functions are discussed here in 
particular its role in DNA DSB repair 
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1.4.2.1 PARP-1 and DSB repair  
It has been known for many years that PARP-1 is activated by DSBs (Benjamin and Gill, 
1980) but its exact role in their repair is only just emerging.  The observations that 
PARP-1 activity is required to rapidly recruit Mre-11, NBS1 and ATM to sites of DSBs 
suggest a role for PARP-1 in mediating the HR repair pathway (Haince et al., 2007; 
Haince et al., 2008). Furthermore Bryant et al. recently published in vitro data showing 
that PARP-1 binds to and is activated by stalled replication forks arising from un-
repaired SSBs; PARP-1 acts together with Mre-11 to re-start the collapsed replication 
fork and enable HR repair of the damaged DNA (Bryant et al., 2009).  
PARP-1 may also have a function within the NHEJ pathway. For example, work by 
Ruscetti and colleagues demonstrated that PARP-1 can modify the protein-kinase 
activity of, the crucial NHEJ protein, DNA-PK (Ruscetti et al., 1998). In particular that, in 
the presence of NAD+, PARP-1 can ADP-‘ribosylate’ and stimulate DNA-PK, which can 
in-turn phosphorylate PARP-1. Consistent with this observation are reports, based on 
studies using PARP and DNA-PK inhibitors in cells lacking either PARP-1 or DNA-PKcs 
that PARP-1 co-operates with DNA-PK to repair ionising radiation-induced DSBs 
(Mitchell et al., 2009). Results of other studies have proposed that PARP-1 participates 
in an alternative ‘DNA-PK/Ku independent’ NHEJ pathway which may operate as a 
back-up to the classical pathway. For example, Wang et al have shown that PARP-1 
directly competes with Ku to bind to DNA DSBs and with the aid of XRCC1 and DNA 
ligase III is able to repair the damage. This mechanism is however prone to error and 
the generation of genomic instability (Wang et al., 2006). 
Further supporting the role of PARP-1 in NHEJ DSB repair is the evidence that the 
combined use of a PARP-1 and a DNA-PK inhibitor is synergistic in terms of 
radiosensitization and the fact that inactive PARP-1 inhibits DNA-PK activity and vice 
versa (Veuger et al., 2003; Veuger et al., 2004). 
1.4.2.2 PARP-1 and gene transcription 
Gene expression profiling of PARP-1 -/- mice cells (Simbulan-Rosenthal et al., 1997) and 
MCF7 human breast cancer cells treated with PARP-1 short hairpin RNAs (Frizzell et al., 
2009) shows PARP-1 to be implicated in the transcription of many genes. These studies 
reveal that loss of PARP-1 results in the down-regulation of the expression of multiple 
  Chapter One - Introduction 
28 
 
genes which can be divided by their function into four main groups: cell cycle control, 
DNA damage response, chromosomal processing and assembly and finally, those 
involved in the response to inflammation and oxidative stress.  
1.4.2.3 PARP-1 response to inflammation and capase-independent cell death 
Results from several studies have shown that PARP-1 is involved in the inflammatory 
response to acute conditions such as cerebral ischaemia, septic shock, and myocardial 
infarction; and in chronic inflammatory diseases such as diabetes mellitus (Oliver et al., 
1999; Schreiber et al., 2006). Over ten years ago, Burkart and colleagues observed that 
PARP-1 -/- mice and mice treated with PARP-1 inhibitors were resistant to developing 
type one diabetes mellitus following exposure to the pancreatic   islet cell toxin 
Streptozocin. They concluded that NAD+ depletion caused by the massive over-
activation of PARP-1 was the main mechanism behind the islet cell destruction and 
that this process was blocked in the mice with non-functional PARP-1 (Burkart et al., 
1999). Studies investigating the response to acute cerebral ischaemia reported that 
following inflammatory stress or reperfusion large numbers of DNA SSBs were 
generated by the synthesis of nitric oxide (NO) from endothelial cells and 
macrophages. These DNA SSBs resulted in over-activation of PARP-1, depletion of 
NAD+, generation of free radicals by mitochondria and ultimately necrotic cell death 
(Szabo and Dawson, 1998). It is now known that in response to inflammation PARP-1 
activates the nuclear factor-B (NF-B) and the AP-1 transcription factors (Hassa et al., 
2003). This results in the release of pro-inflammatory mediators including inducible 
nitric oxide synthase (iNOS) generates NO and reactive oxygen species that cause DNA 
SSBs. It is proposed that free PAR formed from the over-activated PARP-1 and PARP-2 
is somehow transmitted to the mitochondria resulting in a reduction of the 
mitochondrial membrane potential and the release of apoptosis inducing factor (AIF) 
and endonuclease G (EndoG) into the nucleus. This, in combination with overwhelming 
NAD+ and adenosine tri-phosphate (ATP) depletion, leads to cell death. This process of 
PARP-1-mediated, capase-independent cell death could be exploited for therapeutic 
benefit. If PARP-1 could be inactivated either pharmacologically or genetically in acute 
conditions such as myocardial infarction and acute brain injury or in chronic diseases 
such as diabetes mellitus in theory it should be possible to reduce the inflammatory 
response and improve patient outcome. 
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1.4.3 PARP-1 activity 
PARP-1 enzyme activity is reported to be higher in cancer tissue than normal tissue. 
For example, increased PAR formation compared to levels in adjacent non-cancerous, 
normal tissue has been documented in colon carcinoma (Hirai et al., 1983), 
hepatocellular carcinoma (Nomura et al., 2000), melanoma, basal skin carcinoma (Ikai 
et al., 1980) and in cervical cancer (Fukushima et al., 1981). In addition, it has recently 
been proposed that PARP-1 activity is hyper-activated in BRCA deficient cancers 
(Gottipati et al., 2010) and that this may in part explain the mechanism behind their 
sensitivity to PARP inhibitors suggesting an over-reliance on the BER/SSBR. 
Endogenous PARP activity levels have been shown to vary between cancer patients 
(Zaremba et al., 2011) and it has recently been suggested that PARP activity levels may 
prove a useful biomarker to determine which patients will be sensitive to PARP 
inhibitor therapy (Redon et al., 2010).  
1.4.4 PARP-1 expression 
The PARP-1 protein is constitutively expressed in all nucleated human cells except 
neutrophils (Schreiber et al., 2002) and higher levels have been reported in cancer 
tissue compared with non-malignant tissues. For example, significantly higher levels of 
PARP-1 protein in hepatocellular carcinoma compared to normal liver (Shimizu et al., 
2004) and increased mRNA PARP-1 levels in early stage colorectal adenocarcinomas vs. 
adenomas (Nosho et al., 2006) have been observed.   
1.4.5 Genetic factors influencing PARP-1 activity and expression 
Changes within the PARP-1 gene are thought to play a role in determining PARP-1 
activity, expression and the risk of cancer in humans (Zaremba et al., 2009). To date, 
66 PARP-1 single nucleotide polymorphisms (SNPs) have been reported in man 
(http://snp500cancer.nci.nih.gov). The T2444C SNP results in a valine to alanine 
(V762A) change in codon 762 of exon 17 (Cottet et al., 2000). This amino acid exchange 
is located within the catalytic domain of the PARP-1 enzyme and is reported to result 
in a 30-40% reduction in PARP-1 catalytic activity (Lockett et al., 2004; Wang et al., 
2007). The variant form has also been associated with increased risk of prostate cancer 
(Locket et al., 2004), squamous oesophageal carcinoma, lung cancer in Chinese 
smokers (Hao et al., 2004; Zhang et al., 2005) and thyroid cancer (Chiang et al., 2008). 
Polymorphisms within the promoter region of the gene may influence PARP-1 
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expression. For example, a microsatellite polymorphic DNA fragment consisting of a 
variable number of CA repeats [(CA) 11 – (CA) 20] has been identified which may 
contribute to the regulation of PARP-1 expression (Fougerousse et al., 1992; Oei and 
Shi, 2001). 
1.5 The development of PARP inhibitors 
It has long been recognised that inhibiting PARP-1 in patients could have great 
therapeutic potential in the treatment of many diseases such as ischaemic events 
(cerebrovascular and myocardial infarction), diabetes and cancer. This has been the 
focus worldwide of over 20 medicinal chemistry programmes with a peak in 
development between the years 2001 and 2005 (Ferraris, 2010), see figure 1.7.  
The first PARP inhibitor, 3-aminobenzamide (3-AB), was identified over thirty years ago 
following the observation that nicotinamide and 5-methylnicotinamide competed with 
NAD+ as a PARP substrate (Purnell and Whish, 1980). 3-AB causes 96% PARP inhibition 
but requires millimolar intracellular concentrations to achieve this. Furthermore it 
lacks specificity as it is also inhibits de novo purine synthesis (Milam and Cleaver, 
1984). 
 
Figure 1.7: Worldwide PARP-1 medicinal chemistry programmes (Ferraris, 2010). Information 
acquired from the current patent and publication data. 
 
These short-comings in 3-AB led to the development of more potent, more specific 
inhibitors, which inhibit PARP-1 by the same mechanism: competitive inhibition of 
NAD+. In 2003, the first PARP-1 inhibitor entered anti-cancer clinical trials. It was the 
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potent tricyclic indole PARP-1 inhibitor, AG014699 (Pfizer) (Plummer et al., 2008).  
There are now at least nine PARP-1 inhibitors in anti-cancer clinical trial development, 
shown in table 1.2. The PARP inhibitory potency of these compounds is indicated by 
IC50 and Ki values. IC50 is the concentration required to inhibit PARP activity by 50%; Ki 
is the dissociation constant of the enzyme. As shown in table 1.2, some of these 
inhibitors are reported to inhibit PARP-1 and PARP-2 
1.5.1 AG014699 
The studies undertaken for submission of this thesis investigate the role of the PARP 
inhibitor AG014699. As previously stated, AG014699 was the first PARP inhibitor to 
enter anti-cancer clinical trials. It was developed by the laboratories of Roger Griffin 
and Bernard Golding at Newcastle University in collaboration with Cancer Research UK 
and Agouron Pharmaceuticals (now owned by Pfizer). The structures of the lead 
compounds discussed below are shown in figure 1.8. In the early 1990s, the initial 
interest of the Newcastle group was in two core series; the quinazolinones and the 
benzamidazole carboxamides (from which the clinical candidate was later generated) 
(Ferraris, 2010). By the late 1990s, it was clear that the benzamidazole carboxamides 
were the more potent core structures (Ki = 95 nM). The substitution of aryl groups at 
the para position of this core structure resulted in better interactions with the Tyr889 
and Tyr 907 within the nicotinamide binding site of the PARP-1 protein. This led to 
improved potency of the compound and the generation of the first lead compound – 
NU1085 (Ki = 6 nM). NU1085 was confirmed to be more potent than previous 
compounds in its ability to enhance the cytoxicity of temozolomide and topotecan in a 
panel of human cancer cell lines (Delaney et al., 2000).  Despite its early promise, 
NU1085 was found to be poorly water soluble and so the search for a clinical candidate 
continued. In order to address the issue of aqueous solubility, the groups at Agouron 
and Newcastle identified a series of [5, 6, 7]tricyclicimidazole lactams. Optimisation of 
these imidazole lactams led to the discovery of the lead PARP-1 inhibitor - AG014361 
(Shalitzky et al., 2003). AG014361 shared a feature common to other PARP inhibitors in 
development at the time, a secondary or tertiary amine, as shown by the light grey 
circle in figure 1.8 on the compound. It was this amine that was responsible for the 
improved potency (Ki = 5.8 nM) and water solubility of AG014361.  AG014361, at 
concentrations as low as 0.4 M, was later shown to potentiate the anti-tumour 
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effects of temozolomide causing complete tumour regressions in SW620 colorectal 
cancer cell line xenografts (Calabrese et al., 2004). Agouron’s final lead candidate, 
AG014699, emerged from a series of [5, 6, 7]tricyclic indole lactams. AG014699 was 
selected to be the clinical candidate after it was shown to be the most potent PARP-1 
inhibitor in terms of anti-tumour activity in combination with temozolomide in 
xenograft models, reported to be at least ten times more potent than AG014361 
(Thomas et al., 2007). AG014699 is the phosphate salt of the tricyclic indole AG014447, 
with the structure 8-fluoro-2-(4-methylaminomethyl-phenyl)-1,3,4,5-tetrahydro-
azepino[5,4,3-cd]indol-6-one illustrated in figure 1.8. AG014699 is a water soluble 
yellow solid with a molecular weight of 421.36. Crystallographic analysis demonstrates 
AG014699 binds within the NAD+ binding domain of PARP via 3 hydrogen bonds. The Ki 
determined using 32P-NAD+ incorporation into polymer by purified full-length human 
PARP, is 1.4 nM.  
Metabolism of AG014699 is thought to be predominantly via cytochrome (CY) P2D6, 
CYP1A2 and CYP3A4 (unpublished data by Pfizer Inc). Pharmacokinetic studies 
performed as part of the phase I study of AG014699 in cancer patients with advanced 
solid malignancies have shown the drug to have linear pharmacokinetics with C max at 
the end of the infusion and a mean terminal half-life of 9.5 hours (Plummer et al., 
2008). The mean volume of distribution was 212 L indicating extensive tissue 
distribution with only 11% mean recovery of dose in the urine 24 hours post-dose 
suggesting that the major route of drug elimination is not renal.                                                                                                   
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Figure 1.8: The structures of the lead PARP inhibitors developed by Newcastle University and Agouron (adapted from Ferraris, 2010). K i = dissociation constant of 
the inhibitor, PF50 = potentiation factor at 50% survival. 
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Agent Company Potency Phase Therapeutic intention References 
Olaparib 
(AZD2281) 
AstraZeneca IC50 = 5 nM (PARP-1)                    
IC50 = 1 nM (PARP-2) 
II BRCA mutated breast + ovarian cancer, 
TNBC, HGSOC, combination with 
chemotherapy in solid tumours  
Fong et al., 2009; Tutt et al., 2010; Audeh et al., 2010;  
Giaccone et al., 2010; Lederman et al., 2011 
Iniparib              
(BSI-201) 
BiPar ND III Triple negative breast cancer in 
combination with chemotherapy 
O’Shaughnessey et al., 2009; O’Shaughnessey et al., 2011 
Veliparib         
(ABT-888) 
Abbott Ki = 5.2 nM (PARP-1)                        
Ki = 2.9 nM (PARP-2) 
II Solid tumours, BRCA mutated breast and 
ovarian cancers, MM, brain tumours  
Giaccone et al., 2010; Ji  et al., 2010; Kummar et al., 2010; 
Isakoff et al., 2010; LoRusso et al.,2011 
AG014699          Pfizer Ki = 1.4 nM (PARP-1) II MM in combination with TMZ, BRCA 
mutated advanced breast + ovarian cancer  
Plummer et al., 2006; Plummer et al., 2008; Drew et al., 
2011a 
MK-4827 Merck  IC50 = 3.2 nM (PARP-1)                  
IC50 = 4 nM (PARP-2) 
I Solid tumours, BRCA mutated breast + 
ovarian cancer, TNBC 
Schelman et al., 2011 
INO-1001 Inotek ND II MM  in combination with TMZ Bedikian et al., 2009 
CEP-9722 Cephalon IC50 = 20 nM (PARP-1)                  
IC50 = 6 nM (PARP-2) 
I Advanced solid tumours in combination 
chemotherapy 
 
BMN673 Biomarin ND I Advanced solid tumours  
E7016 Eisai ND I Advanced solid tumours in combination 
chemotherapy 
 
Table 1.2: PARP inhibitors in anti-cancer clinical trial development, 2011. ND = not determined 
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1.6 The role of PARP inhibitors in the treatment of cancer  
PARP inhibitor development pipelines are pursuing two therapeutic applications: (1) 
PARP inhibitors as potentiators of chemotherapy and radiotherapy; and (2) PARP 
inhibitors as single agents, selectively killing cells with defects in DNA repair pathways 
such as those with BRCA1/2 mutations. The pre-clinical evidence to support these two 
strategies will now be reviewed.  
1.6.1 PARP inhibitors as chemopotentiators 
1.6.1.1 The monofunctional alkylating agents 
The first suggestion that PARP inhibitors could be used in the treatment of cancer as 
chemosensitisers came from seminal work by Durkacz and colleagues demonstrating 
that the weak PARP inhibitor 3-AB enhanced the cytotoxicity of DNA methylating 
agents in mouse leukaemia cells (Durkacz et al., 1980). Monofunctional DNA 
methlyating agents are the most potent activators of PARP-1 (and -2) and they include 
dacarbazine and temozolomide (TMZ).  Both these chemotherapies undergo 
metabolism within the plasma to the active metabolite 5-(3-methyltriazeno)-
imidazole-4-carboxamide (MTIC). MTIC is able to methylate DNA at the O6- and N7- 
position of guanine and the N3 position of adenine (Denny et al., 1994), with the most 
lethal lesion being the O6-methyl guanine. PARP-1 (and PARP-2) through BER/SSBR are 
required to repair this damage rapidly.  It would therefore seem logical to assume that 
inhibiting these enzymes results in the increase in the cytotoxicity of MTIC.  Evidence 
to support this are the observations that PARP-1 knockout mice and cells derived from 
them are hypersensitive to DNA methylating agents (Menissier de Murcia et al., 1997; 
Masutani et al., 2000) and knockdown of PARP-1 in melanomas increases their 
sensitivity to TMZ, which can further be increased by co-treatment with a PARP 
inhibitor (Tentori et al., 2008; Tentori et al., 2010). To date several classes of PARP 
inhibitors in combination with TMZ have demonstrated potent anti-cancer activity not 
only in brain tumours and melanomas but a variety of different models. For example, 
Calabrese and colleagues showed that AG14361, (Ki < 5.8 nM; a fore-runner to the 
clinical candidate AG014699) enhanced the cytotoxicity of TMZ  in the human colon 
cancer, mismatch repair (MMR)-defective LoVo xenografts by 3-fold and caused 
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complete regressions in mice bearing human colon cancer MMR-proficient SW620 
xenografts (Calabrese et al., 2004). Veliparib (ABT-888), a PARP inhibitor currently in 
clinical evaluation, has been shown to enhance the anti-tumour activity of TMZ in a 
variety of tumour models including human breast and prostate xenografts; models of 
metastasis to lung, brain and bone and sub-cutaneous xenografts of ovarian, 
pancreatic and non small cell lung cancers (Donawho et al., 2007, Palma JP et al., 
2009). 
1.6.1.2 The topoisomerase I inhibitors 
The topoisomerase 1 inhibitors irinotecan and topotecan (both semisynthetic 
derivatives of camptothecin) play a major role in the treatment of many cancers 
including colo-rectal, ovarian and small cell lung cancer. Topoisomerase 1 (TOP1) is an 
important cellular enzyme which is able to form transient complexes with DNA 
catalysing the cleavage, unwinding and religation of DNA to reduce the torsional strain 
caused by transcription and replication. TOP1 cleaves and religates single strands of 
DNA. The TOP1 inhibitors bind to and stabilise these TOP1 – DNA complexes (cleavable 
complexes) in their broken state. The collision of a cleavable complex and the 
advancing replication fork results in the formation of a double strand break and 
possible cell death. The anti-tumour activity of these inhibitors requires cells to be 
replicating and TOP1 to be active. In fact, response to the topoisomerase I inhibitors is 
directly proportional to amount of topoisomerase activity within cells (Pommier, 
2006).  
As early as 1987 it was shown, in the murine lymphocytic leukaemic cell line L1210, 
that inhibiting PARP with 3-AB could potentiate the effects of camptothecin (Mattern 
et al., 1987). Following this, Bowman et al reported that PARP activity was stimulated 
by camptothecin in L1210 cells and inhibition of PARP with NU1025 increased both 
camptothecin-induced DNA breaks and cytotoxicity to a similar extent, suggesting the 
two events were related (Bowman et al., 2001).                                                                    
In addition the PARP inhibitors NU1025 and NU1085 were shown to increase the 
cytotoxicity of topotecan up to 5-fold in a panel of human breast, colon, lung and 
ovarian cancer cell lines (Delaney et al., 2000).  In vivo studies have now confirmed the 
findings of these in vitro studies; the PARP inhibitor AG14361 increased irinotecan-
induced tumour growth delay by 2 to 3-fold in human colon cancer xenografts  
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(Calabrese et al., 2004) and the PARP inhibitor GPI 15427 enhanced irinotecan anti-
tumour activity in colon cancer models (Tentori et al., 2006).  
Several mechanisms have been proposed to explain the potentiation of TOP1 poisons 
by PARP inhibitors. One hypothesis is that PARP is involved in the repair of TOP1 
associated DNA damage. AG14361 has been shown to delay the repair of 
camptothecin-induced DNA breaks and this could not be explained by differences in 
levels of TOP1 activity as no difference was detected in the nuclear extracts from 
AG14361-treated compared to control cells (Smith et al., 2005).  In addition, the 
Chinese hamster ovary EM9 cell line, which lacks the BER scaffold protein XRCC1, has 
been shown to be hypersensitive to camptothecin (Caldecott and Jeggo 1991). This 
suggests that XRCC1 plays a role in the repair of TOP1 inhibitor-induced DNA damage 
and perhaps PARP-1 participates in this process by recruiting XRCC1 to the site of the 
TOP1-DNA -associated break.  
Another explanation for the potentiation of TOP1 poisons by PARP inhibitors is that 
PARP inhibitors can in some way modulate the activity of TOP1. PARP-1 is known to 
poly(ADP-riboslate) TOP1 and down-regulate its activity (Krupitaza et al., 1989). 
Therefore, inhibiting PARP-1 will result in an up-regulation of TOPI, increased DNA 
breakage and ultimately an increase in sensitivity to topoisomerase I poisons. 
Supporting this hypothesis is the observation that following DNA damage, poly(ADP-
ribosylation) of TOP1 inhibited its activity, or its association with automodified PARP-1,  
inhibited TOP1 activity. TOP1 was re-activated by 1 mM benzamide (Bauer et al., 2001; 
Yung et al., 2004).   
1.6.1.3 The platinums 
The platinum analogues cisplatin and carboplatin act by covalently binding to DNA to 
form intra-strand and inter-strand DNA cross-links. These DNA adducts then inhibit 
DNA synthesis, function and ultimately its transcription. Carboplatin and cisplatin form 
the backbone of treatment for many cancers including ovarian cancer, small and non-
small cell lung cancers, germ cell tumours and head and neck cancers (Chu E and 
DeVita V., 2010). PARP-1 has recently been identified as a platinum-DNA damage 
response protein (Zhu et al., 2010). However, reports as to whether PARP inhibitors 
can actually enhance the cytotoxic effects of the platinums are conflicting (Bernges 
and Zeller, 1996; Nguewa et al., 2006). What is clear from the literature is that any in 
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vitro chemopotentiation seen is cell line dependent. For example, cells lacking 
homologous recombination function are hypersensitive to cisplatin and PARP 
inhibition. Synergistic cytotoxicity of the PARP inhibitor AZD2281 (now olaparib) in 
combination with cisplatin was observed in BRCA2-deficient cells, but not with BRCA2-
proficient cells (Evers et al., 2008).  In a recent study, triple negative breast cancer cells 
(TNBC) were hypersensitised to cisplatin and gemcitabine following siRNA knockdown 
of PARP-1 and this chemopotentiation was not seen in non-TNBC cells (Hastak et al., 
2010). Results from experiments undertaken for this thesis (presented in chapter four) 
show that the PARP inhibitor AG014699 enhances the cytotoxicity of carboplatin by 
461% in BRCA2 defective CAPAN-1 xenografts (Drew et al., 2011). The interaction 
between PARP inhibitors and platinums is still not fully understood but these studies 
suggest it may be connected to an underlying defect in HR. 
1.6.2 PARP inhibitors as radio-potentiators 
About a third of all cancer patients will require radiotherapy as part of their treatment 
(cancerresearchuk.org/cancerstats). Radiotherapy induces DNA damage by multiple 
mechanisms including base damage and single and double-strand DNA breaks, damage 
that is dependent on PARP activity for its repair. The idea that PARP inhibitors could be 
used to improve the efficacy of radiotherapy is over 25 years old. It was in the mid-
1980s that one of the first studies was published demonstrating that the 3-AB could 
enhance the effects of ionising radiation in Chinese hamster cell lines (Ben-Hur et al., 
1985). Since then, numerous in vitro and in vivo studies (reviewed in Powell et al., 
2010) using different classes of PARP inhibitors have shown that PARP inhibitors 
enhance the cytotoxicity of radiation in a number of tumour types including colorectal 
cancers (Calabrese et al., 2004) and gliomas (Dungey et al., 2009; Russo et al., 2009). 
More recently work by Anthony Chalmers’s group has shown that this radio-
potentiation is enhanced in rapidly proliferating cells and cells defective in DNA DSB 
repair compared to normal tissue (Laiser et al., 2010). These data support a role for 
combining radiotherapy and PARP inhibitors in patients with cancer and clinical trials 
are finally underway (www.clinicaltrials.gov) with results eagerly awaited. 
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1.6.3 PARP inhibitors as single agents in BRCA-mutated cancers…concept of synthetic 
lethality 
In 2005, two Nature papers reported that cells deficient in BRCA1 and 2 were 100-1000 
-fold more sensitive to PARP inhibitors than BRCA1/2 heterozygote or wild type cell 
lines (Bryant et al., 2005; Farmer et al., 2005). Bryant et al. used the PARP inhibitors 
NU1025 and AG14361, both forerunners to AG014699. They demonstrated reduced 
survival of V-C8 (BRCA2 deficient Chinese hamster) cell lines after continuous exposure 
to the NU1025 or 24 hours exposure to AG14361. In mice xenografts, 3 out of 5 V-C8 
tumours responded to a 5 day dosing of AG14361 with one mouse showing complete 
remission and no sign of tumour at autopsy. In addition, they reported an induction in 
γH2AX foci formation (representing DNA DSBs) and Rad51 foci formation (indicating 
functional HR repair) in the XRCC1 deficient EM9 (Chinese hamster ovary) cell lines. In 
the V-C8 cells, an increase in γH2AX foci formation but not Rad51 was observed 
following exposure to NU1025.  
In the sister Nature paper, Farmer et al. demonstrated the sensitivity of both BRCA1 
and BRCA2 deficient cell lines to the specific inhibition of PARP-1 by two small 
molecule inhibitors KU0058684 and KU0058948 (Farmer et al., 2005). They 
demonstrated that 24 hours exposure to the PARP inhibitor resulted in permanent 
G2/M cell cycle arrest or apoptosis. They also reported a three-fold increase in 
sensitivity over the DNA damaging agent cisplatin for BRCA1/2 deficient cells.  
Both groups independently concluded that BRCA deficient cells were sensitive to PARP 
inhibition and that monotherapy with a PARP inhibitor could selectively kill BRCA 
deficient cancer cells by a mechanism of ‘synthetic lethality’.  
Synthetic lethality describes the relationship between two genes when loss of either 
gene i.e. BRCA or PARP is viable but loss of both genes i.e. PARP and BRCA is lethal 
(Kaelin, 2005). The proposed mechanism for the synthetic lethality of PARP inhibitors 
in BRCA deficient cells is as follows: PARP inhibition leads to the accumulation of DNA 
single-strand breaks that result in un-repaired stalled replication forks and ultimately 
double-strand breaks. These DNA DSBs are normally repaired by the HR pathway (JHJ 
Hoeijmakers, 2001). In HR-defective cells, i.e. those with BRCA1/2 mutations, these 
DSBs are left un-repaired or are repaired in an error-prone way by alternative NHEJ 
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DNA repair; both outcomes can result in genomic instability and ultimately cell death. 
Whereas in cells with functional HR, i.e. those with heterozygous mutations or wi ld 
type BRCA, DSBs will be accurately and efficiently repaired and inhibiting PARP will not 
result in cell death. This process is illustrated in figure 1. 9.  
The safety of inhibiting PARP in BRCA mutant carriers was previously investigated in a 
study by Drew and colleagues using BRCA2 heterozygous (129/C57BL6/DBA) mice 
(Drew et al., 2011b). BRCA2 heterozygote mice and wild type controls were treated 
with either AG014699 (25 mg/kg) i.p. once daily on days 1-5 of a 21 day cycle for six 
cycles or control saline (10ml/kg) i.p. once daily on days 1-5 of a 21 day cycle for six 
cycles. Results show, with a follow-up of 365 days, no difference in mean body weight 
or survival between the four groups suggesting that inhibiting PARP in patients may be 
safe. 
 The use of PARP inhibitors to exploit this ‘synthetic lethality’ in patients with BRCA1/2 
-mutated cancer is a novel and exciting strategy. It may result in anti-tumour activity 
without normal tissue toxicity – the ultimate aim of any anti-cancer treatment. 
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Figure 1.9: Synthetic lethality of PARP inhibitors in BRCA deficient cancer cells. SSB = single 
strand break, SSBR/BER = single strand break repair/base excision repair, DSB = double strand 
break, HR = homologous recombination 
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1.6.4 PARP inhibitors as single agents in sporadic HR defective cancers 
The majority of cancers are not attributed to hereditary germline mutations in the 
BRCA1 and 2 genes (Venkitaraman, 2002), and so a key question is whether single 
agent PARP inhibitors can be used to treat patients within the larger cancer 
population? There is increasing evidence that HR deficiency (HRD) can occur in 
sporadic cancers resulting in sensitivity to PARP inhibition. For example, it is now 
known that high grade serous ovarian carcinomas (HGSOC), in addition to mutated p53 
(Bell et al., 2005; Ahmed et al., 2010), frequently harbour BRCA1/2 dysfunction 
(Hennessy et al., 2010; Press et al., 2008). Press et al reported that germline or somatic 
BRCA1 or 2 mutations or epigenetic loss of BRCA1 (through promoter CpG island 
methylation) occurred in 60% of high grade serous ovarian cancer cases.  Dysfunction 
of BRCA1 is also reported in basal-like breast cancers (BLBC) and triple negative breast 
cancers (TNBC) which are phenotypically similar to BRCA1 breast cancers with 
oestrogen receptor negativity and high nuclear grade (Cleator et al., 2007; Turner et 
al., 2007; Lee et al., 2011). Turner et al reported that BLBC have reduced mRNA BRCA1 
expression and increased expression of ID4, a negative regulator of BRCA1.   
BRCA2 gene methylation is rarely reported but over-expression of the BRCA2 
interacting protein EMSY can result in repression of BRCA2 function which may, 
although this remains uncertain, include its role in HR DNA repair. EMSY over-
expression has been observed in up to 13% of breast cancers and 17% of high-grade 
ovarian cancers (Hughes-Davies et al., 2003) suggesting another group which may 
benefit from PARP inhibition.  
Pre-clinical studies have shown that cells lacking other components of the HR pathway 
such as Rad51, ATR, and CHK2 are sensitive to PARP inhibitiors (McCabe et al., 2006).  
Furthermore mutations within the ATR and CHK2 genes have been reported in some 
cancers (Swift et al., 1991; Miller et al., 2002). Cells deficient in the phosphatase and 
tensin homolog (PTEN) have recently been shown to be sensitive to PARP inhibitors 
(Mendes-Pereira et al., 2009) and PTEN is commonly deleted in sporadic cancers with 
the highest frequencies reported in endometrial cancer (Salmena et al., 2008).   
Hypoxia within cancer cells drives genomic instability and metastasis and can result in 
resistance to conventional therapies. It has been reported that hypoxic 
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microenvironments within cancer cells can lead to reduced expression of essential HR 
proteins (Bindra et al., 2005; Chan et al., 2008). A recent study by Chan and colleagues 
demonstrated that this hypoxia-induced HR dysfunction can be exploited by the use of 
PARP inhibitors (Chan et al., 2010). They observed increased cytotoxicity and 
accumulation of H2AX and 53BP1 foci in hypoxic cells with the addition of PARP 
inhibitor; an effect partially reversed by Rad51 over-expression. In addition, hypoxic 
gassing resulted in growth inhibition of PARP -/- murine embryonic fibroblasts (MEF) 
but not in PARP +/+ MEF cells. In vivo studies confirmed this in vitro work; tumours from 
mice treated with PARP inhibitors displayed increased H2AX and cleaved caspase-3 
expression in Rad51-deficient, hypoxic sub-regions; indicating increased DNA damage 
and apoptosis in a HR-defective environment. This concept that under hypoxic 
conditions PARP inhibitors can be lethal has been termed ‘contextual  synthetic 
lethality’. Given that all cancers are likely to have hypoxic regions this suggests that 
PARP inhibitors may have an even broader role in the treatment of cancer.  
Another mechanism by which cancers could become sensitive to PARP inhibitors is to 
disrupt their HR repair machinery artificially by the addition of another targeted DNA 
response/repair agent. The discovery that CDK1-mediated phosphorylation of BRCA1 is 
required in order for BRCA1 to form repair foci led to the investigation of the effects of 
combining of CDK1 inhibitors and PARP inhibitors. In a recent study Johnson and 
colleagues tested the combination of the PARP inhibitor AG014699 and a CDK1 
inhibitor (Johnson et al., 2011). Following treatment with the PARP-CDK1 inhibitor 
combination, they observed reduced colony formation and reduced Rad51 formation 
in BRCA- wild type cells and tumour regressions in BRCA-wild type xenografts. No 
increase in toxicity was seen in the mice. Previous studies have shown that PARP 
inhibitors alone are non-toxic to BRCA wild type models (Bryant et al., 2005; Farmer et 
al., 2005; Drew et al., 2011). However these recent findings suggest that combining 
PARP inhibitors with CDK1 inhibitors could extend the therapeutic scope into non-
BRCA mutated cancer populations. 
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1.7 Results of PARP inhibitor anti-cancer clinical trials 
At the time this PhD was instigated there were only two PARP inhibitors in the clinical 
trial stage of development (AG014699 and olaparib) and no clinical trial results fully 
published. However, the last 5 years have seen a major leap forward in the 
development of these novel agents with at least nine inhibitors in various stages of 
clinical trial development, see table 1.2. The results of any published trials will be 
reviewed here. 
1.7.1 PARP inhibitors in combination with chemotherapy 
The pre-clinical data (discussed in section 1.6.1) demonstrating the potent anti-cancer 
activity in a variety of cancer models of combining PARP inhibitors with the 
monofunctional, alkylating agent TMZ provided the rationale for the first in-human 
PARP inhibitor study. The phase I trial of  AG014699 in combination with TMZ in 
patients with advanced solid tumours began at the Northern Centre for Cancer 
Treatment, Newcastle, UK in 2003 (Plummer et al., 2008). In the trial a test dose of 
single agent AG014699 was given on cycle one D -7 to allow safety, pharmacokinetic 
(PK) and pharmacodynamic (PD) evaluation of the investigational agent before it was 
combined with TMZ. The study was driven by a PD end-point which was to establish a 
PARP inhibitory dose (PID) of AG014699, before attempting to evaluate the maximum 
tolerated dose (MTD) of the combination. PID was defined as ‘the dose of AG014699 at 
which PARP activity in peripheral blood lymphocytes (PBLs ) was reduced to less than 
50% of the baseline activity value at 24 hours after the first dose’ (Plummer et al., 
2008). The PID was established at 12 mg/m2.  No dose-limiting toxicities (DLTs) of 
single agent AG014699 were reported and the DLT of the combination was 
myelosuppression (a recognised normal tissue DLT of TMZ).  Sustained PARP inhibition 
was demonstrated in PBLs and tumour biopsies; this combination was taken forward 
into a phase II study in metastatic melanoma. This phase II trial reported enhanced 
TMZ-induced myelosuppression when combined with PARP inhibitory doses of 
AG014699 (Plummer et al., 2006). A 25% dose reduction in the TMZ to 150 mg/m2 was 
therefore required for the regimen to be tolerated. Importantly, the study reported an 
increase in the response rate and median time to progression compared to historical 
reports of TMZ alone. These data have yet to be confirmed in a large phase III trial.  
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Since these first in-human studies, multiple phase I/II trials using different PARP 
inhibitors with different chemotherapy combinations have recruited patients and 
some results have been reported in abstract data and are discussed here.  
The Phase Ib combination study of the intravenous PARP inhibitor INO-101 
(Inotech/Genetech) and TMZ in patients with malignant melanoma reported in 2009 
(Bedikian et al., 2009).  DLTs were myelosuppression and elevated transaminases with 
the MTD established in combination with full dose TMZ.  No PD data were reported so 
it is not clear what degree of PARP inhibition was achieved and as only 12 patients with 
metastatic melanoma were treated across the dose ranges it is not possible to 
comment of any improved efficacy. Interestingly, since these results were published 
Genentech has suspended further recruitment to this trial and returned the rights for 
INO-101 to Inotech, who are currently pursuing a role for their PARP inhibitors in 
retinal diseases (Ferraris, 2010).  
The chemo-sensitising potential of the AstraZeneca (AZ) PARP inhibitor, olaparib, is 
being investigated in a number of on-going combination phase I trials including with: 
carboplatin, topotecan, dacarbazine, doxorubicin, gemcitabine and irinotecan 
(www.clinicaltrials.gov). The National Cancer Institute (NCI) sponsored combination 
study of olaparib with cisplatin and gemcitabine reported DLT of myelosuppression at 
the first dose level explored. Investigators were subsequently forced to de-escalate to 
establish tolerable PARP inhibitory doses of olaparib with gemcitabine at 400 mg/m2 
and cisplatin at 40 mg/m2. The study was undertaken in non-heavily pre-treated 
patients (Giaccone et al., 2010). Similarly the phase I combination study of topotecan 
and olaparib reported DLTs of neutropenia and thrombocytopenia at doses of 
topotecan 1 mg/m2/daily for 3 days and olaparib 100 mg twice daily. Further dose 
levels were not explored due to the myelosuppression (Samol et al., 2011). The phase I 
study of olaparib with dacarbazine also observed neutropenia and thrombocytopenia 
as DLTs establishing a recommended phase II dose of olaparib 100 mg twice daily with 
dacarbazine 600 mg/m2 (Khan et al., 2011). 
Preliminary results from four combination studies of the Abbott PARP inhibitor, 
veliparib (ABT-888), with topotecan, metronomic cyclophosphamide, TMZ or 
irinotecan have been reported (Ji et al., 2010; Kummar et al., 2010; Isakoff et al., 2010; 
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LoRusso et al., 2011). In the topotecan study, a DLT of myelosuppression was observed 
at the first dose level and the MTD established with the PARP inhibitory dose was 
topotecan 0.6 mg/m2 days 1-5 (Ji et al., 2010). The cyclophosphamide – veliparib 
combination study did not reach MTD and activity was reported in only a small number 
of BRCA mutated ovarian and triple negative breast cancers (Kummar et al., 2010). The 
TMZ – veliparib study investigated efficacy of the combination in metastatic breast 
cancer and again myelosuppression was seen resulting in a dose reduction of the PARP 
inhibitor Isakoff et al, 2010). In the irinotecan combination study, DLTs were diarrhoea 
and neutropenia, and a MTD of irinotecan 100 mg/m2 (LoRusso et al., 2011). 
A major theme is emerging from these PARP inhibitor-combination studies; enhanced 
normal tissue toxicity, in particular myelosuppression, is a predictable and common 
problem. This increased toxicity may limit the dose and choice of chemotherapy used 
and thus the clinical application of these PARP inhibitor combinations. 
1.7.2 PARP inhibitors as single agents in BRCA mutated cancers 
The first clinical trials investigating PARP inhibitors as single agents in BRCA mutated 
cancers commenced in 2005. The first to report was the pivotal phase I study of the 
oral PARP inhibitor, olaparib (Fong et al., 2009). The study was conducted in patients 
with advanced solid tumours (n=60) and enriched for BRCA1 or BRCA2 mutation 
carriers (n=23). Olaparib was well tolerated in all patients, including those with 
germline BRCA mutations. DLTs were myelosuppression and central nervous system 
side effects with the MTD of 400 mg olaparib twice daily.  PARP inhibition was 
confirmed in surrogate and tumour tissue, and responses were seen in a number of 
patients with BRCA mutations. Anti-tumour activity was reported in both BRCA1 and 2 
mutation carriers which included patients with breast, ovarian or prostate cancer.  
Of the 19 evaluable BRCA mutation carriers, 12 (63%) had a clinical benefit to 
treatment (defined as radiologic or tumour marker response or disease stabilisation ≥ 
four months). Responses were seen in the 100 mg, 200 mg and 400 mg dosing cohorts. 
No responses were observed in non-BRCA mutation carriers. The study incorporated 
an expansion phase which focused specifically on patients with BRCA1/2 mutations, 
and efficacy in a total of 50 patients with ovarian cancer was recently reported, with a 
clinical benefit rate of 46% (Fong et al., 2010). Olaparib was subsequently taken 
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forward in separate phase II BRCA-mutated breast and ovarian cancer studies. Both 
trials investigated response and toxicity in sequential cohorts of patients, who had 
progressed following at least one chemotherapy regimen, treated with olaparib 400 
mg or 100 mg twice daily (the lowest PARP inhibitory dose with clinical activity from 
the phase I) on a 28 day cycle.  The breast cancer study recruited 54 BRCA1 or 2 
mutation carriers (Tutt et al., 2010). In the 400 mg dose group (n=27) an objective 
response rate (ORR) of 41% (11/27) was seen with a progression free survival (PFS) of 
5.7 months. Response rate was lower (22%) in the 100 mg group (n=27).  The ovarian 
cancer study enrolled 57 BRCA1 or 2 mutation carriers with recurrent epithelial ovarian 
cancer, primary peritoneal or fallopian tube carcinoma (Audeh et al., 2010).  In the 400 
mg dose group (n=33) ORR was 33% (11/33) and again ORR was lower (13%) in the 100 
mg group (n=24) suggesting that the degree of PARP enzyme inhibition may be 
important. The toxicity profile in both studies was acceptable with the most common 
toxicities being grade 1 or 2: nausea, vomiting, fatigue and anaemia (ovarian study 
only). The breast cancer study involved patients who had been heavily pre-treated 
with chemotherapy and the overall response rate compares well with that seen with 
standard chemotherapy regimens in the advanced setting (20-30%). The ovarian study 
included both platinum sensitive and resistant patients and response to olaparib was 
seen across both groups. It is however important to note that not all patients 
responded to olaparib and that these are small studies with no randomised control  
arms and where the two dosing cohorts were not designed to be statistically 
compared. Furthermore, with any early phase II results, confirmation of these results is 
needed in larger phase III trials.  
These are however proof of concept studies, the first to report single agent activity of 
a PARP inhibitor in breast and ovarian cancer with defective homologous 
recombination DNA repair through BRCA mutation, which is an exciting breakthrough 
in the treatment of cancer.   
In addition to olaparib there are a number of PARP inhibitors in development for this 
indication (see table 1.2). Preliminary results of some of these studies have been 
presented this year at the 2011 American Society of Clinical Oncology (ASCO) annual 
meeting. A phase I study of the oral Merck PARP inhibitor, MK-4827, in patients with 
advanced solid tumours enriched for BRCA mutated cancers reported a partial 
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response rate of 20% (12/60) (Schelman et al., 2011). The study established a MTD of 
300 mg daily continuous dosing. Interim results of the Phase II trial investigating the 
single agent activity of the PARP inhibitor, AG014699, (Pfizer) in patients with BRCA-
mutated breast and/or ovarian cancer were also presented at ASCO 2011 (Drew et al., 
2011a) and are presented in chapter five of this  thesis.  
1.7.3 PARP inhibitors as single agents in the wider cancer population 
The data discussed in section 1.6.5 suggests that there is a wider role for PARP 
inhibitors in the treatment of cancer. Clinical studies are now underway investigating 
the efficacy of PARP inhibitors in non-germline BRCA-mutated cancers, in particular 
triple negative breast cancer and high grade serous ovarian cancer.  
1.7.3.1 PARP inhibitors and high grade serous ovarian cancers 
In order to investigate the role of the oral PARP inhibitor olaparib in non-germline 
BRCA mutant cancers Gelmon et al embarked on a four-arm phase II correlative study 
recruiting (1) HGSOC patients with BRCA mutations and (2) HGSOC patients with 
unknown BRCA status (3) BRCA- mutated breast cancer and (4) triple negative breast 
cancer patients with unknown BRCA status (Gelmon et al., 2011). All patients received 
continuous olaparib dosing at 400 mg twice daily. All patients underwent BRCA 
mutation testing as part of the study. Results recently reported demonstrated a 
response rate, as assessed by the Response Evaluation Criteria in Solid Tumours 
(RECIST), of 24% in the patients with non germline BRCA mutated HGSOC.      
Responses in the confirmed BRCA mutation ovarian cancer patients was 41%, similar to 
that reported in the seminal phase II olaparib study (Audeh et al., 2010). Responses 
were seen in both the platinum sensitive and resistant patients. Interestingly, no 
responses were observed in the two breast cancer arms of the study which conflicts 
the data from Tutt et al showing that BRCA mutated breast cancer is sensitive to 
olaparib (Tutt et al., 2010). The Gelmon study required biopsy samples to be taken 
before and after olaparib treatment in order to assess BRCA mutation status and 
epigenetic changes to BRCA1 and these results are eagerly awaited. It should be noted 
however that this is the first study to show single agent PARP inhibitor activity in non-
germline BRCA mutated cancers, indicating that sporadic high grade serous ovarian 
cancers could be targeted with PARP inhibitors due to an underlying BRCA defect and 
that accurate sub-classification of these cancers is essential to guide treatment. 
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The role of PARP inhibitors as maintenance therapy in HGSOC is currently being 
investigated with interim results of a phase II study recently announced (Ledermann et 
al., 2011). The study randomised patients with platinum sensitive, (defined by the 
protocol), high grade serous ovarian cancer on a 1:1 basis to olaparib 400 mg twice 
daily or placebo until disease progression. Preliminary results showed a significant 
benefit in progression-free survival (8.4 vs. 4.8 months; P < 0.00001) favouring the 
maintenance olaparib. Overall survival data are not yet mature and are awaited.  
1.7.3.2 PARP inhibitors and basal-like, triple negative breast cancers 
Gene expression profiling has clustered breast cancer into five distinct molecular 
subgroups, one of which is the basal-like breast carcinoma (BLBC) (Perou et al., 2000). 
The majority lack expression of the oestrogen receptor (ER), progesterone receptor 
(PR) and HER2/neu receptor.  Triple negative breast cancers, by definition, lack ER, PR 
and HER2/neu expression and make up around 15% of all breast cancers.  Although the 
terms BLBC and TNBC are often used interchangeably, it is important to note that the 
overlap is not complete. As there is no universal agreement on distinguishing triple 
negative BLBC from TNBC, clinical trials recruiting patients are likely to be 
heterogeneous for both groups.  
In the phase II study previously discussed Gelmon et al reported no single agent 
activity with the PARP inhibitor olaparib in 15 patients with triple negative breast 
cancer (Gelmon et al., 2011) and at present there is no evidence of single agent activity 
in TNBC using this approach. However, remarkable data were presented at ASCO 2009 
of a chemotherapy-PARP inhibitor combination trial, using the PARP inhibitor BSI-201 
(now known as Iniparib) in patients with TNBC (O’Shaughnessey et al., 2009). This 
randomised phase II study, recently reported, investigated iniparib in combination with 
carboplatin and gemcitabine in metastatic TNBC (O’Shaughnessey et al., 2011a). The 
study randomised 120 patients to receive gemcitabine (1000 mg/m2) plus carboplatin 
(AUC2) days 1 and 8 +/- iniparib given days 1, 4, 8, 11 of a 21 day cycle. Results showed 
an increased ORR (52 vs. 32%, p=0.02), median PFS (5.9 vs. 3.6 months, p<0.01) and OS 
(12.3 vs. 7.7 months, p=0.01) with the addition of the PARP inhibitor. These data 
represented a significant result in a breast cancer sub-group with limited targeted 
treatment options.  However, what was not clear from the study was the underlying 
mechanism for potentiation of the chemotherapy response. The original hypothesis 
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was that iniparib, as a PARP inhibitor, was potentiating the chemotherapy by inhibiting 
repair of the chemotherapy-induced DNA damage. However, in contrast to other 
combination studies (discussed in section 1.5.1), no increased toxicity was seen in the 
iniparib plus chemotherapy arm. At the time this trial was reported it raised many 
questions about the lack of toxicity. Was the lack of toxicity due to the intermittent 
dosing of the inhibitor or the lower than standard dose of carboplatin used (AUC2) or 
that the PARP inhibitor was not enhancing the chemotherapy but acting via 
independent mechanisms?  It may even be possible that the intermittent 
chemotherapy, by providing exogenous DNA damage is potentiating the PARP 
inhibitory properties of iniparib. Some of the questions surrounding iniparib were 
answered earlier this year at ASCO 2011 with the reporting of the phase III study of 
this combination. In the phase III trial 519 patients were randomised 1:1 to receive 
gemcitabine (1000 mg/m2) plus carboplatin (AUC2) days 1 and 8 with or without the 
PARP inhibitor given days 1, 4, 8, 11 of a 21 day cycle (O’Shaughnessey et al., 2011b). 
Before the results were presented the study team announced that they had new data 
to confirm that Iniparib was ‘not acting as a PARP inhibitor’ at the concentrations 
achieved in the study population and that iniparib acts by arresting cell cycle at the 
G2/M checkpoint. The trial also failed to meet its primary endpoint and did not show a 
significant benefit in terms of improved OS in patients receiving iniparib plus the 
chemotherapy. Data presented by independent researchers at the same meeting 
proposed that iniparib has numerous off-PARP targets including inhibition of the 
enzyme caspase-3 (Maegley et al., 2011). What is certain is that the mechanism of 
action of iniparib is still unclear and requires further investigation and that this study 
does not add to the case for the use of PARP inhibitors in TNBC.  
1.8 Predictive biomarkers for defective HR 
It is clear that many cancers harbour defects in the HR DNA repair pathway and that 
many cancer patients outside of the BRCA mutation carrier population could benefit 
from PARP inhibitor therapy. The problem is how to identify them given the 
heterogeneous mechanisms by which sporadic cancers can develop defective 
homologous recombination. The development of assays to determine homologous 
recombination deficiency (HRD) is the next big challenge for researchers.  
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Sequencing all cancers for mutations within the individual genes known to be involved 
in HR is one method. However, this is likely to be costly and time-consuming. It also 
limits the search to genes already known to be involved in HR and it will not detect 
HRD secondary to epigenetic silencing. One alternative method is to use gene 
expression arrays to determine a BRCA-like profile in tumours. Konstantinopoulos et al 
identified a 60 gene signature of BRCAness using a publicly available micro-array 
dataset that included 61 patients with epithelial ovarian cancers including those with 
germline BRCA mutations. In a further 70 patient population enriched for sporadic 
cancers this BRCAness profile was shown to correlate with response to PARP inhibitors, 
response to platinums and the ability to form Rad51 foci (Konstantinopoulos et al., 
2010). More recently, Mulligan et al used DNA-microarray technology to profile a 
cohort of breast cancers enriched for BRCA mutants and thus DNA damage response 
and HR deficient (Mulligan et al., 2011). They were able to identify a 44 gene signature 
of the DNA damage response deficient molecular subtype. This signature was then 
validated retrospectively using independent breast cancer data sets and shown to be 
able to predict response to DNA damaging anthracycline chemotherapy. This method 
could be useful to predict response to PARP inhibitors.  
Another approach is to measure Rad51 foci by immunofluoresence. Based on in vitro 
data presented in chapter three of this thesis, Mukhopadhyay et al investigated Rad51 
focus formation as a marker of HRD in primary ovarian cancer cell cultures 
(Mukhopadhyay et al., 2010). The inability to form foci following AG014699 was 
observed in 16 out of 24 cultures and this correlated with ex vivo sensitivity to 
AG014699 with a negative predictive value of 100% and positive predictive value of 
93%. These primary cultures were not developed from known BRCA1/2 mutation 
carriers, highlighting again the extent of HRD in the sporadic cancer population.   
Another option to measure Rad51 foci is in tumour biopsies after ex vivo damage. For 
example, in a small study Willers and colleagues measured Rad51 foci following ex vivo 
irradiation in core breast cancer biopsies (Willers et al., 2009).  No increase in Rad51 
foci was seen in four out of the seven cancers suggesting an underlying HRD. 
Interestingly, three of these tumours were triple negative breast cancers, a phenotype 
that associated with BRCA1 deficiency (Turner et al., 2007). There are problems with 
these approaches: in the study by Mukhopadhyay et al it is the need to obtain viable, 
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replicating cells; in Willer’s study there are technical difficulties in inducing DNA 
damage ex vivo. These assays may not be practical in the normal clinical practice out 
with a translational study. 
In the UK most patients with a confirmed diagnosis of cancer will have had the 
diagnosis made by immunohistochemistry (IHC) analysis of formalin fixed paraffin 
embedded (FFPE) tumour blocks.  IHC of FFPE tissue is another option to help identify 
HR defects. This approach is practical in terms of the availability of tumours but maybe 
very time consuming in terms of the number of proteins that would potentially need to 
be measured. Nevertheless, expression of BRCA1 by IHC has been shown to correlate 
with mRNA BRCA1 expression in such FFPE samples and may prove a simple and useful 
indicator of HR function (unpublished data Dr Judith Carser, Queens University, 
Belfast). In a recent study by Gottipati and colleagues investigating HR competence in 
BRCA2 deficient CAPAN-1 cells and PARPi- resistant revertant clones, hyperactivated 
PARP was observed in the cells with HRD; IHC could be a useful way to detect this 
(Gottipati et al., 2010). 
Finally, the use of circulating tumour cells (CTCs) may eventually prove a useful tool in 
the selection of patients with HRD for PARP inhibitor therapy.  For example, induction 
of γH2AX after treatment with DNA damaging agents has been demonstrated in CTCs  
and studies evaluating Rad51 foci formation are ongoing (Wang et al., 2010). The 
advantage of CTCs is that the actual tumour can be assessed rather than surrogate 
tissues with only minimal invasion such a venepuncture. Such methods are likely to be 
more acceptable to patients and enable serial measurements of biomarkers before 
and after treatments.  
To summarise many of these assays are still in the early stages of development and 
some may prove too expensive or too impractical to use. In addition, these assays will 
require further evaluation and validation within prospective clinical trials before they 
can be adopted as predictive tools directing treatment decisions in patients.  
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1.9 Resistance to PARP inhibitors 
The results from the reported clinical trials of PARP inhibitors in selected cancer 
patient populations are encouraging but it is important to note that not all patients 
respond and most responders eventually develop resistance (Fong et al., 2009; Fong et 
al., 2010). While it may seem premature to determine resistance mechanisms early in 
the development of these novel agents, mechanism-based resistance has frequently 
been found to occur with targeted therapy as it has with chemotherapy. 
Understanding why this happens is important if the clinical outcomes of these novel 
agents are to be improved. Recent studies in cancer cell lines have demonstrated that 
second mutations in the BRCA1 or BRCA2 genes can lead to resistance to PARP 
inhibitors (Edwards et al., 2008; Sakai et al., 2008; Sakai et al., 2009). Secondary 
mutations may restore BRCA function and HR DNA repair in the face of PARP inhibition 
in order to maintain genomic integrity. Edwards and colleagues developed a model for 
drug resistance by producing cells from the BRCA2-deficient cell line CAPAN-1 that 
were insensitive to PARP inhibitors (Edwards et al., 2008). CAPAN-1 cells are derived 
from a pancreatic epithelial tumour arising in a carrier of a c.6174delT BRCA2 
frameshift mutation (Goggins et al., 1996).  They lack a wild-type BRCA2 and the 
c.6174delT allele encodes a truncated protein of 2,002 amino acids (approximately 224 
kDa), compared with the wild-type 3,418–amino acid protein (approximately 390 kDa). 
The mutant protein lacks two whole BRC repeats, the DNA binding/DSS1 interaction 
domain (DBD) and the C-terminus, which contains the TR2 RAD51 binding domain and 
nuclear localization sequences (Esashi et al., 2007).  CAPAN-1 cells are thus unable to 
form damage-induced Rad51 foci and are extremely sensitive to treatment with potent 
PARP inhibitors (Drew et al., 2011; MacCabe et al., 2006).  
The PARP inhibitor–resistant (PIR) clones developed following exposure to the potent 
PARP inhibitor KU0058948 by Edwards et al were shown to be are highly resistant 
(>1,000-fold) (Edwards et al., 2008).  PIR clones are also cross-resistant to the DNA 
cross-linking agent cisplatin, but not to the microtubule stabilizing drug docetaxel.  
Platinum chemotherapy is a well-established strategy in the treatment of ovarian 
cancer, including patients with BRCA1 or BRCA2 mutations. Clinical observations 
suggest that BRCA1/2 mutation ovarian cancer patients respond better to platinum 
therapy, in contrast to patients with no family history of the disease, although 
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resistance does eventually occur (Tan et al., 2008). In addition, systemic chemotherapy 
with the platinums may exert their BRCA1/2-selective effects through similar 
mechanisms to PARP inhibitors.  In view of these findings, the BRCA2 gene was 
sequenced in tumours from patients bearing the BRCA2 c.6174delT mutation whose 
ovarian carcinomas were resistant to carboplatin chemotherapy (Sakai et al., 2009). 
These studies revealed deletions in the BRCA2 gene, which restored the open reading 
frame. This suggests that a specific mutation (c.6174delT) in BRCA2 and sensitivity to 
therapeutics in cell lines and patients can be reversed by intragenic deletion. Similar 
results have been reported for BRCA1 mutated tumours in patients treated with 
platinum based chemotherapy (Swisher et al., 2008). Although resistance to both 
platinums and PARP inhibitors can be mediated by secondary mutations, restoring 
BRCA function, it is likely that the mechanism of resistance is more complex. It is 
important to note that the clinical data have shown that PARP inhibitor resistance does 
not equate to platinum resistance. For example, not all platinum-sensitive ovarian 
cancer patients were sensitive to PARP inhibition and anti-tumour activity was seen in 
platinum-resistant patients in the first single agent trial of olaparib in BRCA1/2 
mutation carriers (Fong et al., 2009). However, post-hoc analysis of the data from all 
50 ovarian cancer patients treated in this study (including the expansion phase) 
showed a significantly higher clinical benefit rate (69.2%) in patients who were 
platinum-sensitive compared to those who were resistant (45.8%) or refractory 
(23.1%), (Fong et al., 2010). It is not clear how much of an issue this will be in clinical 
practice and we await the results of the on-going studies and the mature data from 
those already concluded.  
2.0 Project aims 
This aims of this research project were to investigate through in vitro, in vivo and 
clinical studies the effects of the PARP-1 inhibitor AG014699 in human cancers 
defective in homologous recombination DNA DSB repair. The project focuses 
particularly on cancers defective in the tumour suppressor genes BRCA1 and BRCA2. 
Detailed objectives for each study are found at the beginning of the three results 
chapters. 
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Chapter Two 
2. Materials and Methods 
2.1 General laboratory chemicals and materials 
All chemicals were obtained from Sigma (Poole, Dorset, UK) unless otherwise stated. 
Sterile plasticware for use in tissue culture experiments was supplied by Fisher 
Scientific (Manchester, UK). The PARP inhibitor AG014699 was supplied by Pfizer GRD 
(La Jolla, California, USA). AG014699 was dissolved in dimethyl sulfoxide (DMSO) to 
give a stock solution of 10 mM and stored at – 200C for in vitro studies. For use within 
in vivo experiments it was dissolved in sterile water to give a 1 mg/ml (2.4 mM) 
solution. The sources of other reagents and materials are described, as appropriate, in 
the text. 
2.2 Good Clinical Laboratory Practice 
Laboratory work, undertaken for the phase II PARP-BRCA PH2/052 clinical trial, 
presented in chapter five, was performed in keeping with the principles of the 
International Conference on Harmonisation- Good Clinical Practice (ICH-GCP) 
(www.ich.org).  To ensure that these standards were achieved the project work and 
the laboratory systems were assessed regularly by in-house audits and a two-day study 
audit by CRUK.  
2.3 Culture of cell lines 
Cell lines were maintained in exponential growth in tissue culture grade flasks, petri 
dishes and 6 well plates at 37°C in a humidified incubator atmosphere of 5% CO2 and 
95% air (SANYO; Illinois, USA). All cells were handled separately with their own unique 
reagents, under sterile conditions, in class II tissue culture cabinets. Cells were cultured 
in Roswell Park Memorial Institute (RPMI) 1640 media supplemented with 10% foetal 
bovine serum, penicillin (100 U/ml), and streptomycin (1.0 mg/ml) unless otherwise 
stated. Adherent cells were brought into suspension for sub-culture by aspirating off 
the medium, washing twice with phosphate buffered saline (PBS), followed by five 
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minute incubation with 0.25% trypsin solution in PBS.  Cell cultures were confirmed 
mycoplasma negative by regular testing using the MycoAlert mycoplasma detection kit 
(Lonza; Rockland, Maine, USA). 
2.3.1 Cell lines 
A panel of 11 cell lines, including nine human cancer cell lines, with differing HR repair 
status were selected for use within the in vitro experiments presented in chapter 
three. These cell lines have been subsequently authenticated by an in-house NICR 
programme. Details for each cell line are provided below and a summary is provided in 
table 3.1 of chapter three to aid interpretation of results.  In addition to these cell lines 
two cell lines were cultured for use within PD assays. The mouse lymphocytic 
leukaemic cell line, L1210, was used as quality control (QC) samples for the PARP 
activity assay described in section 2.9. The human lymphoblast cell line, K562, was 
used for QC samples for the PARP-1 expression assay described in section 2.10.  Both 
L1210 and K562 are grown in suspension in RPMI 1640 media supplemented with 10% 
foetal bovine serum, penicillin (100 U/ml), and streptomycin (1.0 mg/ml) and originally 
supplied by the American Type Culture Collection (ATCC). 
2.3.1.1 MCF7 
Breast adenocarcinoma cells derived from the pleural fluid of a 69 year old Caucasian 
female. BRCA 1 hemizygous/BRCA2 wild type, p53 wild type and oestrogen receptor 
positive adherent cells with a doubling time of approximately 28 hours. Original 
supplier: ATCC (Manassas, Virginia, USA). 
2.3.1.2 MDA-MB-231 
Breast adenocarcinoma adherent cell line derived from the pleural fluid of a 51 year 
old Caucasian female. It is hemizygous for BRCA1 and the remaining non-mutated 
allele contains two non-pathogenic single-nucleotide polymorphisms. Original supplier: 
ATCC. 
2.3.1.3 MDA-MB-436 
Breast adenocarcinoma adherent cell line derived from the pleural fluid of a 43 year 
old Caucasian female. BRCA1 mutated (5396 +IG>A), BRCA2 wt type (Elstrodt et al., 
2006). An adherent cell line grown in RPMI 1640 –Leibovitz medium (50:50 vol/vol) 
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supplemented with 4 mM L-glutamine, 10% fetal bovine serum, penicillin (100 U/ml) 
and streptomycin (1.0 mg/ml). Original supplier: ATCC. 
2.3.1.4 HCC1937 
Primary breast carcinoma adherent cell line derived from 23 year old Caucasian 
female. Mutated BRCA1 (5283insC), wild type for BRCA2 (Tomlinson et al., 1998), 
oestrogen and progesterone receptor negative. Original supplier: ATCC. 
2.3.1.5 HCC1937 – BRCA1 
Primary breast carcinoma adherent cell line derived from 23 year old Caucasian female 
(HCC1937) with transfected wild type BRCA1 (Tassone et al., 2003). Original supplier: 
ATCC. 
2.3.1.6 UACC3199 
Primary breast carcinoma, adherent cell line with ≥ 60% BRCA1 promoter methylation, 
which has been shown to result in reduced BRCA1 gene copy number and 
chromosome 17 aneusomy as observed in BRCA1 mutated breast cancer cells (Wei et 
al., 2005). Cell line obtained from the University of Arizona Cancer Research Centre, 
Tucson, USA. The methylation status of BRCA1 in these cells was confirmed by Valerie 
Deregowski (University of Leuven, Belgium) by methylation-specific polymerase chain 
reaction.  
2.3.1.7 CAPAN-1 
Pancreatic adenocarcinoma cells derived from liver metastasis of a 40 year old 
Caucasian male. BRCA2 mutated (6174 delT allele encoding truncated BRCA2 protein; 
other BRCA2 allele is lost), BRCA1 wt type (Goggins et al., 1996).  Adherent cell line 
grown in RPMI 1640 media supplemented with 15% foetal bovine serum, penicillin 
(100 U/ml), and streptomycin (1.0 mg/ml). Original supplier: ATCC. 
2.3.1.8 OSEC1 
Immortalized human ovarian surface epithelial, adherent cell line; heterozygous for 
the BRCA2 mutation 4630insA and wild type for BRCA1. Both OSEC cell lines were 
provided by Richard Edmondson and immortalised with the catalytic subunit of 
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telomerase (hTERT) and a temperature-sensitive form of SV40 large T antigen 
(unpublished data Richard Edmondson, Newcastle University, UK). 
2.3.1.9 OSEC2 
Immortalized human ovarian surface epithelial, adherent cell line; wild type for both 
BRCA1 and 2 (Davies et al., 2003).  
2.3.1.10 AA8 
Chinese hamster ovary cell line wild type for XRCC3 (Pierce et al., 1999); provided by 
Prof Penny Jeggo at the University of Brighton, UK. 
2.3.1.11 IRS-1SF 
Chinese hamster ovary cell line deficient in the HR gene XRCC3 (Pierce et al., 1999); 
provided by Prof Penny Jeggo at the University of Brighton, UK. 
2.4 Preparation of clinical samples from the phase II BRCA-PARP trial  
2.4.1 Preparation of peripheral blood lymphocytes from whole blood for 
pharmacodynamics assays 
Peripheral blood lymphocytes (PBL) were extracted from whole blood for analysis of 
PARP-1 activity and expression. For PARP-1 activity blood samples (10 ml x 4 or x 8 for 
stage one patients) were collected on day (D)1 prior to treatment, at the end of 
infusion, 4 hours post and 24 hours post AG014699 (which is the D2 pre-dose sample). 
For assessment of PARP-1 expression a single 10 ml whole blood sample was taken 
within two weeks prior to starting AG014699. Blood was collected into potassium 
ethylenediaminetetraacetic acid (EDTA) vacutainer tubes (BD, Oxford, UK), stored 
immediately on ice and PBL isolated by lymphopreparation using pre-prepared 
Lymphoprep™ tubes (Axis-shield; Cambridgeshire, UK) within one hour of sampling. 
Each Lymphoprep™ tube contains 10 ml of Lymphoprep™ solution contained below a 
porous membrane disc. 10 ml of chilled PBS was freely added to the Lymphoprep™ 
tube followed by 10 ml of whole blood. The tube is then centrifuged for 10 minutes 
(min) at 1100 relative centrifugal force (RCF) in a horizontal rotor (swing-out head) 
centrifuge at 4°C. After centrifugation, the PBL cells form a distinct band at the 
sample/medium interface. This band of PBL was then collected from the interface 
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using a Pasteur pipette (Axis-shield; Cambridgeshire, UK) and transferred to a 50 ml 
Cellstar tube (Greiner Bio-one; Gloucestershire, UK) and placed on ice. The PBL were 
then diluted by the addition of 20 ml of ice cold PBS and centrifuged for 10 min at 500 
RCF in a horizontal rotor (swing-out head) centrifuge at 4°C. The supernatant was then 
discarded and the cell pellet re-suspended in 2 ml of pre-chilled freezing medium 
consisting of RPMI1640 medium supplemented with 10% foetal calf serum, 10% DMSO 
and x1 strength Halt protease inhibitor cocktail (Pierce; Il linois, USA). Finally, the PBL 
are then placed in 2 separate 1.8 ml cyrotubes (Nunc, supplied by Fisher Scientific; 
Loughborough, UK) and stored at –70oC prior to use.   
 
Figure 2.1: Extraction of peripheral blood lymphocytes (PBL) from whole blood using 
Lymphoprep™ tubes. 
 
2.4.2 Preparation of plasma from whole blood for pharmacokinetic assay 
Blood samples (5 ml x 9 or x 18 for stage one patients) were collected at the following 
time-points: D1 pre-AG014699, end of infusion, 1-3 hours post AG014699; D2 pre-
AG014699; D4 pre-AG014699, end of infusion, 1-3 hours post AG014699 and D5 pre-
AG014699 and D5 end of infusion. Blood was collected into heparinised vacutainer 
tubes (BD, Oxford, UK) and plasma separated within 30 min of sampling by 
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centrifugation at 1000 RCF at room at 4°C. The plasma supernatant was removed and 
separated into 2 x 1 ml samples and stored in 1.8 ml cyrotubes (Nunc, supplied by 
Fisher Scientific; Loughborough, UK) at - 20oC prior to use. 
2.4.3 DNA purification from whole blood for genotyping assays 
For each patient a single sample of whole blood (5 ml) was collected into potassium 
ETDA vacutainer tubes (BD, Oxford, UK) and stored at – 200C prior to use. Samples 
were then thawed at room temperature and DNA extracted using the QIAamp DNA 
Blood Maxi (50) kit, (Qiagen; West Sussex, UK). The concentration (ng/µl) of the eluted 
DNA was determined using the Nanodrop N-D 1000 spectrophotometer system 
(Nanodrop Technologies; Delaware, USA) operating on Nanodrop 3.0.1 software. DNA 
aliquots were then stored as working and stock solutions at 40C and – 200C 
respectively. Working stock solutions were diluted using ultra-high purity (UHP) sterile 
water to give a concentration = 10 ng/µl.  
2.5 Clonogenic cell survival assay 
2.5.1 Background principles 
The clonogenic cell survival assay allows a measurement of cell survival after exposure 
to pharmacological agents. The assay measures viable cells that have undergone at 
least 5-6 rounds of replication to produce a colony and have therefore survived the 
drug exposure. All cell lines listed in section 2.3.1 (with the exception of the HCC1937 
and HCC1937-BRCA1) were used in this assay. 
2.5.2 Assay 
Exponentially proliferating cells were plated into six-well plates and incubated for 48 
hours to allow cells to reach their optimum proliferation rate. AG014699 at 0, 0.1, 1.0, 
10.0, 30.0, 50.0, or 100 μM in 1% DMSO was added to the wells and incubated for 24 
hours. Control cells received no AG014699 but were treated with medium containing 
1% DMSO for 24 hours. Cells were harvested and cultured in drug-free medium in 90-
mm Petri dishes for up to 21 days, depending on the proliferation rate of the individual 
cell line. Colonies were fixed in methanol and acetic acid (3:1 vol/vol), stained with 
methyl violet 10B, and counted with an automated colony counter (Oxford Optronix; 
Oxford, UK).  
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2.5.3 Analysis of results 
Data are expressed as the percentage of colonies in AG014699-treated cultures 
compared with that in control cultures. The concentration that results in death of 50% 
of cell population (LC50) was calculated for each cell line in each independent 
experiment. Each assay contained triplicate samples for each concentration. Results 
represent data from at least three independent experiments. Graphs were produced 
and statistical analysis performed using the GraphPad prism software version 4.0 
(GraphPad Software Inc; La Jolla, California, USA) 
2.6 Sulforhodamine B Assay for Cell Growth Inhibition 
2.6.1 Background principles 
The HCC1937 and HCC1937-BRCA1 cell lines have poor cloning efficiency and were not 
appropriate for the clonogenic cell survival assay. As an alternative, cell growth 
inhibition was measured using the sulforhodamine B (SRB) protein dye assay (Vichai 
and Kirtikara, 2006). This assay determines cell density by measuring cellular protein 
content. Adherent cells are incubated in 96-well plates for a given period of time in 
media containing a range of concentrations of the drug under investigation. Cell 
monolayers are then fixed in trichloroacetic acid and stained for 30 minutes in SRB 
protein dye. After removal of excess dye the protein-bound dye is dissolved in a Tris-
base solution ready for optical density determination (at 520 nm) using a microplate 
spectrophotometer system.  This method enables large numbers of samples to be 
investigated in a short period of time. In addition to the HCC1937 and HCC1937-BRCA1 
cell lines, the MDA-MB-231 cells were also evaluated with this assay so that a direct 
comparison could be made between results from the clonogenic survival assay and the 
SRB assay.  
2.6.2 Assay 
Cells were seeded into 96-well plates at 2000 cells per well and allowed to attach 
overnight. AG014699 at 0.0, 1.0, 10.0, 30.0, 50.0, or 100 μM in 1% DMSO was added, 
and cells were incubated for 120 hours at 37°C, fixed in 50% (wt/vol) trichloroacetic 
acid, and stained with 0.4% SRB solution (diluted in 1% acetic acid) for 30 minutes. 
Absorbance of sulforhodamine B was measured at 520 nm with a SpectroMax 250 
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microplate spectrophotometer system (MDS Analytical Technologies; Toronto, ON, 
Canada) to determine cell density.  
2.6.3 Analysis of results 
The concentration required to produce 50% inhibition of cell growth (GI50) based on 
absorbance measurement was calculated for each cell line in each independent 
experiment. Each assay contained triplicate samples for each concentration. Results 
represent data from at least three independent experiments. Graphs were produced 
and statistical analysis performed using the GraphPad prism software version 4.0 
(GraphPad Software Inc, La Jolla, California, USA) 
2.7 DNA Double strand break determination by γH2AX 
immunofluorescence assay 
2.7.1 Background Principles 
H2AX is one of three types of histone H2A molecules found in eukaryotic cells. 
Phosphorylation by ATM or DNA-PK of H2AX is an early step in the cellular response to 
DNA DSBs. Within 1-3 minutes of a DSB the unique carboxy-terminal tail of H2AX 
serine 139 is phosphorylated forming γH2AX foci (Rogakou et al., 1998). The γH2AX 
foci localise to sites of DSBs and one γH2AX focus is thought to correspond to one DSB 
within the cell nucleus (Rogakou et al., 1999, Paull et al., 2000). This assay uses 
immunocytochemistry to detect the γH2AX foci. A primary antibody specific to γH2AX 
is used, this is then combined with a secondary fluorescent antibody and a DNA 
counter-stain to allow the nucleus of each cell to be visualised by microscopy.  
2.7.2 Cell preparation and assay 
Cells were grown to 50-70% confluence to the day of experiment on sterile circular 
glass cover-slips (22 mm diameter, 1 mm thickness) in 60 mm petri dishes. For cells 
exposed to AG014699; the medium was aspirated and replaced with medium 
containing, at final concentration, 1 or 10 μM AG014699 at time zero on the day of 
experiment. Cells were then incubated for 24 hours at 370C. Cells treated with X-ray 
irradiation were irradiated with 2 Gy (2.5 Gy/min at 310 kV, 10 mA) using the Gulmay 
Medical RS320 Irradiation system (Gulmay Medical Limited; Surrey, UK). Ionising 
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radiation was used as a positive control in all experiments. Cells were returned to the 
incubator for the described length of time before fixation. The cover-slips containing 
cells were then washed twice in 2 ml cold PBS in 6 well plates and subsequently fixed 
in chilled 100% methanol at −200C for 10 min. The cells were then re-hydrated by 
washing in PBS for two 10 minute washes. Fixed control, AG014699-treated, or 
irradiated cells then were blocked for 1 hour at room temperature in KCM buffer (120 
mM KCl, 20 mM NaCl, 10 mM Tris–HCl at pH 8.0, 1 mM EDTA, 0.1% Triton X-100, 2% 
bovine serum albumin, and 10% milk powder). The cells were then incubated 
overnight at 40C in Upstate primary mouse monoclonal IgG1 anti-phospho-histone 
H2A.X Ser 139, clone JBW301 antibody (Millipore; Billerica, Massachusetts, USA) 
diluted 1:400 in the KCM blocking buffer described above. Following incubation with 
the primary antibody the cover-slips were transferred to 6 well plates and washed in 
KCM with 0.1% (v/v) Triton X-100 for three 10 minute washes on a platform shaker. 
Next the cover-slips were incubated in the dark for 1 hour at room temperature in 
secondary fluorescent antibody Alexa Fluor 546 goat anti-mouse IgG (Invitrogen; 
Paisley, UK) diluted 1:200 in blocking buffer. Cells were then washed as described 
above in KCM with 0.1% (v/v) Triton X-100 but shielded from light and with the 
addition of one extra 5 min wash. Following this cover-slips were mounted onto slides 
using Vectorshield hard set mounting medium with DAPI (Vector Laboratories; 
Peterborough, UK), which counter-stains the DNA.  
2.7.3 Analysis 
Images were obtained using Leica DMR microscope and RT SE6 Slider camera 
Advanced Spot software version 3.408 (Diagnostic Instruments Inc; Sterling Heights, 
Michigan, USA).  γH2AX foci were manually quantified in 30 nuclei from three different 
areas of each treatment slide. This method of quantification has been shown to be 
reliable and reproducible (Mukhopadhyay et al., 2010). Graphs were produced and 
statistical analysis performed using the GraphPad prism software version 4.0 
(GraphPad Software Inc, La Jolla, California, USA) 
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2.8 Rad51 focus formation immunofluoresence assay 
2.8.1 Background Principles 
As already discussed in chapter one section 1.2.4 the Rad51 recombinase protein, 
structurally related to the E. coli RecA protein, is a pivotal player in the HR DSB repair 
pathway. In response to DNA damage Rad51 forms nuclear complexes that can be 
detected using microscopy as individual foci. These foci are seen at high levels in cells 
with intact HR pathways following damage with ionizing radiation (IR) and co-localise 
over time with sites of H2AX phosphorylation at the sites of DNA damage (Paull et al., 
2000). Thus the formation of Rad51 foci following DNA damage could serve as a 
biomarker of HR function and to be able to quantify them could enable HR proficient 
and deficient cells to be identified.  
2.8.2 Cell preparation and assay 
The method used was similar to the γH2AX immunofluoresence assay with the 
following changes: Primary antibody used was anti-Rad51 rabbit polyclonal antibody 
(Calbiochem; Merck Serono Ltd, Middlesex, UK) diluted 1:400 with blocking buffer and 
incubated overnight at 40C. Secondary antibody used was Alexa Fluor 488 goat anti-
rabbit IgG (Invitrogen; Paisley, UK) diluted 1:100 in blocking buffer and incubated in 
the dark for two hours at room temperature. For all assays the concentration of 
AG014699 was 10 µM and dose of IR treatments was 2 Gy. 
2.8.3 Analysis 
Images were obtained using Leica DMR microscope and RT SE6 Slider camera with 
Advanced Spot software version 3.408 (Diagnostic Instruments Inc; Sterling Heights, 
Michigan, USA). Rad51 foci were manually counted in 30 nuclei from three different 
areas as described above. Graphs were produced and statistical analysis performed 
using the GraphPad prism software version 4.0 (GraphPad Software Inc, La Jolla, 
California, USA). 
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2.9 PARP activity assay 
2.9.1 Background principles  
PARP activity after treatment with AG014699 is measured using the GCP validated 
immunoblot PARP assay used in the Phase I and II clinical trials of AG014699 in 
combination with TMZ (Plummer et al., 2006, Plummer et al., 2008). The assay 
measures PARP activity by quantifying the amount of PAR synthesized during a 
maximum PARP enzyme stimulation step in which cells are exposed to blunt-ended 
oligonucleotide in the presence of excess NAD+ for a six minute period. The 
oligonucleotide simulates DNA strand breaks. The reaction is then stopped by the 
addition of an ice-cold concentrated AG014699 ‘stop solution’. Samples are 
subsequently placed on ice. A known number of cells (between 2000 and 10,000) are 
then blotted onto a membrane which is then exposed to a primary anti-PAR antibody. 
Bound primary antibody is subsequently exposed to secondary antibody conjugated to 
horse-radish peroxidise. On exposure to chemiluminesence detection reagent, light is 
emitted from areas of the blot containing the primary-secondary antibody complexes 
in proportion to the amount of PAR present. This chemiluminescence is detected and 
expressed as ‘luminescent arbitrary units’ (LAU). It is important to note that this LAU 
value reflects the PAR produced during the reaction step plus the PAR already present 
in the cell prior to the assay. Therefore for each sample a control sample of un-reacted 
cells is also loaded onto the immunoblot. The LAU value for these control samples is 
then subtracted from the former result to give the maximum-stimulated PARP activity 
for the cells. During the validation of this assay a large inter-assay variability was 
observed (unpublished data Dr Chris Jones, Newcastle University, UK), making it 
questionable to compare PARP activity directly between blots using the LAU values. To 
combat this and standardise results between assays the following serially diluted 
standards of PAR: 25, 5, 1, 0.2, 0.04 and 0 pmol ADP-ribose monomer are loaded onto 
the immunoblot at the same time as the cell samples. In addition, for the clinical trial, 
each individual patient’s samples were run on the same blot in order to assess changes 
in PARP activity accurately over time following AG014699. 
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2.9.2 Buffers and solutions 
The isotonic buffer comprised of 36 mM Hepes, 130 mM potassium chloride, 0.57 mM 
dextran, 2.0 mM ethylglyceroltetraacetic acid (EGTA), 2.31 mM magnesium chloride 
and 223 mM sucrose all dissolved in distilled water and pH adjusted to 7.8. The 
solution was then stored at 40C and given an expiry date of three months. The reaction 
buffer consisted of 100 mM Tris.HCl and 120 mM magnesium chloride dissolved in 
distilled water and pH adjusted to 7.8. The solution was stored at 40C and given an 
expiry date of three months. Tris/ Ethylenediaminetetraacetic acid (EDTA) solution 
comprised of 10 mM Tris and 1 mM EDTA dissolved in distilled water; stored at room 
temperature for a maximum of three months.  The stop solution was prepared fresh 
on the day of each experiment by diluting 25 μl of 10 mM AG014699 into 20 ml of PBS 
to give a 12.5 μM AG014699 solution. This was then stored on ice until required in the 
assay. Blocking buffer again made fresh on the day of the assay consisted of PBS with 5% 
Marvel milk powder (Premier Foods; St Albans, Hertfordshire, UK) and 0.05% Tween-
20. 
2.9.3 Preparation of 7 mM NAD+ 
2.5 mg of solid NAD+ (stored at -200C) was weighed on the day of experiment and 
dissolved in 500 µl of distilled water. A 10 µl aliquot of this solution was diluted further 
1:100 with distilled water, transferred into a silica cuvette and the optical density read 
at 260 nm against a control of distilled water using the Lambda 2 Spectrometer (Perkin 
Elmer; Fremont, USA). The molarity of the stock solution was calculated using the 
equation: 1 mM = 18 OD (optical density). The stock solution was subsequently diluted 
in distilled water to give a 7 mM solution.  
2.9.4 Preparation of oligonucleotide 
A pellet of synthesised oligonucleotide with the sequence CGGAATTCCG (Invitrogen; 
Paisley, UK) was dissolved in 10 mM Tris/EDTA and heated to 600C in a water bath. Re-
annealing of the DNA was achieved by cooling the solution to 240C by 10C per minute 
by the addition of ice to the water bath. The solution was then diluted 1:50 with 
Tris/EDTA and the optical density read at 260 nm against a blank cuvette containing 
Tris/EDTA. 1 optical density is equal to 50 µg/ml double stranded oligonucleotide. 
Using this calculation the original oligonucleotide solution was diluted with 10 mM 
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Tris/EDTA to give a 200 µg/ml solution. The solution was then transferred to 
microtubes in 250 µl aliquots and stored at -200C. On the day of experiment one 
aliquot was thawed at room temperature and then stored on ice until required. 
2.9.5 Preparation of PAR standards  
Purified PAR, branched and linear polymers of an average 25 (3-300) monomers,  
(Biomol; Plymouth Meeting, Pennsylvania, USA) was supplied as a 10 µg/ml solution 
where 1 µg is equivalent to 1850 pmol of ADP-ribose monomer and stored at -800C. On 
the day of the experiment one aliquot of PAR was thawed at room temperature and 
292 µl of distilled water added resulting in a 25 pmol ADP-ribose monomer/100 µl 
solution. This was then serially diluted in 200 µl distilled water to give the following 
standards: 25, 5, 1, 0.2, 0.04 and 0.00 pmol. 100 µl of each standard was then mixed 
with 300 µL PBS. For the zero PAR standard 100 µl of distilled water was mixed with 
PBS. These standards were stored on ice until needed. 
2.9.6 Preparation of cell line samples 
Cells were grown to 50-75% confluence on the day of experiment in 35 mm x 10 mm 
Petri dishes containing 10 ml of media. For each cell line the following treatments were 
compared: no treatment (DMSO control) and 10 µM AG014699. On the day of 
experiment medium was aspirated and replaced by medium containing 10 µM 
AG014699 or DMSO for the no treatment control samples. Cells were then incubated 
in this medium for 30 minutes. Following this, cells were washed in PBS x 2, 
trypsinised, re-suspended in 10 ml of medium in universal containers and centrifuged 
at 500 g for 5 min at 40C. The media was then aspirated and the cell pellet placed 
immediately on ice. The cell pellet was then re-suspended in 20 ml ice-cold PBS and 
centrifuged at 500 g for 5 min at 40C twice. The supernatant was discarded and the cell 
pellet re-suspended in 50 µl of ice-cold 0.15 mg/ml digitonin for 5 minutes to 
permeabilise the cells. 450 µL of ice-cold isotonic buffer was then added to the 
permeabilised cells. Permeabilised cells were then counted using an improved 
Neubauer haemocytometer (Weber Scientific, Teddington, UK) after diluting 6 µl of 
cell suspension 1:1 with trypan blue. The cell suspensions were then diluted using 
isotonic buffer to give a final concentration of between 2000-10,000 cells per 60 µl and 
placed back on ice.  
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2.9.7 Preparation of clinical trial samples 
Extraction of peripheral blood lymphocytes (PBL) from whole blood for use within this 
assay is described in section 2.4.1. On the day of the experiment the relevant patients’ 
PBL were removed from -800C storage and thawed at room temperature. The sample 
was then transferred into a clean eppendorf and centrifuged at 500 g for 5 minutes at 
4oC. The supernatant was removed and discarded and the cell pellet re-suspended in 1 
ml of ice-cold PBS. After vortexing the sample was then centrifuged again at 500 g for 5 
minutes at 4oC. The supernatant was discarded and the cell pellet re-suspended in 1 ml 
of ice-cold PBS and washed and centrifuged again as above. Following the second wash 
the supernatant was discarded and the cell pellet re-suspended in 50 µl of ice-cold 
0.15 mg/ml digitonin for 5 minutes to permeabilise the cells. The next steps were 
identical to that described above for the cell line preparation, resulting in a cell 
suspension of PBL of between 2000-10,000 cells per 60 µl. This was then placed back 
on ice and used within one hour of preparation. 
2.9.8 Quality control samples 
As described in section 2.3.1 L1210 cells were used as QC samples in all assays. L1210 
were cultured and stored as necessary in 1 ml aliquots of media (with 10% DMSO) 
containing 1 x 106 cells at -800C. Each time a new batch of L1210 cells was used they 
were tested against the previous batch to ensure that there was no significant inter-
batch difference in the amount of PAR the cells contained. For each assay one aliquot 
of L1210 cells was used and prepared as described in section 2.9.7. 
2.9.9 PARP reaction 
For each sample triplicate reaction tubes were prepared containing 30 µl of Reaction 
Buffer, 5 µl 7 mM NAD+ and 5 µl of oligonucleotide. The reaction tubes and eppendorf 
tubes containing the cell suspensions were warmed to 260C in a shaking water bath. 
After 7 min the cell suspensions were vortexed and 60 µl of each pipetted into the 
reaction tubes. After exactly 6 min for each tube the reaction was stopped by the 
addition of 400 µl of ice-cold 12.5 µM AG014699 and the reaction tubes placed on ice. 
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2.9.10 Immunoblot technique 
Two layers of filter paper followed by a membrane of Hybond N (Amersham 
Biosciences, UK), all pre-soaked in PBS, were placed onto the base plate of 48-well 
purpose built manifold. The top plate of the manifold was screwed down tightly to 
align the wells over the membrane. Following completion of the PARP reaction, 400 µl 
of each reaction tube cell suspension was gently blotted on to each well using a p1000 
Gilson pipette. For each reacted cell suspension sample, an equivalent number of un-
reacted cells from the original cell suspension were loaded onto the membrane, in 
order to give the baseline PAR levels in the cells prior to the reaction. The PAR 
standards and quality control reacted L1210 cells were also loaded. The blotting 
pattern for each assay was recorded in the relevant laboratory books. Suction was 
then applied to the manifold using a Vacusafe aspirator (Integra Biosciences, 
Switzerland) until all the contents of each well had been absorbed onto the membrane. 
400 µl of 10% trichloroacetic acid / 2% sodium pyrophosphate was then pipetted into 
each well and drawn through the membrane using suction. This step was repeated 
using 800 µl 70% ethanol as a fixative. The membrane was then removed from the 
manifold and following 3 x 5 min PBS washes placed in a blocking solution of 5% 
Marvel milk powder (Premier Foods; St Albans, Hertfordshire, UK) and 0.05% Tween-
20 in PBS known as PBS-MT for one hour at room temperature. 
2.9.11 Primary and secondary antibody incubations 
The membrane was then incubated overnight at 40C in mouse monoclonal anti- PAR 
antibody 1.5 mg/ml, donated by Professor Alex Bürkle (University of Konstanz, 
Germany from an established hybridoma clone supplied by Dr Takashi Sugimura, 
National Cancer Centre Research Institute, Tokyo, Japan) diluted 1:1000 in PBS-MT. 
Following this the membrane was then washed in PBS-T to remove any unbound 
primary antibody and incubated in the secondary antibody polyclonal goat anti -mouse 
HRP-conjugated (DAKO; Ely, Cambridgeshire, UK) diluted 1:1000 in PBS-MT for 1 hour 
at room temperature. Following secondary antibody incubation the membrane was 
washed for 1 hour in PBS-T with 5 min changes of the wash. 
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2.9.12 Detection and analysis of chemiluminescence: 
Following the final PBS-T wash, ECL western blotting detection fluid (GE Healthcare; 
Buckinghamshire, UK), (2.5 ml of reagent A + 2.5 ml of reagent B), was pipetted onto 
the membrane ensuring all blotted areas were covered. After one minute the 
membrane was transferred to a dark box and an image of the membrane was acquired 
using a Fuji LAS 3000 camera and imaging software system (Raytest, Sheffield, UK). The 
membrane was placed on the tray in position four; the camera was set to ‘pro’ mode 
to detect chemiluminescence with the iris set to 0.85. A flat frame was applied and 
exposure set to five minutes. The image was then analysed using Aida Image Analyser 
software version 3.28.001 (Raytest; Sheffield, UK). Circular regions were marked out 
over the image corresponding to each blotted well and the luminescence quantified to 
give a result of LAU/mm2 per well. An example of this is shown in figure 3.5 of chapter 
three. The LAU/mm2 values for the un-reacted cells were then subtracted from the 
equivalent reaction cell values giving a result of the PAR produced during the reaction 
step. A standard curve, using non-linear regression, was created using the LAU/mm2 
for the PAR standards using GraphPad prism software version 4.0 (GraphPad Software 
Inc, La Jolla, California, USA). The resulting equation was then used to calculate the 
amount of PAR in each cell sample. PARP activity was then calculated as a % of the 
untreated control samples for each concentration of AG014699 or in the case of the 
clinical samples for each time-point following the AG014699 dosing. 
2.10 PARP-1 expression assay 
2.10.1 Background principles 
Western blotting is a technique developed more than thirty years ago for the detection 
of specific proteins or amino acid sequences (epitopes) in a given cell or tissue extract 
(Burnette, 1981). The process involves the transfer of electrophorectically separated 
proteins from a sodium dodecyl sulphate (SDS)-polyacrylamide gel to a solid 
nitrocellulose membrane. This membrane is then probed with specific monoclonal or 
polyclonal primary antibodies which detect specific epitopes. These bound primary 
antibodies are then detected by secondary antibodies or other immunological agents 
whose interaction can be detected by chemiluminescence or autoradiography. 
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2.10.2 Buffers and solutions 
Laemelli Buffer minus mercaptoethanol and bromophenol blue (LB-ME-BB) consisted 
of 250 nM Tris-HCl (pH = 6.8), 5% SDS and 40% Glycerol. The solution was deemed 
stable for six months. Running buffer (x 1 strength) was prepared on the day of the 
experiment by diluting 100 ml of commercially available Tris/Glycine/SDS running 
buffer (x 10 strength) (BioRad; Hertfordshire, UK) with 900 ml deionised water. 
Transfer buffer (x 2 strength) was prepared on the day of the assay by diluting 160 ml 
of commercially available Novex-Tris Glycine transfer buffer (x 25 strength) (Invitrogen; 
Paisley, UK) with 1840 ml deionised water. Loading dye comprised 52.5 mM 
dithiothreitol and 1% bromophenol blue dissolved in water (pH = 6.8). Blocking buffer 
consisted of PBS with 0.05% Tween-20 and 5% milk powder (Premier Foods; St Albans, 
Hertfordshire, UK). 
2.10.3 Preparation of the PBL lysates 
On the day of the assay the relevant patients’ PBL samples (previously stored in 
freezing medium) were removed from – 800C thawed at room temperature, 
transferred to 1.5 ml eppendorfs and centrifuged at 40C, 500 G for five minutes. The 
supernatant was then removed and discarded. Next 100 l of LB-ME-BB was added to 
the cell pellet together with Pierce protease inhibitor cocktail (x 1 strength), (Pierce; 
Illinois, USA).  
The cell pellet was then resuspended by vortexing and pipetting and placed on ice for 
30 minutes. During this 30 minute period each eppendorf was vortexed every five 
minutes. The lysate was then sonicated (20 microns amplitude) on ice for three times 
five second periods using a Vibra-Cell sonicator (Vibracell; Connecticut, USA). The 
sonicated lysate was then centrifuged at 14000 g for seven minutes at room 
temperature. The supernatant was then transferred to a clean 1.5 ml eppendorf and 
placed on ice. 
2.10.4 Preparation of QC lysates 
For each experiment two aliquots of the K562 cells (cultured as described in section 
2.3.1) were removed from – 800C storage thawed at room temperature and lysates 
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prepared as described in section 2.10.3. The only difference to this was that only 50 l 
not 100 l of LB-ME-BB was added to the cell pellet after the initial centrifugation step. 
2.10.5 BCA protein assay 
In order to determine the amount of protein loaded onto the gel for each sample a 
bioinchoninic acid (BCA) protein assay using the Pierce BCA assay (Pierce; Illinois, USA) 
was performed with each Western Blot. The assay is based on the reduction of Cu2+ to 
Cu+ by peptide bonds in an alkaline medium. BCA chelates with Cu+ in a ratio of 2:1 
forming a purple coloured reaction product. Absorbance of this product can then be 
measured on a MRXTC II Plate Reader (Dynex Technology INC; Virginia, USA) at 570 nm. 
A stock solution of 2 mg/ml bovine serum albumin (BSA) was prepared by diluting 
0.04g BSA in 20 ml LB-ME-BB.  This stock was then diluted, as described in table 2.1, to 
produce the following BSA standard concentrations: 2.00, 1.50, 1.00, 0.50, 0.25, 0.125, 
0.0625 and 0.00 mg/ml.  These standards were then loaded in quadruplicate onto a 96-
well plate as shown in table 2.2.  5 l of each patient and 5 l of each QC sample were 
then transferred to clean labelled eppendorfs containing 45 l of LB-ME-BB to give a 
1:10 dilution. 
10 l of each sample was then loaded in quadruplicate onto the 96-well plate. Next 
190 l of the BCA reagent, mixed as per the manufacturer’s instructions, was added to 
each well. The plate was then incubated at 370C for 30 minutes. The absorbance was 
then measured on the MRXTC II Plate Reader (Dynex Technology INC; Virginia, USA. 
The known concentration of each BSA standard was then plotted against the 
corresponding mean absorbance result at 570 nm. Linear regression analys is was then 
used to calculate the unknown protein concentrations from each patient and QC 
sample. This result was then multiplied by ten to account for the original dilution of 
the sample in LB-ME-BB. For each BCA assay to be valid the R2 must be > 0.9. 
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BSA standard 
(mg/ml) 
Volume (µL) of 2 mg/ml 
stock 
Volume (µL) LB-ME-
BB 
Total Volume 
(µL) 
2.00 500.00 0.00 500.00 
1.50 375.00 125.00 500.00 
1.00 250.00 250.00 500.00 
0.50 125.00 375.00 500.00 
0.25 62.50 437.50 500.00 
0.125 31.25 468.75 500.00 
0.0625 15.63 484.37 500.00 
0.00 0.00 500.00 500.00 
  
Table 2.1: Dilution of 2 mg/ml BSA stock to create the eight BSA standards 
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2.00 
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2 
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1.00 
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0.50 
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0.25 
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10 
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10 
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10 
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10 
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10 
Sample 
11 
Sample 
11 
Sample 
11 
Sample 
11 
0.0625 
  
0.0625 0.0625 0.0625 Sample 
12 
Sample 
12 
Sample 
12 
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12 
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13 
Sample 
13 
Sample 
13 
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13 
0.00 
  
0.00 0.00 0.00 Sample 
14 
Sample 
14 
Sample 
14 
Sample 
14 
Sample 
15 
Sample 
15 
Sample 
15 
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15 
 
 
BSA Standards (mg/ml) Patient and QC samples 
Table 2.2: Loading pattern of standards and samples for BCA assay on the 96-well plate  
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2.10.6 Preparation of PARP-1 standards for electrophoresis 
10 µg/ml PARP-1 standards (Biomol; Exeter, UK) were stored in 15 µl aliquots at – 800C. 
On the day of experiment one vial was removed from storage and placed on ice to 
thaw. To prepare the lower concentrations of the standard curve 2 µl of this PARP-1 
aliquot was removed and mixed by pipetting with 18 µl of LB-ME-BB in a clean 
eppendorf to give a 1:10 dilution. The PARP-1 standards were then made up as shown 
in table 2.3 and placed on ice until needed.  
Volume (µL) of 10 
µg/ml PARP-1 
stock 
Volume (µL) of 1:10 µg/ml       
PARP-1 stock 
Volume (µL) 
of LB-ME-BB 
Final PARP-1 
standard (ng) in 15 
µL volume 
6.00 0.00 9.00 40.00 
3.80 0.00 11.20 25.00 
1.50 0.00 13.50 10.00 
0.00 7.50 7.50 5.00 
0.00 3.70 11.30 2.50 
0.00 0.00 15.00 0.00 
 
Table 2.3 Preparation of PARP-1 standards for electrophoresis 
 
2.10.7 Preparation of cell lysates for electrophoresis 
Cell lysates were diluted in LB-ME-BB with calculations adjusted for the addition of 4 x 
load dye (2.10.2) to each sample. One volume of load dye (x 4) was added to three 
volumes of each sample such that the load dye became x 1 strength for use on the gel. 
When possible both the QC, K562, samples and the patient PBL lysates were loaded at 
30 μg total soluble protein (TSP) protein in a maximum volume of 15 µl per well. In the 
previous validation of this assay it was noted that this level of protein should not be 
exceeded or the signal could become saturated. Once diluted to the required 
concentration the samples were placed into a boiling water bath, for five minutes to 
enable protein denaturation and exposure of the epitope. Samples were then 
immediately loaded into appropriate wells of the gels as described in section 2.10.8. 
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2.10.8 Gel electrophoresis 
One CriterionTM pre-cast (4-20% Tris-HCL) gel (BioRad; Hertfordshire, UK) was removed 
from its case, the white cover slip from the bottom of the gel removed and the gel 
washed briefly in distilled water. The gel was then placed in a BioRad CriterionTM gel rig 
(BioRad; Hertfordshire, UK) and the gel comb removed. The inner well reservoir was 
then immediately filled with the Tris/Glycine/SDS running buffer (x 1), described in 
section 2.10.2, followed by the outer reservoir which was filled to the marked fill line. 
If two gels were run simultaneously the second gel was prepared as above. The gel was 
then loaded from left to right as follows: the first lane was loaded with 4 μl of the 
protein molecular weight marker –MagicMark (Invitrogen; Paisley, UK). MagicMark 
was stored at -20oC and only required defrosting prior to use. 10 µL of each PARP-1 
standard was then loaded in duplicate, followed by duplicate patient samples and 
finally duplicate QC samples. Once loading was completed the top was placed on the 
tank and the BioRad Power Pac 300 (BioRad; Hertfordshire, UK) was set to run for two 
hours at a constant voltage (V) of 100 V. 
2.10.9 Western Blotting technique 
Prior to blotting, two CriterionTM material pads (BioRad; Hertfordshire, UK), two filter 
paper sheets (Whatman; Kent, UK) and one Hybond-C nitrocellulose membrane 
(Amersham Biosciences; Buckinghamshire, UK) all cut to 14 cm x 9 cm, were pre-
soaked in (x 2) Novex transfer buffer. After the gel had run for two hours at 100 V, the 
power was switched off and the gel casing removed. The lower protruding lip of the 
gel was discarded and the pre-cast gel case opened using a flat bladed knife. The top 
10 mm comb section of the gel was then also removed using the blade. The gel was 
then ready for transfer onto the nitrocellulose membrane in the BioRad CriterionTM 
Blotter (BioRad; Hertfordshire, UK). One material pad was placed on the inner side of 
the black section of the transfer case, followed by one filter paper and then the gel. 
The nitrocellulose membrane was then placed on top of the gel (with the upper right 
corner cut), followed by the second piece of filter paper and the second material pad. 
Any air bubbles between the material pads, gel and filter papers were removed by the 
use of a mini-roller. The cassette was then closed and placed into the transfer tank, 
ensuring that the black side of the cassette was closest to the black side of the transfer 
rig. If a second gel was run in section 2.10.8 the procedure was repeated. Finally the 
transfer rig was filled with x 2 transfer buffer and allowed to run for two hours at 100 V. 
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To prevent over-heating during the transfer an ice pack was placed into the rig and the 
rig itself was placed into a container of ice. 
2.10.10 Primary and secondary antibody incubations  
Following transfer the membrane was removed from the cassette and briefly blotted 
dry on tissue paper. It was then transferred to a clean tray, ensuring that the cut right 
hand corner was in place, and blocked for one hour at room temperature under gentle 
agitation with 25 ml of PBS-MT blocking buffer. Next the primary antibody Anti PARP-1 
C2-10 (Trevigen; Maryland, USA) was applied to the membrane diluted 1:2000 in 20 ml 
PBS-MT overnight at 40C using a rotation shaker. The next day the membrane was 
rinsed in three five minute washes of PBS-T (25 ml per wash), before transfer to a 
clean blocking tray and the application of the secondary antibody. The secondary 
antibody - polyclonal goat anti-mouse IgG HRP secondary antibody (Dako; 
Cambridgeshire, UK) was diluted 1:1000 in 20 ml PBS-MT and mixed for one hour with 
gentle agitation on a rotation shaker at room temperature. Following this the 
membrane was finally washed at for one hour at room temperature in PBS-T with 
frequent changes of wash (approximately every five minutes). 
2.10.11 Detection and analysis of chemiluminescence 
Next the membrane was thoroughly drained by holding the edge against absorbent 
paper to remove excess moisture and placed on a sheet of cling film protein transfer 
side up. Then 5.85 ml of solution A was combined with 150 µl of solution B from the 
ECL PlusWestern Blot Detection Kit (GE Healthcare; Buckinghamshire, UK) and mixed 
using vortexing. The entire surface of the membrane was then covered with ECL Plus 
detection fluid and exposed for five minutes. Any excess fluid was drained onto 
absorbent paper and the membrane wrapped in clean cling film, removing any air 
bubble by the use of a roller. The membrane was then transferred to the Fuji LAS 3000 
camera and imaging software system (Raytest, Sheffield, UK). ). The membrane was 
placed on the tray in position two; the camera was set to ‘pro’ mode to detect 
chemiluminescence with the iris set to 0.85. A flat frame was applied and exposure set 
to ten minutes. The image was then analysed using Aida Image Analyser software 
version 3.28.001 (Raytest; Sheffield, UK). Rectangular regions were marked out over 
the image corresponding to each of the PARP-1 standards, QCs and visible patient 
samples as shown in figure 3.7 of chapter three and the luminescence quantified to 
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give a result of LAU per each area (mm2). A standard curve, using non-linear 
regression, was created using the LAU/mm2 for the PARP-1 standards using GraphPad 
prism software version 4.0 (GraphPad Software Inc, La Jolla, California, USA). The 
resulting equation was then used to calculate the amount of PARP-1 (ng) in each cell 
sample. Using the results of the BCA protein assay, this value could then be expressed 
as a value of ng PARP-1 detected per µg of TSP. Patient samples were run in duplicate 
wells on two separate assays and their mean value (ng per µg TSP) calculated as above.  
It was proposed that on completion of the Western blotting assay for all patients 
within the trial, the expression values would be compiled and patients PARP-1 activity 
stratified into five groups based on the scoring system described in table 2.4. The 
rationale behind this was that a semi quantitative scale would limit data errors from 
both intra and inter assay variability, whilst still providing absolute numerical values on 
an individual patient’s expression level. 
0 No signal visible after exposure of the membrane or variability of the generated 
replicates resulting in a CV > 50. 
1 Patients mean expression value falls into the lowest quartile of values 
2 Patients mean expression value falls into the second quartile of expression values  
3 Patients mean expression value falls into the third quartile of expression values  
4 Patients mean expression value falls into the highest quartile of expression values  
   
Table 2.4: Semi-quantitative system for scoring PARP-1 expression levels in patients. CV = 
coefficient of variation. 
 
2.11 Development and validation of an analytical method for the 
determination of AG014447 in human plasma. 
2.11.1 Background Principles 
AG014447 is the parent drug of AG014699 and it is AG014447 that is detected in 
human plasma following administration of AG014699. The AG014699 pharmacokinetic 
(PK) studies for the phase I and II combination TMZ studies were performed by 
Quintiles Preclinical Services, Edinburgh, UK on behalf of Pfizer. However, for this 
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BRCA-PARP phase II study, PK analysis was to be performed in-house. One of the 
objectives of this research fellowship and thesis was to develop and validate an 
analytical method to determine the concentration of the analyte AG014447 in human 
plasma using protein precipitation extraction followed by high performance liquid 
chromatography (LC) with tandem Mass Spectrometry (MS). Validation of this assay to 
GCLP standards was performed by testing an assessment of linearity, range, accuracy 
and recovery, intra and inter-assay precision, lower limit of detection, specificity and 
freeze/thaw stability of AG014447. The assay method is described below. The 
validation report is not included as part of this thesis. 
2.11.2 Analytical system 
The analytical system used was the API4000 LC/MS/MS from Applied Biosystems 
(California, USA) with a series 200 Micro pump, autosampler and Peltier column oven, 
all from Perkin Elmer (Beaconsfield, UK). The column used was the Gemini 3u C18 
110A, 20 x 4 mm supplied by Phenomenex (Macclesfield, UK). A Phenomenex guard 
column (C18 (ODS Octadecyl), 4mm L x 2.0mm) was also used for every run and 
changed after every fifty patient samples. Analysis was performed us ing Analyst 
software version 1.5 (Applied Biosystems; California, USA) 
2.11.3 Preparation of mobile phases 
Prior to use the deionised water and the acetonitrile (Fisher Scientific; Loughborough, 
UK) used to make the mobile phases were filtered through 0.45 µm phenex filter 
membranes using the Phenomenex filtration apparatus (Macclesfield, UK). Mobile 
phase A (10:90 acetonitrile: water + 0.1% formic acid) was prepared by adding 50 ml of 
acetonitrile to 450 ml of deionised water in a 1000 ml measuring cylinder plus 0.5 ml 
formic acid (Fisher Scientific; Loughborough, UK). The solution was then mixed, 
transferred to a 500 ml Duran bottle (Duran group; Wertheim, Germany) and given an 
expiry date of seven days. Mobile phase B (65:35 acetonitrile:water + 0.1% formic acid) 
was prepared by adding 325 ml of acetonitrile to 175 ml deionised water in a 1000 ml 
measuring cylinder followed by 0.5 ml formic acid. The solution was mixed, transferred 
to a 500 ml Duran bottle with an expiry date of seven days. The needle-wash (solution 
C) was prepared by adding 250 ml acetonitrile to 250 ml deionised water in a 1000 ml 
measuring cylinder to give a 50: 50 mix. The solution was then mixed, stored in a 500 
ml Duran bottle and stable for one month. 
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2.11.4 Preparation of AG014447 and deuterated d7-AG014447 stock solutions 
AG014447 and its corresponding internal standard (IS) deuterated d7-AG014447 were 
supplied by Pfizer. Compounds were all weighed out using a Mettler 5 place balance 
(Mettler-Toledo; Leicester, UK). AG014447 1mg/ml stock solution was made by 
weighing out 2 mg AG014447 and dissolving in 2 ml of 100% methanol and stored, 
protected from light, at -200C. Internal standard d-7 AG014447 200 μg/ml stock 
solution was prepared by weighing out 2 mg and dissolving in 10 ml of 100% methanol. 
This was then separated into 1 ml aliquots and stored, protected from light, at -200C. 
2.11.5 Preparation of AG014447 standard curve  
For each analytical run a new standard curve was prepared on the day of experiment. 
The following eight concentrations of AG014447 were prepared in duplicate:  2, 4, 10, 
20, 50, 100, 250 and 500 ng/ml by diluting the 1 mg/ml stock solution in blank plasma 
(supplied by the Blood Bank Service, Newcastle-upon-Tyne, UK) shown in table 2.5. 
The standard curve was determined from the plasma standards by linear regression 
with a 1/x2 weighting of the analyte to IS area ratios using the Analyst programme 
version 1.5. 
1000ng/ml 447 
(ml) 
100ng/ml 447 
(ml) 
10ng/ml 447 
(ml) 
Volume plasma 
(ml) 
Final 
concentration 
AG014447 
(ng/ml) 
0.50   0.50  500.00 
0.25   0.75 250.00 
0.10   0.90  100.00 
 0.50  0.50  50.00 
 0.20  0.80  20.00 
 0.10   0.90  10.00 
  0.40  0.60  4.00 
  0.20  0.80  2.00 
 
Table 2.5: Preparation of AG014447 standard curve 
 
2.11.6 Preparation of QC samples 
For use within each analytical run QC samples for the three concentrations: lowest QC 
(LQC) 2 ng/ml, medium QC (MQC) 50 ng/ml and the highest QC (HQC) 500 ng/ml were 
prepared. These were made up in advance of use and stored at – 200C (stable for five 
months). New batches were tested to ensure consistency with the preceding batch 
prior to use within patient sample analysis. On the day of a run triplicate QCs for each 
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concentration were removed from - 200C and thawed at room temperature. In 
addition to the nine QCs a single blank plasma sample, containing only the IS and a 
double blank sample of plasma only were also prepared. 
2.11.7 Preparation of samples 
On the day of the run 200 μl of each sample (blank plasma, standards, QCs, patient 
samples) were pipetted into 1.5 ml labelled microtubes. To each sample 10 μl of the IS 
at concentration 100 ng/ml was added except to the double blank plasma.  
Some patient samples required dilution 1:10 with blank plasma prior to extraction 
process depending on the dose of AG014699 administered and the sampling time-
point to ensure that the results lay within the standard curve (2 ng/ml to 500 ng/ml). 
Protein precipitation was achieved by the addition of 0.4 ml acetonitrile to each 
sample whilst vortexing. The samples were then centrifuged at 12,000 RCF for 5 min in 
a Heraeus biofuge15 centrifuge (Heraeus Sepatech GmbH; Osterode, Germany). The 
supernatant was then transferred to a labelled 12 x 75 mm borosilicate tube (Fisher 
Scientific; Loughborough, UK) and evaporated to dryness in nitrogen at 40oC using a 
Zymark evaporator (Caliper Life Sciences; Cheshire, UK). The residue was then 
reconstituted in 180 μl of mobile phase A (described above), vortexed and placed in 
autosampler limited volume inserts ready to be run on the LC/MS/MS. 
2.11.8 Order of sample injections 
For each analytical run the samples were tested in the sequence shown in figure 2.2. 
An un-extracted AG014447 sample was always tested before any clinical samples were 
removed from -200C to ensure that the LC/MS/MS system was operational that the 
analyte could be detected to a similar sensitivity to previous runs. 
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Figure 2.2: Flow diagram showing the sequence in which samples were run on the LC/MS/MS 
for each analytical run 
 
 
2.11.9 Preparation of carry over prevention samples 
To eliminate carry-over of the analyte between high and low concentrations, three 
samples of mobile phase A were run after the highest standard (500 ng/ml), the 
highest QC samples and any anticipated high patient samples, for example the end of 
infusion time-points.  
2.11.10 LC/MS/MS conditions 
Mobile phase: pump A - 10:90 acetonitrile: water + 0.1% formic acid, pump B - 65:35 
acetonitrile: water + 0.1% formic acid. Needle wash – 50:50 acetonitrile: water. 
Retention time of the analyte was 2.33 minutes. The time-table used for the gradient 
elution is shown in table 2.6. The settings for the mass spectrometer for analyte 
detection and the parameters for the mass spectrometer environment are shown in 
table 2.7 
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Step Time (min) Flow rate 
(ml/min) 
Gradient % Mobile 
phase A 
% Mobile 
phase B 
1 0.00 0.50 1 100.00 0.00 
2 1.00 0.50 1 100.00 0.00 
3 1.50 0.50 1 0.00 100.00 
4 2.00 0.50 1 0.00 100.00 
5 2.50 0.50 1 100.00 0.00 
6 6.00 0.50 1 100.00 0.00 
 
Table 2.6: Chromatography gradient of mobile phases across the column  
 
 
Compound Q1 mass Q3 mass Dwell (msec) DP (volts) CXP 
AG014447 324.00 293.20 150.00 41.00 14.00 
IS 331.30 297.10 150.00 51.00 10.00 
Parameter 
Collison gas (CAD) 5.00 
Curtain gas (CUR) 50.00 
Ion source gas 1 65.00 
Ion source gas 2 50.00 
Ion spray voltage (IS) 5500.00 
Temperature 500.00 
 
Table 2.7: Mass spectrometer parameters 
 
2.12 Taqman® Real-Time PCR genotyping 
2.12.1 Background Principles  
To determine the single nucleotide polymorphisms (SNPs) within the CYP2D6 gene (*2 
and *4) associated with the metabolism of AG014699 (Plummer et al., 2008) and the 
PARP-1 gene (T2444C) associated with reduced enzyme activity (Lockett et al., 2004; 
Wang et al., 2007), genotyping was performed using Taqman® Real-time Polymerase 
chain reaction (PCR). All reagents and equipment described in this section were 
purchased from Applied Biosystems (Warrington, UK), unless otherwise stated. The 
Real-time and ‘allelic discrimination’ runs were performed on the ABI 7500 Fast System 
operating 7500 Fast system software (Applied Biosystems; Warrington, UK). Taqman® 
Real-time PCR for each SNP under investigation was performed by incubating the DNA 
template with Taqman® genotyping master mix and the specific SNP genotyping assay 
mix which contained two fluorescent probes: VIC and FAM. During the extension cycle 
of PCR these reporter probes are cleaved off specific target sequences and fluoresce. 
This fluorescence is subsequently detected using the ‘allelic discrimination’ software 
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on ABI 7500 Fast system. The programme is set for the VIC probe to denote the 
presence of the wild-type (wt) allele and the FAM probe to denote variant (v) alleles. 
Therefore for any given SNP, wild-type homozygotes (wt/wt) fluoresce only VIC, 
variant homozygotes (v/v) fluoresce only FAM and any heterozygotes (wt/v) will 
contain equal amounts of both VIC and FAM fluoresence. An example of this ‘allelic 
discrimination’ process is shown in figure 2.3. Specific primers for the SNPs under 
investigation were obtained ready for use from Applied Biosystems. The details of 
these ‘off the shelf’ genotyping assays are found in table 2. 8.  
Gene SNP  Taqman® Genotyping assay 
PARP-1 T2444C 
rs 113640 
X 40 assay C_1515368_1 
CYP2D6 C245R (*2) 
rs 16947 
X 20 assay C_27102425_10 
G1846A (*4) 
rs 3892097 
X 20 assay C_27102431_10 
 
Table 2.8: Details of the Taqman® Genotyping assays used for the specific SNPs.  
 
2.12.2 Preparation of the DNA template 
DNA was purified from patients’ whole blood (method described in section 2.4.3) and 
stored at 40C as 10 ng/l working solutions. For each genotyping assay 1 µl of each 
patient’s working solution was added to the reaction mixture. Sample testing was not 
duplicated unless the primary results were inconclusive. 
2.12.3 Preparation of the PCR plate 
All reactions were run on 96-well MicroAmp Fast Optical 0.1 ml PCR plates. The plates 
were loaded with one DNA sample per patient; in addition, three no DNA template 
controls (NTC) and any available known genotype controls for validation were also run. 
Each well of the plate was loaded to contain 1 µl of sample DNA, x1 Taqman® 
Genotyping PCR Master Mix and x1 Genotyping Assay mix (as per table 2.9) made up 
to a total volume of 25 µl with sterile UHP water. The NTC were made as above but 
without the sample DNA. The plate was then sealed with MicroAmp Optical adhesive 
film (to avoid evaporation of reagents during PCR) and centrifuged at 1500g for one 
minute at 40C. 4.2.7. The plate was then immediately loaded into the ABI 7500 Fast 
machine. If there was any delay in loading the plate was stored at 40C whilst waiting 
for machine. 
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2.12.4 PCR 
For all real-time assays the default conditions on the ‘Absolute Quantitation’ plate 
documents were selected. The conditions were: initial hold at 950C for 10 minutes 
followed by a total of 40 cycles at 950C for 15 seconds then 600C for one minute. 
  
 
 
Figure 2.3: Taqman® Real-time PCR allelic discrimination results chart of analysis of the PARP-1 
SNP T2444C (rs 113640, C-1515368) for the BRCA-PARP clinical trial patients.  
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2.12.5 Data analysis 
Following PCR amplification an end-plate read was performed using the Applied 
Biosystems Sequence Detection System. The Sequence Detection System software 
uses the fluorescence measurements made during the plate read to plot fluorescence 
values based on the signals within each well. These plotted fluorescence signals 
indicate which alleles are present in each well and thus the genotype for each patient 
sample can be determined.  
The frequencies of the genotypes were tested in accordance with the principles of 
Hardy-Weinberg. The validity of each assay was confirmed by cross -checking the 
results of known genotype controls. 
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Chapter Three 
3. In vitro studies of the effect of AG014699 in a panel of human 
cell lines with differing BRCA status 
3.1 Introduction 
Assumptions regarding the selective cytotoxicity of single agent PARP inhibitors to 
Homologous Recombination deficient models have been based on studies in non-
cancerous, genetically naïve, BRCA1/2-negative embryonic stem cells; BRCA2-deficient 
Chinese hamster lung fibroblasts and genetically modified human cell lines using the 
potent PARP inhibitors AG14361, KU0058684 and KU0058948 (Bryant et al., 2005; 
Farmer et al., 2005).  In contrast, results of experiments examining the sensitivity of 
human cancer cell lines to single agent PARP inhibitors have been conflicting. For 
example, Gallmeier et al reported that the BRCA2-defective human pancreatic cancer 
CAPAN-1 cells were not sensitive to PARP inhibition (Gallmeier et al., 2005) whereas 
McCabe et al did demonstrate sensitivity of CAPAN-1 cells to the PARP inhibitors 
KU0058684 and KU0058948 (McCabe et al., 2005). In addition, De Soto et al observed, 
in a panel of human breast cancer cell lines, that the BRCA1 negative cell lines: 
HCC1937 and SUM1315MO2, were not significantly more sensitive to the PARP 
inhibitors 3-Aminobenzamide, NU1025 and AG14361 compared to non BRCA mutated 
controls (MCF7 and MDA-MB-231) (De Soto et al., 2006).   
A possible explanation for the conflicting data is that some of these studies were 
conducted using less potent PARP inhibitors than the current clinical candidates.  
Another theory is that these experiments were conducted with human cancer cells 
originating from naturally occurring BRCA1/2 mutations and that the lack of sensitivity 
may reflect the ability of cancer cells to adapt to mutation defects to promote survival; 
a recently recognised enabling characteristic of cancer cells (Hanahan and Weinberg, 
2011).  
Therefore tumours from patients with BRCA1/2 mutations may not be as exquisitely 
sensitive to PARP inhibitors as reported by the pivotal 2005 Nature publications 
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(Bryant et al., 2005; Farmer et al., 2005). In view of the conflicting pre-clinical data, a 
comprehensive study of the therapeutic potential of the PARP inhibitor AG014699 in 
human cancer cell lines with differing BRCA/ HR status and an investigation into the 
mechanism behind any observed selective sensitivity was undertaken.   
3.2 Objectives 
The aims of this study were as follows: 
 To investigate the effect of AG014699 on cell viability and growth using clonogenic 
cell survival assays and sulforhodamine B assays. 
 To determine baseline levels of PARP-1 activity in cell lines and investigate the 
effect of AG014699 on PARP-1 activity.  
 To test the hypothesis that DNA double strand breaks accumulate in cells after 
exposure to AG014699 and that Homologous Recombination functions only in the 
BRCA1/2 proficient cell lines. 
3.3 Materials and Methods 
Materials and methods for the assays listed are described in full in chapter two. 
Deviations from these methods and their reasoning’s are detailed in the individual 
assay results sections.  
A panel of 11 mammalian cell lines were used in this study, characteristics of which are 
detailed in chapter two, Materials and Methods. A summary is provided here in table 
3.1 as an aide-memoire. The panel included two paired HR proficient and deficient cell 
line models; the human BRCA1 mutant breast cancer HCC1937 cell line and the BRCA1 
corrected counterpart HCC1937-BRCA1; and the Chinese hamster ovary (CHO) cell line 
AA8 and its XRCC3-deficient derivative IRS-1SF. The panel also included the 
immortalised human ovarian surface epithelial (OSE) BRCA2 heterozygote cell line, 
OSEC1, and the immortalised human OSE BRCA wt type OSEC2 cell line. 
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Cell line HR/BRCA  status Origin  
MCF7  BRCA 2 wt type, BRCA1 hemizygous  Breast carcinoma cells derived from pleural fluid  
MDA -MB -231  BRCA2 wt type, BRCA1 hemizygous  Primary breast carcinoma cells  
OSEC-2  BRCA1/2 wt type  Ovarian surface epithelial cells  
OSEC-1  BRCA2 heterozygote (4630insA ,exon 11), BRCA1 wt type  Ovarian surface epithelial cells  
UACC3199  Epigenetically silenced BRCA1 by promoter methylation  Primary breast carcinoma cells  
MDA -MB -436  BRCA1 mutated (5396 +IG>A), BRCA2 wt type Breast carcinoma cells derived from pleural fluid  
HCC1937  BRCA1 mutated (5283insC), BRCA2 wt type  Ductal breast carcinoma  
HCC1937 – BRCA1  Transfected wild type BRCA1 , BRCA2 wt type Ductal breast carcinoma  
CAPAN -1  BRCA2 mutated  (6174delT), BRCA1 wt type  Pancreatic adenocarcinoma cells derived from a liver metastasis  
IRS-1SF XRCC3 deficient Chinese Hamster Ovarian surface epithelial cells 
AA8 XRCC3 wt type Chinese Hamster Ovarian surface epithelial cells 
Table 3.1: Cell line characteristics 
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3.4 Results 
To make for easier discussion of the results, cells with BRCA1/2 or XRCC3 mutations 
are grouped by the term ‘HR deficient’ (HR-) and cells with wt type BRCA1/2, XRCC3 or 
heterozygous for BRCA1/2 are grouped ‘HR proficient’ (HR+). As the level of BRCA1 
function in the UACC3199 (BRCA1 methylated) cell line is not known, results for this 
cell line were analysed separately. 
3.4.1 Clonogenic cell survival and Growth inhibition in response to AG014699 
For these studies cells were exposed to increasing concentrations of AG014699 ranging 
from 0.00 to 100.00 µM. Methods for which are described fully in chapter two, 
Materials and Methods. Results are illustrated in figure 3.1 and LC50 values 
summarized in table 3.2. These clonogenic cell survival assays were undertaken jointly 
by Yvette Drew and Suzanne Kyle. 
Clonogenic cell survival assays demonstrated that BRCA mutated human cancer cell 
lines are significantly more sensitive to AG014699 than human cell lines with wild type 
or heterozygote BRCA (mean LC50 = 4.0 ± 2.9 vs. mean LC50 = 25.1 ± 9.2; P < 0.0001). 
Reviewing the data for all nine cell lines tested, the known HR- cells (CAPAN-1, IRS-1SF 
and MDA-MB-436) were 9-fold more sensitive to AG014699 than the HR+ cell lines 
(AA8, MCF7, MDA-MB-231, and OSEC2) (P=0.0001, unpaired t-test).  
Of note, the UACC3199 cell line, with epigenetically silenced BRCA1, had 3-fold greater 
sensitivity than the HR proficient cells (P=0.002, unpaired t-test) and a mean LC50 
within the range of the HR deficient cells (0.9 – 8.3 M). Using the mean LC50 
concentrations of each cell line there was a significant difference between all 3 groups 
- the HR deficient cells, the BRCA1 methylated UACC3199 cells and the HR proficient 
cells (LC50 = 3.3 μM vs. LC50 = 7.6 μM vs. LC50 = 29.7, P <0.0001, 1 way ANOVA), see 
figure 3.2. 
The most sensitive human cancer cell line to AG014699 was the BRCA1 mutated MDA-
MB-436 cell line (LC50 = 1.3 μM). 
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Encouragingly, the sensitivity of the BRCA2 heterozygote, OSEC1 cells (mean LC50 = 
44.8 μM) was within the range observed in the HR proficient cells (16.2 – 58.6 µM) and 
interestingly, less sensitive than the BRCA2 wt type OSEC2 cell line (mean LC50 = 31.6 ± 
11.1 μM). These results infer that PARP inhibition is non-toxic to heterozygote models 
and thus may be safe in BRCA mutation carrier patients.  
 
 
 
 
 
Figure 3.1: Clonogenic survival assays of cells treated with 24 h AG014699 (data presented 0.0-
10.0 µM). Solid symbols/lines = HR proficient’ cells, open symbols/dashed lines = ‘HR deficient’ 
cells. Data are the mean and SEM values for each concentration from ≥ 3 independent 
experiments.   
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Cell line 
 
Mean IC50 M ± SD Mean % survival at  
10 M AG014699 
MCF7 20.2 ±  3.5 66.8 
MDA-MB-231 21.9 ±  2.6 71.2 
OSEC1 44.8 ± 14.3 82.7 
OSEC2 31.6 ± 11.1 83.2 
AA8 50.7 ± 6.9 114.4 
UACC3199 7.6 ± 1.2 43.9 
MDA-MB-436 1.3 ± 0.6 18.3 
CAPAN-1 5.5 ± 2.5 34.4 
IRS-1SF 1.4 ± 0.4 00.5 
 
Table 3.2: Mean IC50 and % Survival at 10 M AG014699 data for cell lines from the clonogenic 
cell survival assays.  
 
 
 
 
 
Figure 3.2: Box and whiskers plot (minimum to maximum) with + showing mean LC50 data for 
the HR proficient, HR deficient and the UACC3199 BRCA1 methylated cell lines. P value 
calculated using 1 way ANOVA demonstrates a significant difference between the 3 groups 
(P=0.0001). 
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The HCC1937 and HCC1937-BRCA1 cell lines had poor cloning efficiency and were not 
appropriate for the clonogenic cell survival assay. As an alternative, the 
sulforhodamine B (SRB) protein dye assay was used to determine cell growth in 
response to AG014699. MDA-MB-231 cells were also evaluated in the SRB assay to 
provide a direct comparison between results from the two cell viability assays. Using 
the SRB assay, BRCA1 deficient HCC1937 cells were significantly more sensitive to 
AG014699 than the BRCA1 complemented HCC1937-BRCA1 cell line (mean GI50 = 10.5 
μM vs. 16.7 μM, P=0.001, unpaired t-test) and the sensitivity of the HCC1937-BRCA1 
cell line was similar to that of the MDA-MB-231 (mean GI50 = 16.5 μM), shown in figure 
3.3. Comparing the two assays the results for the MDA-MB-231 cell line were similar 
with a mean LC50 = 21.9 μM and a mean GI50 = 16.5 μM.  
 
 
 
Figure 3.3: SRB cell growth assays of HCC1937, HCC1937-BRCA1 (blue) and MDA MB 231 cells 
treated with AG014699 (0 - 100µM) for 6 days, data presented for 0.00-30.00 µM. Data are 
mean and SEM values from 3 independent experiments.  
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Cell line 
 
Mean GI50 M ± SD Mean % growth at  
10 M AG014699 
MDA-MB-231 16.5 ±  0.7 63.7 
HCC1937 10.5 ± 0.7 50.3 
HCC1937-BRCA1 16.7 ± 1.1 64.0 
 
Table 3.3: Mean GI50 and % Growth at 10 µM AG014699 data for three cell lines from the SRB 
assays 
 
These experiments demonstrate that HR deficient human and non-human cells of 
cancerous and non- cancerous origin are much more sensitive to AG014699 induced 
cytotoxicity than HR proficient cells of similar origin.  These data suggest that this 
increase in AG014699-induced toxicity is secondary to the HR deficiency and the 
underlying mechanism behind this is investigated in the subsequent experiments.  
Reviewing the LC50 and GI50 data in tables 3.2 and 3.3 respectively, the cut off of 50% 
survival following the exposure of cells to 10 μM AG014699 discriminated between 
those cells with functional HR (>50% survival) and cells with dysfunctional HR (< 50% 
survival) and for this reason a dose of 10 μM AG014699 was chosen for use in 
subsequent experiments. 
3.4.2. Baseline PARP-1 activity and inhibition in response to 10 µM AG014699 
To investigate whether differences in cell line sensitivity to AG014699 were secondary 
to variations in baseline levels of PARP activity or the degree of AG014699-induced 
PARP inhibition we used the validated PAR formation immunoblot assay (Plummer et 
al., 2008). The assay, described in chapter two, Materials and Methods, detects 
maximally stimulated PARP activity as pmol PAR. An example of an immunoblot and a 
typical PAR standard curve are shown in figures 3.4 and 3.5 respectively. PARP activity, 
based on detected pmol PAR, was calculated from the non-linear regression equation. 
Inhibition of activity following AG014699 was then expressed as % of the un-treated 
control value. Un-stimulated PARP activity i.e. endogenous PAR levels for each line was 
also calculated from cell samples that did not undergo the reaction as described in the 
chapter two, section 2.9.1. 
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Figure 3.4: PAR formation immunoblot. Wells 1-6 = PAR standards (pmol) 25, 5, 1, 0.2, 0.04, 
0.00. Wells 7-9 = QC L1210 samples. Well 10 = background. Wells 11-17 = a single patient time-
point with 11-13 being the control reacted samples, 14-16 the reacted cells + AG014699 and 
well 17 = the un-reacted sample showing the endogenous PAR present. 
 
 
 
 
 
 
Figure 3.5 A standard curve showing the non-linear relationship between PAR standards and 
the luminescent arbitrary units (LAU) for a given area detected by the Fuji -LAS imaging system. 
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For this study, cells in culture were pre-exposed to 10 μM AG014699 or control (DMSO) 
for 30 minutes and maximum stimulated PARP activity subsequently assessed. PARP 
activity is expressed as pmol PAR per 106 cells. Results for all cell lines are summarised 
in table 3.4. 
There was a large variation in the baseline levels of PARP enzyme activity between the 
cell lines. For all cell lines mean endogenous baseline PARP activity was 157.40 pmol 
PAR per 106 cells. This ranged from as low as 27.67 up to 594.70 pmol PAR per per 106 
cells, with a CV of 101%. As expected the baseline (maximum stimulated) PARP activity 
levels were higher but there was less inter-cell variation with a mean of 4507.00 pmol 
PAR per per 106 cells, range 881.70 to 8760.00 pmol and CV of 42%. There was a trend 
towards higher baseline endogenous PARP activity in the HR- cell lines compared to 
the HR+ cell lines but this was not statistically significant (mean = 210.2 vs. 112.8 pmol 
PAR per 106 cells, P = 0.34, un-paired t-test). In addition higher activity was seen in the 
HR- cells in a sub-group analysis of the human cancer cell lines but no statistical 
significance (mean = 246.2 vs. 146.2 pmol PAR per 106 cells, P = 0.52), (figure 3.6).  
The results for baseline maximum stimulated activity showed a similar trend with 
higher baseline PAR in the HR- cells (mean = 5046.00 vs. 3968.00 pmol PAR per 106 
cells, P = 0.15, un-paired t-test) and the subset analysis of the HR-human cancer cells, 
but again levels of statistical significance were not met, see figure 3.7. 
To determine whether there was any relationship between the baseline PARP activity 
and sensitivity to AG014699 (represented as LC50), a Pearsons correlation analysis was 
performed. Results, shown in figure 3.8, demonstrate no significant relationship 
between the two parameters (R2 = 0.05, P = 0.32). 
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Figure 3.6: Floating bars showing maximum to minimum and mean values (line) of baseline 
endogenous PARP activity  levels by pmol PAR per 106 cells in HR proficient and HR deficient 
cells for A: all cell lines and B: human cancer cell lines only. Line = mean value and P values 
calculated using un-paired t-test shows no significant difference between the groups. 
 
 
 
 
  Chapter Three - in vitro studies 
98 
 
 
 
Figure 3.7: Floating bars showing maximum to minimum and mean values (line) of baseline 
maximum stimulated PARP activity  levels by pmol PAR per 106 cells in HR proficient and HR 
deficient cells for A: all cell lines and B: human cancer cell lines only. Line = mean value and P 
values calculated using un-paired t-test shows no significant difference between the groups. 
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Figure 3.8: Relationship between baseline PARP activity and AG014699 sensitivity (log10 LC50). 
 
A dose of 10 M AG014699 resulted in > 95% inhibition of PARP activity in all cell lines 
(mean = 96.6%) with no significant difference observed in the degree of inhibition 
between the HR + and the HR- cell lines. Results for certain cell lines are shown visually 
with an immunoblot example in figure 3.9 and the absolute % activity for all cell lines is 
shown graphically in figure 3.10. 
 
Figure 3.9: PAR formation immunoblot showing the affect on PAR levels by reduced 
luminescence following AG014699 treatment in MCF7 and OSEC1 cell lines. 
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Figure 3.10: PARP activity following a 30 min exposure to 10 µM AG014699. Data expressed as % 
activity compared to the un-treated control are the mean (+ SEM) of three independent 
experiments. Note maximum value on y axis is 10% 
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Cell line HR  
status 
Mean PARP activity pmol PAR per 106 cells ± SD 
 
PARP inhibition (%)  
over baseline levels 
(maximum stimulated) Endogenous baseline Maximum stimulated 
Control 
Maximum stimulated 
+ 10 M AG014699 
MCF7 + 75.30 ± 72.20 3901.00 ± 994.00 76.00 ± 73.60 98.05 
MDA-MB-231 + 132.00 ± 31.20 2047.00 ± 1648.00 65.70 ± 21.60 96.79 
OSEC1 + 27.70 ± 27.50 3500.00 ± 2357.00 145.30 ± 214.50 95.85 
OSEC2 + 168.50 ± 21.90 3884.00 ± 2066.00 77.30 ± 79.20 98.01 
AA8 + 42.00 ± 9.20 5633.00 ± 2589.00 72.30 ± 58.60 98.72 
HCC1937-BRCA1 + 231.30 ± 75.40 6373.00 ± 94.30 294.00 ± 86.40 95.39 
UACC3199 - 135.30 ± 20.40 4688.00 ± 1867.00 136.00 ± 14.00 97.10 
HCC1937 - 594.70 ± 157.80 5615.00 ± 2874.00 352.00 ± 230.40 93.73 
MDA-MB-436 - 192.30 ± 51.90 2649.00 ± 975.60 131.00 ± 47.50 95.05 
CAPAN-1 - 62.70 ± 27.10  5830.00 ± 1395.00 106.70 ± 75.00 98.17 
IRS-1SF - 66.00 ± 56.90 5532.00 ± 2125.00 68.30 ± 43.00 98.77 
 
 
 
Table 3.4: Summary data for PARP activity expressed as pmol PAR per 106 cells for all 11 cell lines. SD = standard deviation. Homologous Recombination (HR) 
status + denotes cells with proficient HR and – denotes deficient HR. 
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3.4.3 DNA double strand break formation in response to AG014699 
To determine whether DNA double strand breaks (DSBs) accumulate after exposure to 
AG014699, DSBs were measured using the γH2AX focus Immunofluoresence assay, 
described in chapter two, section 2.7. Time-course experiments were undertaken to 
measure γH2AX foci after cell lines were treated with 10 μM AG014699 in 1% DMSO or 
vehicle control (1% DMSO) for up to 24 hours in culture medium at 37oC.  In addition, 
as a positive control for DNA damage, cells were exposed to 2 Gy (2.5 Gy/minute at 
310 kV and 10 mA) of x-ray irradiation followed by incubation for 30 minutes in culture 
medium at 37oC.   
Results show a very rapid accumulation of DNA DSBs in all cell lines within the first 
hour following exposure to AG014699. Examples of the full time-course for the MCF7, 
UACC3199, MDA-MB-436 and CAPAN-1 cell lines are shown in figure 3.11.     
In contrast, exposure to 2 Gy ionising radiation (IR) resulted in a peak of γH2AX foci at 
30 minutes and disappearance of all foci by 8 hours indicating that DSB repair had 
occurred. The majority of the repair occurred during the first two hours. An example of 
these time-courses for the MCF7 human breast cancer cell line is included in figure 
3.11.  
Results for all 11 cell lines comparing the fold-change in γH2AX after 24 hours of 
AG014699 over the un-treated controls are shown in figure 3.13.  24-hours of 10 μM 
AG014699 resulted in a mean increase of 6-fold (range 1.9-10.2) in H2AX foci 
compared with untreated control cells. Fold change was calculated by dividing the 
mean number foci per 30 nuclei in treated cells by the mean number of foci per 30 
nuclei in control cells. There was no difference between the fold-change between the 
HR+ and the HR– cells when comparing the paired cell lines.  
Of note, the number of H2AX foci after 10 μM AG014699 counted were similar to that 
measured in the cells exposed to 2 Gy IR, see figure 3.14, highlighting the fact that 
AG014699 causes significant DNA damage. This point is also made visually by the 
fluorescent microscopy images of H2AX foci in MCF7 cells following DNA damage 
from IR and AG014699 in figure 3.12. 
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Figure 3.11: γH2AX foci time-course experiments in MCF7, UACC3199, MDA-MB-436 and 
CAPAN-1 cells following continuous exposure to 10 µM AG014699. For comparison, a time -
course experiment following 2 Gy in MCF7 cells is shown. Results are the mean no. of cells with 
≥ 5 foci per nucleus from three independent assays. 
 
 
 
 
 
 
3.12: Immunofluoresence images for control, 2 Gy IR plus 30 minutes incubation and 24 hours 
of 10 M AG014699 treated MCF7 cells. Nuclei are stained blue with DAPI and γH2AX foci 
detected fluoresce in red.  
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Figure 3.13: γH2AX foci following continuous exposure to 24h 10 µM AG014699. Data are fold 
change in foci + SEM for each cell line in 3 independent assays.  
 
 
 
 
Figure 3.14: γH2AX foci following continuous exposure to 24h 10 µM AG014699 and following 
2 Gy + 30 minutes. Data are mean fold change in foci in 3 independent assays.  
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3.4.4 Rad51 foci formation assay as a marker of Homologous recombination 
following AG014699 
Localisation of Rad51 foci at DNA double strand breaks is an essential step in the HR 
repair pathway (Shinohara et al., 1992). The presence of nuclear Rad51 foci is 
considered a marker of functional homologous recombination in cells. To determine 
whether cells were able to repair AG014699-induced DNA DSB by HR, Rad51 foci were 
detected using the immunofluoresence assay described in chapter two, section 2.8. 
Cells were treated with 10 μM AG014699 in 1% DMSO or no drug (vehicle control; i.e. 
1% DMSO) for 24 hours in culture medium at 37o C or 2 Gy IR plus 2 hours incubation 
at 37o C. An incubation of 2 hours following 2 Gy IR was chosen for these experiments 
as previous time-course experiments had demonstrated peak of Rad51 foci two hours 
following DNA damage with IR (unpublished data Yvette Drew, Newcastle University, 
UK). 
Results show the number of Rad51 foci significantly increased in response to 
AG014699-induced DNA damage in cells with no known defect in HR but not in HR 
deficient cells. Examples of fluorescent microscopy images for control, 2 Gy IR plus two 
hours incubation and 24 hours 10 M AG014699 treated MCF7 cells are shown in 
figure 3.15 below. Fold changes in the numbers of nuclear Rad51 foci in the human 
cancer cell lines in response to the three treatments are illustrated in figure 3.16 
 
 
 
Figure 3.15: Immunofluoresence images for control, 2 Gy IR and AG014699 treated MCF7 cells. 
Nuclei stained blue with DAPI and Rad51 foci fluoresce in green.  
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Figure 3.16: Fold-change in Rad51 foci in selected cell lines following; 24h 10 µM AG014699, 
2Gy IR + 2 h incubation over un-treated controls. Data for each cell line (as labelled) is mean 
fold-change + SEM from 3 independent assays. 
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Results for all cell lines following treatment with AG014699 are seen in figure 3.17. The 
data demonstrate a statistically significant increase (mean increase = 3.8-fold, P<0.001) 
in the number of Rad51 foci compared with corresponding untreated control cells in 
the cell lines with functional HR (MCF7, MDA-MB-231, OSEC-2, AA8 and HCC1937-
BRCA1) and in cells heterozygous for BRCA2 (OSEC1). However, AG014699 exposure 
did not cause a significant increase in Rad51 foci in the BRCA1/2 mutated MBA-MB-436, 
CAPAN-1 and HCC1937 cells, the BRCA1 epigenetically silenced UACC3199 cells, or the 
XRCC3-mutated IRS-1SF cells (mean change = 1.0-fold).  
 
Figure 3.17: Rad51 foci Immunofluoresence following continuous exposure to 24h 10 µM 
AG014699. Data are fold change in foci + SEM for each cell line in 3 independent assays.  
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The cell lines were subsequently separated into two groups based on their ability (yes 
or no) to increase nuclear Rad51 levels by ≥ 2-fold over baseline levels following 
AG014699 corresponded exactly to the original HR – and HR+ groupings; with the 
UACC3199 cell line falling into the ‘No’ group. There was, as expected, a difference in 
the sensitivities to AG014699 between the two groups with mean LC50 = 4.6 M in the 
No group significantly lower than the mean LC50 = 29.7 M in the yes group.  
These data suggest that changes in nuclear Rad51 foci in response to AG014699 could 
be used a biomarker of functional HR and should be further investigated. 
 
 
 
 
 
Figure 3.18: Box and whiskers plot of LC50 of AG014699 by cell lines ability to increase Rad51 
foci by ≥ 2-fold in response to 10 M AG014699. The line represents the median values. 
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3.5 Discussion 
Several important observations have emerged from these studies. Firstly, the results of 
cytotoxicity assays demonstrate that PARP inhibition is selectively toxic to human 
cancer cell lines with mutated BRCA1/2 confirming the concept of synthetic lethality. 
In addition, these data demonstrate that inhibiting PARP-1 is synthetically lethal to 
non-germline BRCA mutated cells i.e. those with epigentically silenced BRCA1 or cells 
deficient in XRCC3, suggesting a wider therapeutic role for these novel agents. The 
immunofluorescence studies have shown that DNA damage accumulates with on-going 
AG014699 exposure highlighting the mechanism of action of PARP inhibitor-induced 
cytotoxicity. Results of PARP activity assays confirm that this selective toxicity is not 
due to differences in degree of PARP enzyme inhibition. Finally, Rad51 
immunofluorescence assays have demonstrated that a ≥ 2-fold increase change in 
Rad51 foci after AG014699 can discriminate between HR proficient and deficient cells 
suggesting that this may be useful as a biomarker in patients and requires further 
investigation.  
3.5.1 AG014699 is synthetically lethal in BRCA1/2 mutated and epigenetically 
silenced BRCA1 
Human cancer cell lines with mutated BRCA1 and BRCA2 are sensitive to PARP inhibitor 
therapy. These results support those previously published showing selective sensitivity 
to PARP inhibitors in non-cancer, non-human BRCA1/2-deficient models (Bryant et al., 
2005; Farmer et al., 2005) and contrast with previous studies that failed to show such 
sensitivity in human cancer models (Gallmeier and Kern, 2005; De Soto et al., 2006). 
The BRCA1 mutant MDA-MB-436 cells were the most sensitive human cancer cell line 
to AG014699-induced cytotoxicity. They also formed the lowest number of Rad51 foci 
in response to AG014699, suggesting that these cells had the most profound HR 
deficiency. The highlight of these cytotoxicity experiments is the discovery that BRCA1 
methylated UACC3199 breast cancer cells were sensitive to AG014699 with mean LC50 
significantly lower than the HR proficient cells (7.6 M vs. 29.7; P = 0.002).  
 
The methylation status of BRCA1 in these cells had been confirmed by Valerie 
Deregowski (University of Leven, Belgium) by methylation-specific polymerase chain 
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reaction and a defect in HR is suggested by the observation in these studies that 
prolonged exposure to AG014699 failed to induce a significant increase in Rad51 foci.  
 
These UACC3199 data are highly relevant as they suggest that PARP inhibitors could 
have therapeutic potential in sporadic, non-germline BRCA mutated tumours with 
epigenetic changes in the HR genes. BRCA1 dysfunction by epigenetic gene silencing 
has been reported in 18% of high grade serous ovarian cancers (HGSOC) (Press et al., 
2008) and reduced BRCA1 mRNA expression is known to be a common feature of triple 
negative breast cancers (Turner et al., 2007). Clinical trials of PARP inhibitors in these 
populations are on-going (www.clinicaltrials.gov).  A phase II study investigating the 
single agent role of the PARP inhibitor olaparib recently reported a response rate, as 
assessed by the RECIST; of 24% in the patients with non-germline BRCA mutated 
HGSOC (Gelmon et al., 2011). In addition, PARP inhibitors as maintenance therapy in 
HGSOC is currently being investigated with the interim results of a phase II study 
recently announced (Ledermann et al., 2011). The study randomised patients with 
platinum sensitive (defined by the protocol) HGSOC on a 1:1 basis to olaparib 400 mg 
twice daily or placebo until disease progression. Preliminary results showed a 
significant benefit in progression-free survival (8.4 vs. 4.8 months; P < 0.00001) 
favouring the maintenance olaparib.  
To date no single agent activity has been seen in patients with triple negative breast 
cancer and this may mean that the degree of BRCA1 dysfunction is not enough to 
induce HRD. However the results of further studies are awaited.  
The results of in vivo studies investigating the anti-tumour effect of AG014699 on BRCA 
deficient animal models, including UACC3199 xenografts, are presented and discussed 
in chapter four. 
3.5.2 PARP activity and response to AG014699 
In order to further investigate the underlying mechanisms behind the selective 
sensitivity of HR defective cells to AG014699, levels of baseline PARP activity and PARP 
enzyme inhibition following AG014699 were determined. Results for all 11 cell lines 
showed an increase in the mean baseline PARP activity of the HR deficient vs. the HR 
proficient cell lines but this did not reach statistical significance (P = 0.34). Data for the 
human cancer cell lines showed a higher mean activity in the HR deficient cells vs. 
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proficient cells but again this was non-significant (P = 0.52). Data for the paired human 
breast cancer HCC1937 and HCC1937-BRCA1 cell lines however did show a significant 
difference in endogenous PAR levels with higher levels seen in the HR deficient 
HCC1937 line (mean = 594.7 vs. 231.3 pmol PAR per 106 cells, P = 0.02, un-paired t-
test). These data suggest that PARP activity might be higher in HR deficient cells and is 
supported by the recent report by Gottipati et al that PARP-1 is hyperactivated 
(measured by baseline PAR levels) in BRCA2 deficient replicating cells. The authors 
proposed that HR defective cells may have an over-reliance on PARP-1 and that this 
may, in part, explain their increased sensitivity to PARP inhibitors (Gottipati et al., 
2010).  
PARP activity levels have been measured in patient samples in a number of PARP 
inhibitor clinical trials to determine the efficiency of PARP inhibitors. A recent review 
of these studies proposed that baseline PARP activity levels may be able to determine 
which patients are sensitive to these agents and prove a useful biomarker of HR 
function (Redon et al., 2010).  Results of baseline PARP activity and patient response to 
AG014699 from the phase II BRCA-PARP study are presented and discussed in chapter 
five of this thesis.  
Following a dose of 10 M AG014699 profound inhibition of PARP-1 (>95%) was 
achieved in all cell lines; demonstrating that the PARP inhibitor freely permeated cells, 
binds to and inactivates PARP-1, and that the PARP inhibition persists during cell 
permeabilization and subsequent PARP enzyme stimulation. There was no statistically 
significant difference in the degree of PARP inhibition across the cell lines. This 
suggests that the difference in sensitivity seen in the cytotoxicity assays is unlikely to 
be due to differences in drug delivery or binding and more likely due to differences in 
pathways downstream of PARP enzyme inhibition.  
3.5.3 The mechanism of AG014699 selective cytotoxicity 
The proposed mechanism of selective AG014699 toxicity in HR defective cells is that 
PARP-1 inhibition leads to accumulation of DNA single-strand breaks which during 
replication are converted to DNA double-strand breaks, represented by H2AX foci. In 
HR competent, BRCA1/2-proficient cells, these double-strand breaks will eventually be 
repaired by the error-free HR repair pathway, accompanied by Rad51 foci formation. 
However, in HR-deficient cells, repair does not occur resulting in the accumulation of 
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double-strand breaks and cell death. To investigate this, H2AX and Rad51 foci 
immunofluoresence experiments were undertaken. Results of H2AX 
immunofluoresence assays demonstrate an increase in H2AX foci in all 11 cell lines 
treated with 24 hours 10 µM AG014699 compared with the untreated control cells. 
Results of time-course experiments seen in figure 3.10 confirm that DNA DSBs do 
accumulate with continuous AG014699 exposure with little resolution despite 
functional HR. 
The variation in the absolute numbers of H2AX foci seen between cell lines could be 
secondary to differences in DNA content, S-phase cell fraction, and cell-number 
doubling times between individual cell lines. It is less likely as a result of differences in 
HR status because no difference was found in control cells for the parental BRCA1-
mutated HCC1937 and the BRCA1-corrected HCC1937–BRCA1 cell lines (mean no. foci 
per nucleus = 11.5 ± 3.4 vs. 6.5 ± 0.7, P = 0.12, un-paired t-test).   
The data presented in figure 3.13 shows that a 24-hour exposure to 10 μM AG014669 
induces a level of DNA DSBs similar to that caused by 2 Gy IR.  This raises the question 
could continuous PARP inhibition in BRCA mutation carrier patients be dangerous 
resulting in an accumulation of DNA damage and subsequent genomic instability?  
Encouragingly, the cytotoxicity data from these studies have not shown the BRCA1/2 
heterozygous cell lines to be sensitive to short-term AG014699 exposure. In addition, 
early clinical trials using the continuous dosing schedule of the PARP inhibitor, olapa rib, 
have reported the drug to be well tolerated; although long-term safety data from 
these studies is not yet available (Fong et al., 2009; Tutt et al., 2010; Audeh et al., 2010; 
Gelmon et al., 2011).   
3.5.4 Rad51 as a biomarker of HR 
Rad51 foci formation was assessed in all 11 cell lines following a 24 hour exposure to 
AG014699 or 2 Gy IR plus 2 hour incubation.  Results following AG014699, presented in 
figure 3.13, show that all cell lines have some level of baseline nuclear Rad51 foci but a 
significant increase is only seen in the HR proficient cells, confirming the proposed 
mechanism of PARP inhibitor-induced synthetic lethality.  
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The UACC3199, BRCA1 methylated, cells also failed to increase Rad51 foci significantly 
in response to AG014699 suggesting that the sensitivity to AG014699 observed in 
clonogenic assays is most likely secondary to defective HR.   
A ≥ 2-fold increase in Rad51 foci after AG014699 appears to discriminate between the 
HR proficient and deficient cells. This observation was further tested in a clinical study 
of 25 primary cell cultures derived from ascites from ovarian cancer patients with 
unknown HR status. The study demonstrated that a 2-fold or greater increase in Rad51 
foci following ex vivo treatment with AG014699 could predict subsequent sensitivity to 
the PARP inhibitor AG014699 in cytotoxicity assays with 100% positive predictive 
value. The authors concluded that Rad51 should be further investigated as biomarker 
for HR (Mukhopadhyay et al., 2010).  
However, the use of Rad51 as a biomarker to predict for HR function is problematic. 
For example, these studies have shown the presence of Rad51 foci in the control, un-
treated cells of the known HR – cell lines. This confirms published work by Tarsounas 
et al demonstrating that Rad51 foci form in un-irradiated CAPAN-1 cells. Using laser-
scanning cytometry to determine cell cycle stage, they unequivocally showed the 
Rad51 foci to be S-phase replication associated (Tarsounas et al., 2003).  In addition, 
Henry-Mowatt et al demonstrated that Rad51 localises to chromatin and plays a role in 
the progression of stalled replication forks when they encounter DNA lesions during S 
phase (Henry-Mowatt et al., 2003). These studies show that Rad51 foci form not only 
as part of the HR response to DNA damage but also in a BRCA2-independent manner 
as part of the normal cell cycle.  Interestingly, data for the HR-, BRCA1 mutant 
HCC1937 cell lines shows a significant increase in Rad51 foci following IR over un-
treated controls (mean = 40.33 vs. 12 foci per nucleus, P < 0.0001, un-paired t-test) 
and no significant increase in Rad51 foci following exposure to 10 M AG014699. One 
possible explanation for this is that these foci were all S-phase related and not part of 
the DNA damage HR repair process. Another is that radiation-induced DNA damage is 
heterogeneous and can result in base modifications, inter-strand crosslinks, single 
strand and double strand breaks and recent work by Petermann et al demonstrates 
that IR -induced DNA damage can contribute to the formation of replication-induced 
DSB which can be detected as Rad51 foci (Petermann et al., 2010).  
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These studies all suggest that two distinct Rad51 mediated pathways exist; one 
involved in HR the other localising to the exposed single strand DNA ends during 
replication and that the presence of nuclear Rad51 foci per se cannot be used to reflect 
functional HR.  What is needed are functional assays that can assess changes in Rad51 
foci in real time following DNA damage. But there are problems with these approaches, 
the most obvious is the need to obtain viable, replicating cells; another is the technical 
difficulties in inducing DNA damage ex vivo. In the end such assays may not be 
practical in the normal clinical practice out with a translational study. 
3.6 Conclusions 
To conclude, these in vitro studies demonstrate that the PARP inhibitor AG014699 is 
selectively toxic to cancers defective in HR DNA repair. They have shown that DNA 
DSBs accumulate following treatment with AG014699 and that a subsequent failure to 
activate HR repair underlies this selective toxicity. No significant differences were seen 
in the degree of PARP inhibition or baseline PARP activity levels between the cell lines 
to account for the selective cytotoxicity.  In addition these data have shown the 
epigenetically silenced BRCA1 UACC3199 cell line to be sensitive to PARP inhibition 
suggesting a wider role for PARP inhibitors in cancers defective in homologous 
recombination repair in the absence of germline BRCA mutations. 
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Chapter Four 
4. In vivo studies of the effects of AG014699 in BRCA deficient 
xenografts 
4.1 Introduction 
Data presented in chapter three of this thesis and recently published (Drew et al., 
2011b) have shown that AG014699 is selectively toxic to human cancer cell lines with 
mutations within the BRCA1 and 2 genes. This supports the theory of synthetic 
lethality and adds weight to the original reports demonstrating PARP inhibitor 
sensitivity in non-cancerous and non-human cell lines (Bryant et al., 2005; Farmer et 
al., 2005).  The results of experiments presented in chapter three also highlight that 
cells with defects in the HR repair pathway, other than by BRCA mutation, i.e. by 
methylation of BRCA1 or loss of XRCC3, can also be sensitive to PARP inhibition by 
AG014699.  
At the time this work was undertaken published in vivo data supporting the theory of 
the synthetic lethality of PARP inhibitors in BRCA defective cancers were limited. In 
2005 Bryant et al  had reported that treatment of tumours derived from BRCA2 
deficient V-C8 Chinese hamster lung fibroblast cell line with the PARP inhibitor 
AG14361 [5 days intra-peritoneal (i.p.)] resulted in 3/5 responses including one 
complete remission. There were no responses in the BRCA2 complimented (V-C8+B2) 
xenografts (Bryant et al., 2005), suggesting that anti-tumour activity with AG14361 
occurs only in the xenografts with defective DNA repair capacity. In the sister Nature 
paper Farmer et al investigated the role of the PARP inhibitor KU0058684 in preventing 
the formation of teratocarcinomas in athymic mice after transplantation of BRCA2 
deficient embryonic stem (ES) cells or BRCA2 proficient ES cells. A significant reduction 
was observed in the number of tumours formed in the BRCA2 deficient ES cell lines 
compared to the proficient ES cells. It should be noted that these studies have 
limitations; they used only BRCA2 deficient models and tested non-human and non-
cancerous cell lines. It may be difficult to reproduce these results in genetically more 
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complex models such as human cancers. Therefore the question remained 
unanswered: can PARP inhibitors selectively kill human cancers with BRCA mutations? 
De Soto and colleagues set out to answer this question by investigating the effects of 
different PARP inhibitors on both BRCA1 -/- and BRCA1 +/+ human breast cancer 
xenografts (De Soto et al., 2006). They first compared the in vitro sensitivity of a panel 
of 12 cell lines, including BRCA1-/-, BRCA1+/- and BRCA1 +/+ embryonic stem (ES) cells, 
three murine mammary tumour cell lines and four human breast cancer cell lines with 
differing BRCA1 status, to the PARP inhibitors AG14361, NU1025 and 3-AB. The human 
breast cancer cell lines were MCF7 (BRCA1+/+), MDA-MB-231 (BRCA1+/-), HCC1937 
(BRCA1-/-) and SUM1315M02 (BRCA1-/-). Using clonogenic cell survival and growth 
inhibition assays they observed that the BRCA1-/- mutant ES cells were significantly 
more sensitive to the PARP-1 inhibitor AG14361 than the wild type or heterozygous 
BRCA1 ES cells. The mouse mammary cell lines displayed a similar result, with the 
BRCA1-/- mutant cell being the most sensitive to AG14361. However it was not 
significantly more sensitive than its BRCA1 complemented controls and it was much 
less sensitive to PARP inhibition than the BRCA1-/-mutant ES cell line. Finally the human 
breast cancer cell lines failed to show any selective toxicity by BRCA1 status to 
AG14361-induced PARP-1 inhibition. These findings were confirmed in the in vivo 
studies when nude mice with human breast cancer xenografts of differing BRCA1 
status were exposed to three consecutive days of AG14361 (30 mg/kg) i.p. starting on 
D2, 9 and 16. The authors concluded that non-cancerous, non-human genetically naïve 
BRCA mutant cells were selectively sensitive to PARP-1 inhibitors but not BRCA1 
mutated human cancers. They proposed that this was because human cancers have 
acquired resistance through secondary mutations and suggested that PARP inhibitors 
as single agents do not have a therapeutic role in the treatment of BRCA-mutated 
cancers.  
In view of the limited and conflicting published data, studies were undertaken as part 
of this thesis to develop xenograft models of the BRCA1 mutated human breast cancer 
cell line MDA-MB-436, the BRCA2 mutated human, pancreatic carcinoma cell line 
CAPAN-1 and the BRCA1 methylated breast cancer cell line UACC3199, to investigate 
both the anti-tumour effects and the toxicity of differing schedules of the potent, 
specific PARP-1 inhibitor AG014699 in these models. UACC3199 cells were investigated 
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in order to confirm or refute the in vitro data presented earlier that UACC3199 cell 
lines are also sensitive to PARP inhibition.  
Additionally, in vitro studies have shown BRCA mutant cells to be hypersensitive to 
platinum agents (Bhattacharyya et al., 2000). Therefore the cisplatin analogue, 
carboplatin, was also used to act as a positive control and to investigate combined 
PARP inhibitor anti-tumour activity. 
4.2 Objectives 
The aims of this study were as follows: 
 To establish xenograft models in mice using the following human cancer cell 
lines mutated BRCA1 (MDA-MB-436), mutated BRCA2 (CAPAN-1) and 
epigenetically silenced BRCA1 (UACC3199). 
 To investigate the anti-tumour activity and toxicity of AG014699 in these 
xenografts.  
 To determine whether different scheduling of AG014699 in the above 
xenograft models could affect anti-tumour activity. 
 To investigate the activity of AG014699 combination with carboplatin 
4.3 Materials and Methods 
4.3.1 General animal husbandry 
CD-1 nude mice (female and aged 10–12 weeks) from Charles River laboratories 
(Wilmington, MA) were used in all xenograft experiments. These mice were 
maintained and handled in isolators under specific pathogen-free conditions, with five 
mice per cage and 20 cages per isolator. All experiments involving mice were reviewed 
and approved by the relevant institutional animal welfare committee and then per-
formed according to the UK Coordinating Committee on Cancer Research Guidelines 
for the Welfare of Animals in Experimental Neoplasia and UK law. For these 
experiments, mice were treated with drug or control vehicle between the hours of 
09.00 and 11.00. Treatments were all administered by i.p. injection in the animal’s 
home cage within the animal facility. Mice were killed by cervical dislocation for the 
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following reasons: tumour size was greater than 10 × 10 mm, weight loss was more 
than 15% of baseline, or the study ended as defined a priori. 
4.3.2 Cell line implantation 
MDA-MB-436, CAPAN-1, and UACC3199 xenografts in CD-1 nude mice were used to 
test the efficacy of AG014699 because these models represent BRCA1-mutated, 
BRCA2-mutated, and BRCA1-silenced tumours, respectively. Further characteristics of 
these cell lines and including details of their respective BRCA mutation are found in 
table 3.1 in chapter three. 
Exponentially growing MDA-MB-436, CAPAN-1 and UACC3199 cells were re-suspended 
in phosphate-buffered saline at a concentration of 1 × 107 cells per 50 μl. 50 l of the 
cell suspension was then injected subcutaneously into one site on the right flank of 
each mouse. When sufficient mice (to allow five mice per treatment group) had 
palpable tumours (i.e. ≥5 x 5 mm), the mice were randomly assigned, to avoid bias, to 
treatment groups. Investigators were not blinded to the treatment groups.  
This work was undertaken by Dr Yvette Drew and Dr Evan Mulligan under the 
supervision of Mr Huw Thomas. Details of the individual experiments undertaken for 
each xenograft model are listed below. 
4.3.3 UACC3199  
Treatment groups for mice bearing UACC3199 xenograft tumours in experiment one 
were as follows: control normal saline (10 ml/kg) administered once daily for 10 days, 
AG014699 (25 mg/kg) administered once daily for 10 days or a single dose of 
carboplatin (75 mg/kg) administered on day 1.  Treatment groups in experiment two 
were as follows: control normal saline (10 ml/kg) administered once daily for 5 days of 
a 7-day cycle for six cycles, AG014699 (10 mg/kg) administered once daily for 5 days of 
a 7-day cycle for six cycles or a single dose of carboplatin (75 mg/kg) on day 1. 
4.3.4 MDA-MB-436 
Treatment groups were as follows: control normal saline (10 ml/kg) administered once 
daily for 5 days of a 7-day cycle for six cycles, AG014699 (10 mg/kg) administered once 
daily for 5 days of a 7-day cycle for six cycles or a single dose of carboplatin (75 mg/kg) 
on day 1. 
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4.3.5 CAPAN-1 
The six treatment groups were as follows: (i) control normal saline (10 ml/kg) daily for 
10 days, (ii) AG014699 (10 mg/kg) once a day for 10 days, (iii) AG014699 (10 mg/kg) 
once daily for 5 days of a 7-day cycle for six cycles (iv) a single dose of carboplatin (75 
mg/kg) on day 1, (v) a combination of carboplatin (75 mg/kg) on day 1 and AG014699 
(10 mg/kg) once a day for 10 days or (vi) a combination of carboplatin (75 mg/kg) on 
day 1 with AG014699 (10 mg/kg) once a day for 5 days of a 7-day cycle for six cycles. 
4.3.6 Rationale for dose and schedule of AG014699 
The initial schedule and dose of AG014699 selected for these in vivo experiments was 
25 mg/kg i.p. once daily for ten consecutive days. A dose of 25 mg/kg in mice has been 
shown (unpublished data by Huw Thomas, Newcastle University, UK) to give 
equivalent plasma drug concentrations to that measured in patients who received a 12 
mg/m2 dose of AG014699 in the phase II combination study (Plummer et al., 2006). 
This dose, when given intermittently i.e. D1-5 of a 21 D cycle for six cycles, has also 
been shown to be safe and non-toxic in BRCA2+/- transgenic mice (Drew et al., 2011). 
At the time these experiments began a more prolonged or even a continuous dosing 
schedule of AG014699 had not been considered. It was not until preliminary data from 
these in vivo experiments and clinical efficacy data from the PARP-BRCA phase II 
clinical trial became available that this was proposed. These interim data suggested 
that longer, more sustained PARP inhibition might be necessary to improve the anti -
tumour activity of AG014699 in BRCA-defective cancers. Therefore subsequent 
experiments investigated the prolonged AG014699 regimen of 10 mg/kg once daily for 
5 days of a 7 day cycle for six cycles.  
4.3.7 Use of carboplatin 
The cytotoxic platinum analogue carboplatin was developed in the late 1980s at the 
Institute for Cancer Research, London, UK (Harrap, 1985). It acts by covalently binding 
to DNA to form intra-strand and inter-strand DNA cross-links. These DNA adducts then 
inhibit DNA synthesis, function and ultimately its transcription. Carboplatin forms the 
backbone of treatment for many cancers including ovarian cancer, small and non-small 
cell lung cancers, germ cell tumours and head and neck cancers (Chu E and DeVita V., 
2010). It is postulated that a patient’s BRCA status may modulate their subsequent 
response to the platinum agents. Pre-clinical studies have shown that cancer cell lines 
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with mutations in either the BRCA1 or BRCA2 genes are more sensitive to the platinum 
analogue - cisplatin than their wild type matched controls (Bhattacharyya et al., 2000; 
Tan et al., 2008; Tassone et al., 2003). Tassone and colleagues demonstrated that the 
BRCA1 mutated human breast cancer cell line HCC1937 was significantly more 
sensitive to cisplatin than MCF7 (BRCA1 wild type) and the MDA-MB-231 (BRCA1 
heterozygote) cell lines. In addition, the HCC1937 cancer cell line was shown to be less 
sensitive or even resistant to the anti-microtubule agent paclitaxel (Tassone et al., 
2003). Small retrospective studies in patients with ovarian cancer (discussed in chapter 
one, section 1.3.6) also suggest that BRCA mutation carriers respond better to 
carboplatin than non-carriers (Tan et al., 2008).  
This question of platinum sensitivity and taxane resistance in BRCA mutation carriers 
has not yet been proven in a randomised clinical trial setting. However, a phase II trial 
is currently ongoing randomising patients with BRCA1/2 mutated breast cancer at first 
presentation of metastatic disease to six cycles of carboplatin or standard treatment 
with the anti-microtubule agent docetaxel (www.brcatrial.org).  
In light of all these data, it was considered important to investigate carboplatin in 
these experiments. Firstly, to act as a positive control for DNA damage, secondly to 
enable any observed anti-tumour effects of the PARP inhibitor AG014699 to be directly 
compared with a cytotoxic to which these xenografts should be sensitive, and finally to 
investigate anti-tumour effect and toxicity of the combination. 
4.3.8 Anti-tumour response assessment 
Mice were weighed and tumour volumes determined daily from two-dimensional 
calliper measurements using the equation: 
 a2 × b/2, where a = width and b = length of the tumour.  
Tumour data are presented in the results section as the dimension-less parameter, 
relative tumour volume (RTV). For example, RTV1 is the tumour volume on the first 
day of treatment (day 0), RTV2 is two times larger than RTV1; RTV3 is three times 
larger than RTV1 and so on. Tumour growth delay (TGD) was measured in days using 
the formula:  
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TGD = Time to specified RTV in treatment group (days) – Time to specified RTV in control group 
(days) 
Any additional effect of combining AG014699 to the cytotoxic carboplatin on tumour 
growth delay (TGD) was assessed by measuring % Enhancement (E) using the formula:    
 % E = [(TGD of the combination treatment/TGD of cytotoxic alone) × 100] - 100. 
4.3.9 Statistical analysis 
Values relating to the comparison of means are generated using un-paired t-tests for 
comparisons of two means or one way analysis of variance (ANOVA) for comparisons 
of greater than two means.  All statistical tests were considered significant if the P 
value < 0.05. Statistical tests were two-sided. 
 
4.4 Results 
All in vivo data and statistical analysis are summarised in table 4.1 and results of 
individual experiments are analysed and discussed in the relevant text. To facilitate 
interpretation of these results a key is provided in figure 4.1 below. Each symbol and 
line pair represents a different treatment arm and is used consistently throughout the 
figures in this chapter. The only exception is  in figure 4.8 and 4.9 where the D 1-10 
schedule of AG14699 is dosed at 10 mg/kg rather than 25 mg/kg. 
 
Figure 4.1:  Key for in vivo experimental treatment arms. 
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4.4.1 Epigenetically silenced BRCA1 UACC3199 xenografts: experiment one 
Of the 30 mice implanted with epigenetically silenced BRCA1 UACC3199 cells, only 15 
developed tumours by day 40. These 15 mice were then randomly assigned to the 
following treatment groups (five mice per group): normal saline control (10 ml/kg D1-
10), AG014699 (25 mg/kg daily for D1-10) or carboplatin (single dose of 75 mg/kg on 
D1). The fifteen tumours that developed did so at different rates with a lag time from 
implantation to palpable tumour (≥ 5 mm x 5 mm) ranging from 21 to 32 days. Due to 
this variable lag time, there was an up to seven-fold variation in the individual tumour 
volumes (range = 33 mm3 – 242 mm3) when the treatments were initiated on day one. 
However, the mean tumour volumes of the five mice in each treatment group: control 
(99 mm3), AG014699 (105 mm3) and carboplatin (122 mm3) did not differ significantly 
(99 vs. 105 vs. 122 mm3; P = 0.87). Following day one of treatment, the UACC3199 
tumours in all three groups grew relatively slowly; the control tumours reached only a 
mean RTV of 2.63 at day 10. However, because of the large range of tumour volumes 
at day one, by day 12 at least 2/5 mice in each group had to be killed because their 
individual tumour burden was greater than the specified 10 × 10 mm. For this reason 
and to make for more accurate comparisons of the results, only the data collected up 
to and including day 12 are presented here. Results for the RTV over time of each 
individual mouse within each treatment group are shown in figure 4.2 with mean data 
for each treatment arm presented in figure 4.3. 
RTV at day 10 in the AG014699-treated group was significantly less than that in the 
saline-treated control mice (RTV = 1.55 vs. 2.63; P = 0.02). Reviewing the data shown in 
figure 4.3 it appears that during the 10-day dosing period of AG014699 tumour growth 
is retarded or even arrested, with no significant change in mean RTV at D10 from the 
mean RTV at D2 (RTV D10 = 1.55 vs. RTV D2 = 1.27; P = 0.44). However, as the graph 
shows, when AG014699 treatment was stopped tumour growth increased significantly; 
comparing mean RTV at D12 with D10 (RTV D10 = 1.55 vs. RTV D12 = 2.80; P = 0.02).  
In response to carboplatin (75 mg/kg D1) no difference in tumour growth was 
observed until D9 when a slowing of tumour growth was detected. Mean RTV on D10 = 
1.72, but this was not significantly different from the mean RTV in the control group at 
the same time-point (RTV D10 = 1.72 vs. RTV D10 = 2.63; P = 0.13). 
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This experiment demonstrated that AG014699 suppressed UACC3199 tumour growth 
only during the dosing period. One possible explanation for this is that PARP enzyme 
inhibition was not sustained for long enough in this experiment allowing recovery of 
PARP activity and tumour re-growth. Therefore a more prolonged AG014699 schedule 
was subsequently evaluated. 
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Figure 4.2: Experiment one: UACC3199 xenograft tumour growth in CD-1 nude mice. Growth, 
calculated as the relative tumour volume (RTV) after each treatment, is shown as a function of 
time from the start of treatment. A: Saline control 10 ml/kg i.p. D 1-10, B: AG014699 25 mg/kg 
i.p. D 1-10 and C: Carboplatin 75 mg/kg D1. 
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Figure 4.3: Experiment one: UACC3199 xenografts mean tumour growth in CD-1 nude mice. 
Results are mean RTV + SEM. Solid circles and line = saline vehicle alone; open circles and solid 
line = AG014699 (25 mg/kg per day for 10 days); open triangles and dashed line = carboplatin 
(single dose of 75 mg/kg on day 1). 
 
4.4.2 Epigenetically silenced BRCA1 UACC3199 xenografts: experiment two 
In this study, 40 mice were implanted with UACC3199 cells. Treatment was 
commenced 42 days later when nine mice had confirmed tumours (i.e. when there 
were sufficient mice for at least three per treatment group). Mice were randomised to 
the following treatment groups: normal saline control (10 ml/kg daily for 5 days of a 7-
day cycle for six cycles), AG014699 (10 mg/kg daily for 5 days of a 7-day cycle for six 
cycles; known as the prolonged schedule), or as in experiment one; carboplatin (75 
mg/kg) single dose on D1.  Comparing the groups, growth of the xenografts was more 
consistent than the previous experiment, with up to five-fold variation in the individual 
tumour volumes (range = 15 mm3 – 79 mm3) when treatments were initiated on day 
one. In addition, there was no significant difference in the mean tumour volumes of 
each treatment group on day one (control = 38 mm3 vs. AG014699 = 55 mm3 vs. 
carboplatin = 45 mm3; P = 0.31).  
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Figure 4.4: Experiment two: UACC3199 xenografts tumour growth in CD-1 nude mice. RTV is 
shown as a function of time from the start of treatment. A: Saline control 10 ml/kg i.p. D 1-5 of 
a 7 day cycle for 6 cycles, B: AG014699 10 mg/kg i.p. D 1-5 of a 7 day cycle for 6 cycles and C: 
Carboplatin 75mg/kg D 1. 
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Results for the RTV over time of each individual mouse within each treatment group 
are shown in figure 4.4 with mean data for each treatment arm presented in figure 4.5. 
The mean time to RTV5 in saline-treated control mice was 25.2 days and this was 
extended by 37% to 34 days in the AG014699-treated mice, representing a significant 
tumour growth delay of 9.1 days over untreated controls (P = 0.05). For the 
carboplatin-treated mice, the time to RTV5 increased by 45%, again representing a 
significant 10.4-day tumour growth delay (P = 0.02) (figure 4.5 and table 4.1). 
Importantly, treatment with AG014699 appeared to be non-toxic to these mice, with 
the maximum weight loss among treated mice being 6.6% compared to 3% in control 
mice. Carboplatin caused marginal toxicity, with the maximum weight loss being 9.6%. 
 
 
Figure 4.5: Experiment two: UACC3199 xenografts mean tumour growth in CD-1 nude mice. 
Results are mean RTV +SEM. Solid circles and line = saline vehicle alone; open circles and 
dashed line = AG014699 (10 mg/kg D1-5 every 7 days for 6 cycles); open triangles and dashed 
line = carboplatin (single dose of 75 mg/kg on day 1). 
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4.4.3 BRCA1 mutated MDA-MB-436 xenografts  
In light of the data from the UACC3199 xenografts, which suggested that greater anti-
tumour activity may be seen following a more sustained PARP inhibition, the 
prolonged schedule of AG014699 was chosen for the studies with MDA-MB-436 
xenografts. Unfortunately, only 15 out of 50 mice that were implanted with MDA-MB-
436 cells developed tumours. This poor xenograft take rate (30%) meant that only 
three treatment arms were possible in this experiment and so the AG014699 schedule 
was compared to a matched saline control group and a single dose of Carboplatin (75 
mg/kg) on D1 group. It had been intended to compare both the schedules of 
AG014699 tested in the UACC3199 studies. Treatment for all three arms began 44 days 
after implantation. On day one of treatment there was an up to a nine-fold variation in 
the volumes of the individual tumours (range 14 mm3 – 135 mm3). However there was 
no significant difference comparing the mean tumour volume of each treatment group 
(control = 46 mm3 vs. AG014699 = 70 mm3 vs. carboplatin = 44 mm3; P = 0.48). 
The results for individual mice within each treatment group are shown in figure 4.6 
with mean data presented in figure 4.7 and summary data in table 4.1. These data 
demonstrate that AG014699 significantly delayed tumour growth with mice reaching 
RTV4 in 29 days when compared to tumours in untreated control mice, which reached 
RTV4 after 19 days (P = 0.03). Of note, in the AG014699-treated group, one mouse had 
a transient complete tumour regression (i.e. no detectable tumour) between days 15 
and 17. The MDA-MB-436 tumours were extremely sensitive to carboplatin treatment 
(see figure 4.6 C), with complete tumour regressions observed in three mice; one on 
days 17–50, the second on days 20–34 and the third mouse experiencing a sustained 
durable complete tumour regression from day 15 until it was killed at the end of the 
study. Time to RTV4 in the tumours of the remaining two mice were 57 and 63 days; 
giving a mean RTV4 of 60 days,  significantly higher than that seen in the untreated 
control group (60 vs. 19 days; P = 0.001). 
AG014699 was again found to be non-toxic in this study, with the maximum weight 
lost in AG014699-treated mice being 4% and compared to 6.4% in control mice. Carbo-
platin, however, caused considerable toxicity, with maximum weight loss being 13%. 
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Figure 4.6: MDA-MB-436 xenografts tumour growth in CD-1 nude mice.  RTV is shown as a 
function of time from the start of treatment. A: Saline control 10 ml/kg i.p. D 1-5 of a 7 day 
cycle for 6 cycles, B: AG014699 10 mg/kg i.p. D 1-5 of a 7 day cycle for 6 cycles and C: 
Carboplatin 75mg/kg D 1. 
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Figure 4.7: MDA-MD-436 xenografts mean tumour growth in CD-1 nude mice. Results are 
mean RTV +SEM. Solid circles and line = saline vehicle alone; open circles and dashed line = 
AG014699 (10 mg/kg D1-5 every 7 days for 6 cycles); open triangles and dashed line = 
carboplatin (single dose of 75 mg/kg on day 1). 
 
4.4.4 BRCA2 mutated CAPAN-1 xenografts 
All 40 CD-1 nude mice implanted with CAPAN-1 cells developed tumours. This 100% 
take rate meant that multiple schedules of AG014699 could be directly compared 
within the same controlled study. Thus, 15 days after implantation, mice were 
randomly assigned to one of the following six treatment groups: saline control (10 
mL/kg) daily for 10 days, AG014699 (10 mg/kg) once a day for 10 days, AG014699 (10 
mg/kg) once daily for 5 days of a 7-day cycle for six cycles, a single dose of carboplatin 
(75 mg/kg) on day 1, a combination of carboplatin (75 mg/kg) on day 1 with AG014699 
(10 mg/kg) once a day for 10 days, or a combination of carboplatin (75 mg/kg) on day 1 
with AG014699 (10 mg/kg) once a day for 5 days of a 7-day cycle for six cycles. 
On day one of treatment there was an up to a six-fold variation in the size of the 
individual tumours, with volumes ranging from 10 mm3 to 61 mm3. Statistical analysis 
of the mean tumour volume of each treatment group showed no significant 
differences between the groups except when comparing the AG014699 prolonged 
  Chapter Four – in vivo studies 
131 
 
schedule (45 mm3) with the combination of carboplatin (75 mg/kg) day 1 and 
AG014699 (10 mg/kg) once a day for 10 days arm (23 mm3; P > 0.05). 
Results for individual mice from each treatment group are shown in figure 4.8 with 
mean data presented in figure 4.9. The data for mean RTV presented in figure 4.9 is 
presented as two figures (A and B) to make for easier visual interpretation.  
The most toxic regimen in terms of weight loss was Carboplatin in combination with 
the prolonged AG014699 course which resulted in maximum weight loss of 6.3% 
compared to < 5% seen in the other groups.  
The mean time to RTV4 in the saline-treated control group was 11.5 and this is 
consistent with previous published reports (Van der Heijden et al., 2005). 
 A single dose of carboplatin (75 mg/kg) on D1) resulted in one complete tumour 
regression and a statistically significant longer mean time to RTV4 of 18 days (P = 0.03) 
compared with that of the control mice.  
Treatment with AG014699 for 10 days resulted in an approximate doubling of the 
mean time to RTV4 to 24 days equivalent to a 12.5-day growth delay and significantly 
different from the controls (P = 0.02). This TGD was further improved when the longer 
schedule of AG014699 was applied. The prolonged schedule of AG014699 resulted in a 
27.5-day growth delay compared with the control mice (i.e. time to RTV4 of 39 days vs. 
11.5 days; P = 0.02). These results generate the hypothesis that degree of PARP 
inhibition and duration of PARP inhibition are both important for tumour cell kill. 
The best anti-tumour responses were seen in the combination of AG014699 and 
Carboplatin treatment arms. Carboplatin combined with AG014699 (10 mg/kg) once 
daily for 10 days resulted in two complete tumour regressions (one at day 28 and the 
other at day 35) and a significant tumour growth delay of 27.5 days over the control 
group (mean time to RTV4 = 39 days ; P = 0.04). The most effective regimen in terms of 
longer time to RTV4 was the carboplatin with AG014699 given on the prolonged 
schedule.  
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Figure 4.8: CAPAN-1 xenograft tumour growth as RTV in CD-1 nude mice. A: Control (saline daily for 10 days). B: Carboplatin (75 mg/kg on day 1). C: AG014699 (10 
mg/kg daily for 10 days). D: AG014699 (10 mg/kg daily for days 1-5 of a 7-day cycle for six cycles, prolonged schedule). E: Combination therapy with carboplatin 
(75 mg/kg on day 1) + AG014699 (10 mg/kg daily for 10 days). F: Combination therapy with carboplatin (75 mg/kg on day 1) + AG014699 prolonged schedule. 
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Figure 4.9 CAPAN-1 xenografts mean tumour growth in CD-1 nude mice. Results are mean RTV 
+SEM. A: Solid circles and solid line = saline control; open circles and solid line = AG014699 (10 
mg/kg D1-10); open circles and dashed line = AG014699 (10 mg/kg D1-5 every 7 days for 6 
cycles) B: Solid circles and solid line = saline control; open triangles and dashed line = 
carboplatin (single dose of 75 mg/kg on day 1); solid triangles and solid line = carboplatin 
(single dose of 75 mg/kg on day 1) + AG014699 (10 mg/kg D1-10); solid triangles and dashed 
line = carboplatin (single dose of 75 mg/kg on day 1) +AG014699 (10 mg/kg D1-5 every 7 days 
for 6 cycles 
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This regimen resulted in two complete tumour regressions (one at day 7 and the other 
at day 12) and a mean tumour growth delay of 36.5 days in the remaining tumours. 
This gave a mean RTV4 = 48 which is significantly higher than the untreated control 
group (mean time to RTV4 = 48 days vs. 11.5 days; P = 0.01).  
The addition of AG014699 (in both schedules) to carboplatin resulted in greater 
tumour growth delay than the use of carboplatin alone as measured by % 
Enhancement (E). With the ten day AG014699 schedule resulting in 323% increase in 
efficacy and the more prolonged AG014699 schedule of treatment over six weeks a 
461% increase, see table 4.1. 
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Xenograft and treatment Mean time (D) to 
RTV4 (95%CI) 
Mean time (D) to 
RTV5 (95%CI) 
Mean TGD (D) Enhancement 
(%) 
No. CRs P 
(A) UACC3199       
Control saline (10 ml/kg D1-5 every 7D x6)  25.2 (14-36) N/A  0/5  
AG014699 (10 mg/kg D1-5 every 7D x 6)  34.25 (25-46) 9.1  0/5 0.05 
Carboplatin (75 mg/kg D1)  35.60 (26-44) 10.4  0/5 0.02 
(B) MDA-MB-436       
Control saline (10 ml/kg D1-5 every 7D x6) 19 (9.4-25)  N/A  0/5  
AG014699 (10 mg/kg D1-5 every 7D x6) 29 (13-45)  10  1/5 0.03 
Carboplatin (75 mg/kg D1) 60 (57, 63)*  41  3/5  
(C) CAPAN-1       
Control saline (10 ml/kg D1-5 every 7D x6) 11.5 (4-20)  N/A  0/5  
AG014699 (10 ml/kg D1-10)  24 (7-44.8)  12.5  0/5 0.02 
AG014699 (10 mg/kg D1-5 every 7D x6) 39 (27-50)  27.5  0/5 0.02 
Carboplatin (75 mg/kg D1) 18 (1-35)  6.5  1/5 0.03 
AG014699 (10 ml/kg D1-10)  + Carboplatin (75 mg/kg 
D1) 
39 (22.8-55.4)  27.5 323 2/5  
AG014699 (10 ml/kg D1-5 every 7D x 6) + Carboplatin 
(75 mg/kg D1) 
48 (10.9-86.3)  36.5 461 2/5 0.01† 
 
Table 4.1: Summary of in vivo efficacy data, following treatment with: saline control, AG014699 or Carboplatin. Data are mean and 95% CI unless < 3 tumours 
were available for evaluation* due to tumour regressions. P values are shown comparing treatments to un-treated controls, with the exception of † which 
compares the combination treatment to carboplatin alone. D = days, CI = confidence interval, CR = Complete remission. 
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4.5 Discussion 
Three important observations have emerged from these studies. Firstly, a prolonged 
exposure to the PARP inhibitor AG014699 is needed for single agent anti-cancer 
activity. Secondly, inhibiting PARP-1 is synthetically lethal to epigentically silenced 
BRCA1 xenograft models confirming the in vitro data presented in the previous 
chapter. Thirdly, that the platinum analogue carboplatin has anti-tumour activity in 
BRCA1 and 2 defective xenografts as a single agent and in combination with 
AG014699. 
4.5.1 Schedule of AG014699 matters 
These xenograft studies have shown that the PARP inhibitor AG014699 has activity 
against BRCA defective cancers and that duration of exposure, in addition to dose, of 
the PARP inhibitor is important in terms of its single agent anti-tumour effect.  
The UACC3199 experiments investigated two schedules of AG014699:  (1) 10 mg/kg D1 
-10 and (2) 10 mg/kg D1-5 every 7 days for 6 weeks. Reviewing both sets of data, 
summarised in table 4.1, it appears that the longer and more sustained inhibition of 
PARP provided by the prolonged schedule two resulted in better anti-tumour effect. 
This effect was also seen in the CAPAN-1 experiments, which investigated the same 
two single agent schedules of AG014699. The results, shown in figures 4.8C and 4.8D 
and table 4.1, are clear; the prolonged regimen of AG014699 resulted in a longer TGD 
and a significantly longer time to RTV4 than the ten day AG014699 dosing schedule. 
This is illustrated further in figure 4.10 which shows the data for both schedules head 
to head together with the exposure to AG014699. 
Interestingly, single agent AG014699 (in both schedules) was shown to be at least as 
equivalent to a single dose of carboplatin in the UACC3199 and CAPAN-1 studies. In 
addition, the anti-cancer activity of AG014699 came at a lower cost in terms of toxicity 
than the carboplatin. 
 These data suggest that PARP inhibitors should be evaluated against carboplatin in 
randomised clinical trials of selected cancer patients.  
Results of the BRCA1 mutated MDA-MB-436 in vivo experiments, shown in figures 4.6 
and 4.7, demonstrate that MDA-MB-436 tumours are sensitive to the anti-cancer 
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activity of AG014699. Treatment with the prolonged schedule resulted in significant 
delays in tumour growth; with tumours reaching RTV4 in 29 days compared to 19 days 
in tumours of untreated control mice. These data support the in vitro findings in which 
the MDA-MB-436 cell lines were the most sensitive to AG014699 in clonogenic cell 
survival assays (mean IC50 = 1.3 M). 
The low implantation rate of the UACC3199 and the MDA-MB-436 cell lines meant that 
multiple treatment arms in these experiments were not possible and that the two 
schedules of AG014669 were not investigated within the same controlled experiment. 
This limits the interpretation of the results; in addition one might question the 
accuracy of any comparison of the results. However, the studies in the CAPAN-1 
xenografts were tested within the same controlled experiment and these results 
demonstrate superiority of the prolonged AG014699 schedule, confirming the 
hypothesis that prolonged exposure to AG014699 is better.  
The scientific explanation for this greater anti-tumour effect is that single agent PARP 
inhibitor cytotoxicity is dependent on cells replicating. That is, for unrepaired SSBs to 
become DSBs or lethal stalled replication forks, cells must go through S-phase of the 
cell cycle. If PARP is inhibited for short periods of time only a fraction of the total 
cancer cell population will have passed through S-phase and been affected. However, 
if the time of PARP inhibitor exposure is prolonged, the greater percentage of the cells 
will have been in S-phase during the PARP enzyme inhibition and the greater the cell 
kill. Therefore, during schedule two of AG014699 dosing it is proposed that PARP-1 is 
fully inhibited for five days allowing the accumulation of DNA double strand breaks, 
stalled replication forks and cell death. The 48 hours without treatment is then not 
enough time for PARP enzyme activity levels to recover to 100% and the damage to 
cells continues. PARP activity is furthered inhibited when the treatment cycle re-starts. 
Whereas in the simple ten day dosing regimen (schedule one) full recovery of PARP 
enzyme function and loss of the synthetic lethality will eventually occur. This theory 
may also explain the lack of selective cytotoxicity of AG14361 in BRCA1 mutated breast 
cancer xenografts presented by De Soto and colleagues as intermittent (30 mg/kg i.p. 
for 3 days on D2, 9 and 16) AG14361 dosing was used (De Soto et al., 2006). 
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What is not known is how long it takes for PARP enzyme activity to recover following a 
single dose of AG014699. Pharmacodynamic studies in mice measuring changes to 
PARP activity levels over time after AG014699 doses are planned and the results will 
greatly inform future clinical studies. 
 
 
Figure 4.10: ‘Schedule matters’: CAPAN-1 xenograft mean tumour growth represented by 
mean RTV following treatment with:  AG014699 (10 mg/kg D1-10) = solid grey circles + grey 
line; AG014699 (10 mg/kg D1-5 every 7 days for 6 cycles) = solid red circles + red line. The 
treatment periods for the AG014699 arms are represented by the corresponding coloured 
lines along the x-axis. 
 
This observation that ‘schedule matters’ as well as dose is also important as it may in-
part explain the lack of patient responders to AG014699 in the current phase II PARP-
BRCA clinical trial.  The intermittent dosing regimen (D 1–5, every 21 days) of 
AG014699 was selected as it was previously shown to be safe in combination with 
temozolomide in the phase I trial (Plummer et al., 2008). These in vivo data strongly 
suggest that continuous not intermittent dosing may be needed for greater efficacy in 
BRCA mutation carrier population. These results also provide further justification to 
amend the current clinical trial. This is discussed further in chapter five (section 5.5.6).  
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4.5.2 AG014699 is synthetically lethal in epigenetically silenced BRCA1 
The clinical application of PARP inhibitors as single agents was originally thought to be 
limited to cancers harbouring germ-line BRCA mutations and phase I/II clinical trials 
have since confirmed the activity of the PARP inhibitor olaparib in this patient 
population (Fong et al., 2009; Audeh et al., 2010; Tutt et al., 2010). However, it is now 
proposed that PARP inhibitors may be a therapeutic option in non-BRCA mutated 
cancers which have other defects within the HR repair pathway (discussed in chapter 
one section 1.6.4).  
The breast cancer cell line UACC3199 has epigenetically silenced BRCA1 through 
promoter gene methylation (Wei et al., 2005). In chapter three (section 3.4.1) of this 
thesis, in vitro data demonstrate that UACC3199 cells are sensitive to AG014699 and 
have impaired ability to form Rad51 foci following DNA damage, suggesting that they 
are HR defective. Results of in vivo UACC3199 experiments presented here (see figure 
4.5 and table 4.1) demonstrate that AG014699 significantly delays tumour growth 
compared to untreated controls. Interestingly, this TGD of 11 days was the same as 
that seen following a single dose of carboplatin (75 mg/kg) on D1. AG014699 was less 
toxic, in terms of maximum weight loss, than the carboplatin (6.6% vs. 9.6%). These 
findings confirm the in vitro data and add further weight to the proposal that PARP 
inhibitors could have a wider clinical application. 
Defective HR DNA repair through epigenetic silencing of BRCA1 or other mechanisms is 
now known to occur commonly in sporadic cancers; in particular high grade serous 
ovarian carcinomas (HGSOC) (Press et al., 2008) and triple negative breast cancers 
(Turner et al., 2007). In a recent study of sporadic epithelial ovarian cancers 
Mukhopadhyay and colleagues demonstrated a failure to form Rad51 foci (an indicator 
HR function) following exposure to AG014699 in 67% (16/24) of primary cultures. This 
failure of Rad51 foci induction correlated with ex vivo sensitivity to AG014699 
(Mukhopadhyay et al., 2010). In another study, Graeser et al observed a low Rad51 
score in 26% of breast cancer core biopsies taken 24 hours after the first cycle of neo-
adjuvant chemotherapy (Graeser et al., 2010). These two studies highlight that HR 
dysfunction is common in non-BRCA germline mutated cancers and perhaps more 
prevalent in ovarian than triple negative breast cancers. Clinical data is now emerging 
to support this; reports of a phase II study investigating the PARP inhibitor olaparib 
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showed encouraging activity in non-BRCA mutated HGSOC with response rates of 24% 
(11/46 patients) (Gelmon et al., 2011). Disappointingly, no responses have been 
reported in the 15 patients with non-BRCA mutated triple negative breast cancer.   
In summary it is clear from these in vitro and in vivo studies that BRCA1 methylated 
breast cancer cells (UACC3199) are sensitive to the PARP inhibitor AG014699 and 
future clinical studies of this novel agent should include patients without non-germ-
line BRCA mutated cancers. 
4.5.3 Carboplatin as a single agent and in combination with AG014699 
These studies have shown that single agent carboplatin is active in BRCA deficient 
xenografts. The MDA-MB-436 cell line was the most sensitive to AG014699 in vitro, 
had the lowest fold change in Rad51 foci following AG014699 and was the most 
sensitive to carboplatin in these in vivo studies confirming that these cells harbour a 
severely defective HR phenotype. These experiments also demonstrate that combining 
AG014699 with carboplatin is better than either treatment alone in BRCA2 mutant 
models. In the CAPAN-1 xenografts the most effective regimen, defined by longer time 
to RTV4, was the prolonged AG014699 schedule in combination with carboplatin (75 
mg/kg) on D1. This resulted in two complete tumour regressions and a mean tumour 
growth delay of 36.5 days in the remaining tumours.  
These results confirm the findings of a number of studies which have investigated the 
efficacy of the PARP inhibitor-platinum combination; in mice bearing BRCA1- and p53-
deleted transplanted mouse mammary tumours (Rottenberg et al., 2008) and in mice 
bearing autochthonous BRCA2- and p53-deleted mouse mammary tumours using the 
PARP inhibitor AZD2281 (now known as olaparib) (Hay et al., 2009), which 
demonstrated that the combination of cisplatin and a PARP inhibitor resulted in 
prolonged recurrence-free and overall survival compared with mice treated with either 
drug alone. The rationale for combining AG014699 with a platinum analogue is further 
supported by work by Evers and colleagues who demonstrated selective cytotoxic 
synergy between cisplatin and the PARP inhibitor AZD2281 (now olaparib) in BRCA2-
deficient but not proficient mammary mice tumour cell lines (Evers et al., 2008).  
Reviewing these results and the published literature (chapter one, section 1.6.1) it 
appears that prolonged, higher doses of PARP inhibitors are required as single agents 
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to exploit the synthetic lethality concept but that in combination with cytotoxics these 
doses may be too toxic for patients where only shorter, less potent PARP inhibiton is 
tolerated. For example, in the case of AG014699, chemopotentiation in vivo studies 
have reported that concentrations as low as 0.1 M AG014699 are able to cause > 
100% enhancement of temozolomide induced tumour growth delay and that the 
maximum tolerated dose in combination of AG014699 was 1mg/kg (Thomas et al., 
2007). However, these studies have shown that higher AG014699 doses (10mg/kg) are 
needed to produce single agent activity and therapeutic concentrations (around 3.9 
M); such doses were found by Thomas et al to be lethal in combination with 
temozolomide.  
Clinical studies are now underway investigating the safety and efficacy of combining 
PARP inhibitors with chemotherapy including the platinum agents both to act as 
chemosensitisers and to exploit the HR defective phenotype. One of the problems 
these trials will face is which dosing schedule of the PARP inhibitor to use in order to 
get the balance right between efficacy and toxicity. 
4.6 Conclusions 
To conclude, these studies provide the first evidence that UACC3199 tumour 
xenografts are sensitive to single agent AG014699, confirming the in vitro data 
presented in chapter three suggesting that PARP inhibitors may be a therapeutic 
option in non-BRCA mutated cancers. Secondly, the data in the CAPAN-1 tumours 
directly comparing the two schedules of AG014699 shows that TGD is significantly 
longer with a prolonged continuous dosing schedule of the PARP inhibitor. These 
results have impacted on the current CRUK PARP-BRCA clinical trial where AG014699 is 
given only intermittently on D1-5 allowing PARP enzyme recovery during the 
remainder of the 21 day cycle. These data have provided valuable weight to support 
the amendment of this multi-centre UK study which is now open to recruitment 
(October 2011) to investigate an oral continuous AG014699 dosing schedule. Finally, 
these experiments have shown that carboplatin has anti-tumour activity in BRCA 
defective xenografts and may be a therapeutic option in BRCA mutation carrier 
patients either in combination with a PARP inhibitor or as a single agent and these 
issues are the subjects of on-going clinical trials. 
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Chapter Five 
5. Pharmacodynamic, Pharmacokinetic, Pharmacogenomic and 
Clinical outcomes of AG014699 in patients; results of the Phase 
II PARP-BRCA clinical trial 
5.1 Introduction 
A better understanding of the molecular biology of cancer is leading to the 
identification of distinct cancer sub-types, new anti-cancer targets and as a result more 
individualised patient treatment approaches through the development of targeted 
agents (Schilsky et al., 2010). An example of this in action can be seen in the 
development of PARP inhibitors. Since the discovery of the first PARP; PARP-1, over 40 
years ago (Chambon et al., 1963), the abundant nuclear enzyme has emerged as an 
important novel target in cancer therapy. The first inhibitor of PARP, 3-AB, was 
identified in 1980 (Durkacz et al., 1980). Pre-clinical studies using the next generation 
of more potent more specific inhibitors suggested that the main anti-cancer role of 
PARP inhibitors would be as chemotherapy and radiotherapy potentiators (Delaney et 
al., 2000; Calabrese et al., 2004). Thus the first inhibitor to enter anti-cancer clinical 
trials was AG014699 (Pfizer GRD) in a phase I combination study with the oral, 
alkylating agent temozolomide in 2003. At this time this trial was conceived there were 
no data to support single agent AG014699 activity in the treatment of cancer.  
However, whilst this early phase combination AG014699 study was recruiting, two 
Nature papers reported results from two independent research groups showing that 
cells deficient in the BRCA1 and 2 genes were 100-1000 - fold more sensitive than 
heterozygote or wild type cell lines to PARP inhibitor monotherapy (Bryant et al., 2005; 
Farmer et al., 2005). Bryant et al demonstrated reduced survival in BRCA2 deficient 
cells to the PARP inhibitors NU1025 and AG14361, both forerunners to AG014699.    In 
the sister paper, Farmer et al demonstrated sensitivity of both BRCA1 and 2 deficient 
cell lines to two small molecule PARP-1 inhibitors-: KU0058684 and KU0058948, both 
forerunners to olaparib. Both groups concluded that BRCA deficient cells were 
sensitive to PARP inhibition by the proposed mechanism of ‘synthetic lethality’ 
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discussed in chapters one and three. Encouragingly both groups showed that PARP 
inhibition was non-toxic to models with restored BRCA function. These data suggested 
that, in patients, PARP inhibitors could selectively kill BRCA deficient tumours sparing 
normal tissue. 
Proof of concept clinical trials investigating the efficacy and safety of PARP inhibitors as 
single agents in BRCA mutated cancers commenced shortly after these studies were 
published in 2005.  The first study, a phase I dose escalation study of the oral, potent 
PARP-1 and 2 inhibitor olaparib (previously known as AZD2281/KU0059436) was 
actually on-going at the time of the 2005 Nature publications (Fong et al., 2009). It was 
however a standard phase I dose escalation study open to patients with advanced solid 
malignancies. On reviewing the BRCA-PARP in vitro and in vivo data (Bryant et al., 
2005; Farmer et al., 2005) the study was promptly amended to enrich for BRCA1 or 
BRCA2 mutation carriers (n=23). Two major findings came out of this study; results 
discussed in detail in chapter one, section 1.6.3. The first, that olaparib was well 
tolerated in patients, including those with the germ-line BRCA mutations. The second, 
that olaparib had anti-tumour activity only in the mutation carriers. The study 
incorporated an expansion phase, which focused specifically on patients with BRCA1/2 
mutations. Efficacy in a cohort of 50 patients all with BRCA1/2 mutated ovarian cancer 
was recently reported a clinical benefit rate of 46% for olaparib (Fong et al., 2010).  
As a result olaparib was taken forward into two separate phase II studies investigating 
the response in BRCA mutated breast and ovarian cancers respectively. Both these 
trials have demonstrated that olaparib is active in BRCA mutated cancers; confirming 
the phase I findings (Audeh et al., 2010; Tutt et al., 2010). The breast cancer study 
involved patients who had been heavily pre-treated with chemotherapy and the 
overall response rate compared well with that seen with standard chemotherapy 
regimens in the advanced setting (20-30%). The ovarian study included both platinum 
sensitive and resistant patients and response to olaparib was seen across these two 
groups. The greater response rates in patients receiving the 400 mg twice daily dose in 
both studies suggested that the degree of PARP inhibition is important.  
It is also important to note that not all BRCA1/2 mutation carriers responded to 
olaparib and that resistance to PARP inhibition has recently been reported through 
mechanisms of secondary genetic mutations of BRCA1 or BRCA2 restoring their 
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functions (discussed in chapter one section 1.7, Edwards et al., 2008; Sakai et al., 2008 
and 2009). The DNA repair capacity judged by homologous recombination status was 
not investigated in these studies and it is not yet clear how often such genetic 
reversions could occur in patients.  
Therefore, as with any early phase trial results; confirmation is required in larger phase 
III trials and it is prudent to await the results of other on-going trials investigating other 
classes of PARP inhibitor. 
One such study is the phase II Cancer Research UK (CRUK) trial of the activity of the 
intravenous PARP-1 inhibitor, AG014699, in patients with BRCA1 or 2 mutated locally 
advanced/metastatic breast cancer or advanced ovarian cancer (known as the PARP-
BRCA PH2/052 trial). At the time of writing, the PARP-BRCA PH2/052 study is ongoing. 
The protocol has recently been amended to investigate an oral, continuous dosing 
regimen, the reasons for which will be discussed in later on in this chapter. The 
pharmacokinetic, pharmacodynamic and pharmacogenomic assays developed and 
performed on the clinical samples collected within this study fall within the remit of 
this thesis.  Results are presented and discussed in this chapter together with any 
available clinical outcome data.  
5.1.1 The Phase II PARP-BRCA PH2/052 clinical trial  
This is a national, multi-centre, phase II study of the PARP-1 inhibitor AG014699 in 
patients with BRCA1 or 2 mutated locally advanced/metastatic breast cancer or 
advanced ovarian cancer. The study is being conducted by CRUK in collaboration with 
Pfizer GRD and the Northern Institute for Cancer Research, Newcastle upon Tyne. The 
participating cancer centres are the Beatson West of Scotland Cancer centre, Glasgow, 
University College London Cancer Trials Centre, The Christie Hospital, Manchester, St 
James University Hospital, Leeds, The Northern Centre for Cancer Care, Newcastle-
upon-Tyne, Plymouth Oncology Centre and Birmingham University Hospital. The study 
is being conducted under full ethical approval and all laboratory work for the primary 
and secondary objectives undertaken to Good Clinical Practice (GCP). The study is 
registered with the European Clinical Trials database (EudraCT no. 2006-002348-27). 
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5.1.1.1 Trial eligibility criteria 
The study is open to patients with confirmed germline BRCA1 and or 2 mutations and 
locally advanced/metastatic breast cancer or advanced ovarian cancer. A summary of 
the main inclusion and exclusion criteria are shown in table 5.1. 
5.1.1.2 Trial design and end-points 
The trial is an open label, single arm study of AG014699 given over a 30 minute 
intravenous infusion on day (D) one to five every 21 days for six cycles.  The primary 
end-points of the study are: response rate and toxicity. Response is measured by the 
Response Evaluation Criteria in Solid Tumours (RECIST) (Eisenhauer et al., 2009) and 
assessed following every two cycles of AG014699. Toxicity is recorded at every patient 
visit and coded by the Common Terminology Criteria for Adverse Events (CTCAE) version 
3.0. Secondary end-points: Time to progression (TTP), Overall survival (OS), PARP-1 
activity and AG014447 pharmacokinetics following AG014699. Tertiary end-points 
include the analysis of PARP-1 expression and the genotyping of single nucleotide 
polymorphisms (SNPs) within genes involved in the metabolism of AG014699 
(CYP2D6*2, *4) and PARP-1 activity (PARP-1 T2444C).  
At study conception it was not known whether a difference in response to AG014699 
would be seen between the patients with BRCA1 or 2 mutations and between those 
with breast or ovarian cancer. Therefore the study was designed to recruit patients 
into four subgroups of 14 patients each: BRCA1 ovary, BRCA1 breast, BRCA2 ovary and 
BRCA2 breast to allow response to be assessed. If one response was seen in the 14 
then this was considered to be significant and the null hypothesis of the drug being 
inactive in this sub-group could be rejected.  
At the time of study design, no safety data on the use of PARP inhibitors in this patient 
population were available. Therefore in order to address concerns about potential 
toxicity in patients the study was conducted in two stages.   
Stage one consisted of two cohorts; cohort one in which three BRCA1 and three BRCA2 
mutation carriers received a daily dose of 4 mg/m2 for five days for the first cycle.  In 
the previous phase I study a 4 mg/m2 dose was shown to inhibit PARP-1 but with 
recovery of enzyme activity within 24 hours (Plummer et al., 2008). If no dose limiting 
toxicity (DLT) was observed these patients received subsequent cycles at a daily dose 
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of 12 mg/m2 for five days.  In cohort two, three BRCA1 and three BRCA2 mutation 
carrier patients received 12 mg/m2 AG014699 for 5 days for the first cycle and if no 
DLT was observed patients were dose escalated to receive subsequent cycles at a dose 
of 18 mg/m2.  
In Stage two of the study patients received 18mg/m2 for the first cycle and all 
subsequent cycles unless a dose reduction was required as per the protocol. Patients 
who were responding to and tolerating AG014699 treatment after six cycles were 
permitted to continue on study at the discretion of the investigators.  
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Inclusion criteria: 
 
Proven carriers of a known mutation in BRCA1 or BRCA2  
Histologically documented locally advanced or metastatic breast cancer or advanced ovarian 
cancer 
Patients with ovarian cancer who have ≤ 3 prior chemotherapies and in whom > 2 months have 
elapsed since their last treatment with a carboplatin- or cisplatin-containing regimen 
Patients with breast cancer who have had  ≤ 3 prior chemotherapy regimens  
Measurable disease as measured by X-ray, Computerised Tomography (CT), or Magnetic 
resonance imaging (MRI) scan as defined by the Response Evaluation Criteria in Solid Tumours 
(RECIST) criteria.   
Life expectancy ≥ 12 weeks 
World Health Organisation (WHO) performance status of 0 or 1 
Written informed consent and be capable of co-operating with treatment and follow-up 
≥ 18 years  
Haematological and biochemical indices within the ranges shown below: 
 Haemoglobin ≥9.0 g/dl, Neutrophils ≥1.5 x 109/L, Platelets  ≥100 x 109/L 
 Serum bilirubin  ≤1.5 x upper normal limit  
 Alanine amino-transferase  or aspartate amino-transferase ≤ 2.5 x upper limit of normal,  
or ≤ 5 if liver metastases present 
 Glomerular Filtration Rate ≥50 ml/min  
 
Exclusion criteria: 
 
Radiotherapy (except for palliative reasons), endocrine therapy, immunotherapy or 
chemotherapy during the previous 4 weeks before start of study drug (six weeks for nitrosoureas 
and Mitomycin-C) 
Any unresolved toxicities > Grade 1 Common Terminology Criteria for Adverse Events (CTCAE) 
from previous treatments, except for alopecia. 
Known brain metastases 
Pregnant or breast feeding patients. Female patients who have a negative serum or urine 
pregnancy test before enrolment and agree to use two highly effective forms of contraception 4 
weeks before entering the trial, during the trial and for 6 months afterwards are considered 
eligible.   
Male patients with partners of child-bearing potential (unless they agree to use one form of 
highly effective contraception during the trial and for 6 months afterwards). 
Major thoracic and/or abdominal surgery in the preceding 4 weeks from which the patient has 
not recovered. 
At high medical risk because of non-malignant systemic disease including active uncontrolled 
infection. 
Current malignancies at other sites, with the exception of adequately treated cone-biopsied in 
situ carcinoma of the cervix uteri and basal or squamous cell carcinoma of the skin and 
concurrent breast and ovarian carcinoma.   
Patients with active or unstable cardiac disease or history of myocardial infarction within six 
months.   
 
Table 5.1: PARP-BRCA PH2/05 trial eligibility criteria 
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5.1.2 Pharmacodynamic, Pharmacokinetic and Pharmacogenomic end-points 
5.1.2.1 PARP-1 activity  
In this study PARP-1 enzyme activity levels were measured in patients’ peripheral 
blood lymphocytes (PBL) using the GCLP validated PAR formation immunoblot assay 
described in chapter two, section 2.9. Baseline pre-AG014699 PARP-1 activity levels 
were determined to investigate differences in endogenous (un-stimulated) PARP 
activity or maximum stimulated PARP activity between patients and to investigate if 
any relationship exists between PARP activity and the clinical response to AG014699, 
patient’s age and PARP-1 protein expression levels. Maximum stimulated PARP-1 
activity was also quantified in response to AG014699 to determine the efficiency of on-
target effect of the PARP inhibitor and to relate this to the pharmacokinetic evaluation 
of AG014699.  
5.1.2.2 PARP-1 expression 
To determine whether inter-patient variation in levels of PARP-1 activity could be 
attributed to differences in PARP-1 expression and to compare results of this patient 
population with other published data sets; PARP-1 expression levels were measured 
from patients’ PBL using the validated semi-quantitative Western blotting assay 
described in chapter two, Materials and Methods, section 2.10.  
5.1.2.3 PARP-1 T2444C single nucleotide polymorphism genotyping 
For this study, the T2444C SNP was determined from DNA extracted from whole blood 
using the PARP-1 TaqMan Real-time PCR genotyping assay kit (c1515368-1, rs number 
113640; Applied Biosystems, Warrington, UK) as described in chapter two, Materials 
and Methods, section 2.12. Results of patient’s endogenous baseline PARP-1 activity 
were then correlated with the T2444C SNP results. 
5.1.2.4 Pharmacokinetics of AG014699 
The pharmacokinetics of AG014447 (the free base of AG014699) was determined from 
plasma extracted from patient’s whole blood using LC/MS/MS.  The method, 
developed and validated to GCLP for this research study, is described in chapter two, 
section 2.11. The PK sampling schedule for this study permitted only limited analysis 
but would allow for relationships between the AG014699 pharmacokinetics and 
pharmacodynamic and clinical response data to be investigated. 
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5.1.2.5 CYP2D6 single nucleotide polymorphism genotyping 
Cytochrome P450 2D6 (CYP2D6, debrisoquine/asparteine hydroxylase) is a member of 
the Cytochrome P450 super-family. It is involved in the metabolism of ~ 25% of all 
commonly prescribed drugs (Sistonen et al., 2007) and including AG014699 (Pfizer 
GRD). CYP2D6 gene is highly polymorphic and over 75 major alleles have been 
identified to date (www.cypalleles.ki.se). Single nucleotide polymorphisms within 
CYP2D6 can result in increased, decreased or abolished gene function. This can result 
in complete deficiency up to excessive metabolism of a given drug resulting in either 
excess toxicity or lack of efficacy.   For this study, the CYP2D6*2 and *4 were 
determined from DNA extracted from whole blood using TaqMan Real-time PCR 
genotyping assay kits (Applied Biosystems, Warrington, UK) listed and described in 
chapter two, Materials and Methods, section 2.12. Results were then used to 
investigate any association between toxicity and response to AG014699. 
5.2 Objectives 
The end-points of the phase II PARP-BRCA PH2/052 trial are detailed above but the 
objectives for the specific studies carried out for this thesis are as follows: 
 Pharmacodynamic (PD) endpoints: To investigate the effects of AG014699 on 
PARP-1 activity and investigate baseline PARP-1 activity and PARP-1 expression 
levels in patients. 
 Pharmacokinetic (PK) endpoints: To establish and validate a method to determine 
the concentration of AG014447, the active drug of the pro-drug AG014699, in 
human plasma samples.  
 Pharmacogenomic (PG) endpoints: To determine the SNPs within the genes 
associated with the metabolism of AG014699 (CYP2D6) and PARP-1 activity (PARP-
1). 
 Clinical endpoints: To determine the response rate, time to progression, overall 
survival and toxicity following AG014699 in this patient population 
 
 To investigate any possible relationships between the above parameters 
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5.3 Materials and Methods 
Materials and methods for the listed assays are described in full in chapter two, 
Materials and Methods. Any deviations from these methods for specific experiments 
are detailed in the individual results sections below. Preparations of the clinical 
samples for analysis within the listed assays are also described in chapter two. The 
schedules of the different clinical samples taken for use within this study are detailed 
in figure 5.1. All stage one patients, who were dose escalated between, cycle one and 
two, underwent PK and PD blood sampling on both these cycles whereas stage two 
patients underwent PD and PK sampling in cycle one only.  
 
 
 
 
Figure 5.1: Summary of the schedule of clinical samples taken as part of the PARP-BRCA 
PH2/052 phase II trial. Stage two patients had pharmacokinetic (PK) and pharmacodynamic 
(PD) sampling in C1 only. Pre = pre-treatment, EOI = end of infusion, PBL = peripheral blood 
lymphocytes, LC/MS = liquid chromatography mass spectrometry, C = cycle, D = day, SNP = 
single nucleotide polymorphisms. n=actual number of patients/ biopsies at the time of writing.  
 
n = 38 
n = 1 
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5.4 Results 
5.4.1 Patient demographics 
Between January 2007 and September 2010 38 patients were entered into the study. 
Baseline characteristics are shown in table 5.2. It was initially envisaged that accrual of 
the 56 patients would take approximately 24 months, with an average of 2-3 patients 
recruited per month. However recruitment has been slower than predicted. Possible 
reasons include the restriction on the prior number of chemotherapies permitted in 
the breast cancer patients (this has been addressed in a recent protocol amendment) 
and the restriction of excluding non-UK residents. The low number of BRCA2 ovarian 
cancer patients recruited may reflect the lower risk of developing ovarian cancer in 
BRCA2 mutation carriers (Ford et al., 2004).  
The mean age of the 38 patients is 51.4 years which is lower than the reported average 
age at diagnosis of breast cancer (61 years) and ovarian cancer (63 years) patients 
(www.cancerresearch.uk.org/cancerstats). This is not surprising given that one of the 
hallmarks of BRCA mutation carriers is the early age at cancer presentation (King et al., 
2003).  
Patients were all of good performance status and had received a median number of 
two prior chemotherapies.  
For reporting of results patients are identified by their specific study number e.g. 40-
001; where the first number represents the treatment centre i.e. 40 is Newcastle and 
the second number is the patient recruitment number. Two additional patients were 
recruited to stage one, cohort two; one to replace patient 40-007 who withdrew due 
to clinical evidence of disease progression during cycle one. The second additional 
patient arose due to two patients at different treatment centres being given the 
information about the study at the same time and it was considered unethical to 
withdraw the offer of treatment. 
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Patient baseline characteristics n=38  
 
Patient no. (%) 
 
Sex – no. (%)  
Female  
Male  
 
 
38 (100) 
0 (0) 
 
Age - yr  
Mean  
Range  
 
 
51.4 
28 - 72 
 
Tumour type – no. (%)  
Breast  
Ovarian  
 
 
16 (42) 
22 (58) 
BRCA mutation/ Tumour type –no. (%)  
BRCA1 breast 
BRCA2 breast 
BRCA1 ovary 
BRCA2 ovary 
 
5 (13) 
11 (29) 
16 (42) 
6 (16) 
 
WHO PS – no. (%) 
0 
1 
 
 
10 (26) 
28 (74) 
 
Mean no. (range) prior chemotherapies  
 
 
2 (1 – 4) 
 
Table 5.2 Baseline patient characteristics for the PARP-BRCA PH2/052 phase II trial 
 
5.4.2 Patients baseline PARP-1 characteristics 
5.4.2.1 PARP-1 activity in Peripheral Blood Lymphocytes 
PBL samples were collected for all 38 patients, but the samples for baseline PARP-1 
activity, as described in figure 5.1, were obtained in 35 patients. The main reason for 
not obtaining a result for a given patient was that either the blood sampling was not 
possible at a given time-point or blood was taken but insufficient PBL were harvested 
to enable results to be generated. PARP-1 activity was assessed using the validated 
immunoblot assay described in chapter two, Materials and Methods and is expressed 
as pmol of PAR formation per 104 PBL. Examples of an immunoblot and PAR standard 
curve are shown in figures 3.5 and 3.6 respectively in chapter three.  
Patients’ baseline PARP-1 activity was obtained from the cycle one, D1 PBL sample 
which was taken immediately prior the first AG014699 dose. This time-point enables 
  Chapter Five – Clinical studies       Chapter Five – Clinical studies 
153 
 
the amount of PARP-1 activity to be assessed in the un-stimulated, un-reacted sample, 
which represents the endogenous PARP activity and secondly the amount of PARP 
activity in the sample after maximum stimulation of the enzyme after the addition of 
oligonucleotide in the assay reaction.  
 Results for all 35 patients for endogenous un-stimulated PARP activity are shown in 
figure 5.2. This shows low levels of PARP-1 activity with a mean value = 0.097 pmol 
PAR per 104 PBL (median = 0.05 pmol PAR, range = 0.00-0.75 pmol PAR per 104 PBL) 
and a large variation between patients (coefficient of variation (CV) = 146.5%). 
Interpreting these data is difficult as the majority of results lie at the lower end of the 
standard curve and no published data is yet available for comparison of endogenous 
PBL PARP-1 activity measured in similar populations or even in non-BRCA mutated 
cancer populations or healthy volunteers using these methods.   
Results for the pre-treatment PARP-1 activity samples after maximum enzyme 
stimulation for the 35 patients are shown in figure 5.3 and table 5.3. Similar to the 
endogenous PARP-1 activity data, a large inter-patient variation is seen (range = 0.38 – 
40.26 pmol PAR per 104 PBL, CV = 144.7%). Mean PARP-1 activity = 6.80 pmol PAR per 
104 PBL and median = 2.71 pmol PAR per 104 PBL.  This is almost double the PARP-1 
activity levels reported by Zaremba et al. (Zaremba et al., 2011) of a large cohort of 
118 cancer patients with unknown BRCA status where a mean baseline PARP-1 activity 
after maximum enzyme stimulation = 3.60 pmol PAR per 104 PBL was seen.  
A large variation in PARP-1 activity was also seen in Zaremba’s study (CV = 129.9%, 
range = 0.10 – 26.00 pmol PAR per 104 PBL) confirming that PARP-1 activity varies 
markedly between individuals. 
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Figure 5.2: Mean endogenous PARP-1 activity in pre-AG014699 treatment PBL samples.  
Error bars = SEM. 
 
 
 
Figure 5.3: Mean maximum stimulated PARP-1 activity in pre-AG014699 treatment PBL 
samples. Error bars = SEM.  
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5.4.2.2 PARP-1 protein expression in Peripheral Blood Lymphocytes 
PBL samples for PARP-1 protein expression were collected for 30 of the 38 patients. 
The main reason for not obtaining a result for a given patient was that either the blood 
sampling was not possible at the specified time-point or blood was taken but 
insufficient PBL were harvested to enable results to be generated. PARP-1 expression 
was assessed using the semi-quantitative Western Blotting assay described in chapter 
two, section 2.10 and is expressed as ng PARP-1 per g of total protein loaded.  
Analysis of PARP-1 expression results, shown in figure 5.4 and table 5.3; demonstrate 
mean PARP-1 expression of 0.21 ng per g and a median of 0.16 ng per g protein 
loaded. Like PARP-1 activity levels, a large variation is seen between subjects with CV = 
92.5% and range of 0.00 to 0.93 ng per g protein. These results are similar to data 
reported by Zaremba et al. where a mean PARP-1 expression of 0.23 ng per g protein 
was seen in a population of 118 cancer patients (Zaremba et al., 2011). 
 
 
Figure 5.4: Mean baseline PARP-1 protein expression in pre-AG014699 PBL samples. 
Error bars = SEM. 
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5.4.2.3 PARP-1 activity vs. PARP-1 expression 
To determine whether any relationship exists between PARP-1 protein expression and 
maximum stimulated PARP-1 enzyme activity; results from both assays were analysed 
after log 10 transformation as both data sets were positively skewed. Results shown in 
figure 5.5 demonstrate a weak but non-significant correlation with increased protein 
expression and increased PARP-1 activity (R2 = 0.14, P = 0.06, Pearsons correlation 
coefficient).  
 
Figure 5.5: Relationship between log 10 PARP-1 expression and activity  
 
5.4.2.4 PARP-1 activity and PARP-1 expression vs. age 
Studies investigating a link between PARP-1 activity, expression and longevity have 
been conflicting.  Grube and Burkle demonstrated that poly(ADP-ribosylation) capacity 
decreases with age in both rats and humans. In addition they showed that maximally 
stimulated PARP activity in PBL of 13 mammalian species directly correlated with 
species-specific life span with a 5-fold difference between the longest lived (man) and 
shortest lived (rat) species tested (Grube and Burkle., 1992).  
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Figure 5.6: Relationship between (A) log 10 PARP-1 activity (B) log 10 PARP-1 expression and age 
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In contrast to this, Muiras et al reported significantly higher maximum stimulable PARP 
activity in a population of 49 French centenarians vs. 51 younger controls aged 20-70 
years (Muiras et al., 1998).  
Analysis of the data from this study using a Pearson correlation coefficient does not 
show any significant relationship between log10 PARP-1 activity (R
2 = 0.02, P = 0.47) or 
log10 PARP-1 expression (R
2 = 0.02, P = 0.42) and age. See figure 5.6 
5.4.2.5 PARP-1 T2444C genotyping 
Whole blood samples for analysis of the PARP-1 T2444C SNP were received for 31 out 
of 38 patients. The main reason for not obtaining a result for a given patient was that 
the blood sample was not taken due to error at the treatment centre. DNA was 
extracted from whole blood and analysed using the Taqman kit as described in chapter 
two, Materials and Methods. Results for all 31 patients are shown in table 5.3 together 
with the corresponding pre-AG014699 PARP-1 activity levels. The frequencies of the 
genotypes were as follows: major genotype (T/T) 77.4%, the heterozygote genotype 
(T/C) 19.4% and the minor variant genotype (C/C) 3.2%. The minor allele frequency of 
13% is consistent with the published data reports of between 5-33% and the allele 
frequency was consistent with Hardy Weinberg Equilibrium (X2 = 0.60, P= 0.44). Only 
one patient (35-013) was found to have the C/C variant genotype and interestingly this 
patient had the second lowest PARP-1 activity of the group at 0.43 pmol PAR per 104 
PBL, see figure 5.7. However as this was the only C/C patient it was not possible to do 
further statistical comparisons of this single result but analysis of PARP-1 activity data 
by genotype grouping (T/T vs. [T/C + C/C]) shows a trend towards lower PARP-1 activity 
with the variant C allele but this did not reach statistical significance (P = 0.17, un-
paired t-test).   
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Figure 5.7: PARP-1 activity by PARP-1 T2444C genotype 
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Patient 
study no. 
T2444C SNP Baseline endogenous 
PARP-1 activity  
(mean pmol PAR per 
10
4 
PBL) 
Baseline maximum 
stimulated PARP-1 
activity 
(mean pmol PAR per 10
4 
PBL) 
Baseline PARP-1 
protein expression  
(ng/g protein) 
40-001 T/C 0.00 3.75 0.93 
40-002 T/C 0.06 6.38 0.64 
40-003 T/T 0.08 4.18 0.16 
40-004 T/C 0.10 1.69 0.10 
40-005 T/C 0.34 1.19 0.11 
40-006 T/T 0.30 3.22 0.06 
40-007 T/T 0.03 2.24 0.11 
40-008 T/T 0.22 1.50 0.12 
20-009 T/T 0.09 21.13 0.24 
35-010 T/T 0.05 5.32 * 
35-011 T/T 0.01 1.21 * 
20-012 * 0.04 1.32 * 
35-013 C/C 0.04 0.43 0.17 
40-014 T/T 0.11 36.56 0.21 
35-015 * 0.00 2.34 * 
20-016 T/T 0.03 0.36 * 
35-017 T/T 0.03 2.42 0.14 
40-018 T/T 0.07 5.27 0.16 
20-019 T/T 0.03 2.71 0.00 
35-020 T/T 0.05 3.04 0.11 
35-021 T/C 0.05 0.56 0.05 
40-022 T/T 0.15 4.77 0.57 
36-023 T/T 0.75 9.05 * 
35-024 T/T 0.09 0.70 0.07 
36-025 T/T 0.07 1.34 0.11 
06-027 * 0.04 20.00 0.29 
52-028 T/T 0.03 0.93 0.36 
40-029 T/C 0.06 5.93 0.18 
35-030 T/T 0.05 40.26 0.28 
35-031 T/T 0.20 16.97 0.15 
52-032 T/T * * 0.18 
06-033 * 0.01 1.19 0.16 
35-034 * * * * 
35-035 T/T * * 0.24 
52-036 * * * * 
35-037 T/T 0.01 2.35 0.18 
35-038 T/T 0.00 14.05 0.09 
 
 
Table 5.3: PARP-1 T2444C SNP genotyping results with patients’ C1 baseline endogenous 
PARP-1 activity, maximally stimulated pre-AG014699 PARP-1 activity levels and pre-AG014699 
PARP-1 protein levels.  
* indicates result unavailable due to sample not being taken or insufficient sample to do 
analysis. 
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5.4.3 PARP-1 activity in PBL in response to AG014699  
Blood samples were taken, as described in section 5.3.1, to assess PARP-1 activity 
levels in PBL pre- and post-AG014699. A complete set of samples (four time-points per 
cycle) were received for 26 patients but providing the pre-AG014699 sample was taken 
it was possible to assess the affect of AG014699 on the remaining time-points. This 
was possible for 33 patients and results, expressed as % PARP-1 activity of the pre-
AG014699 baseline sample, for all 33 patients are shown in table 5.4, with summary 
data provided in table 5.5. The D2 pre-dose blood sample was intended to be taken 
approximately 24 hours post the D1 dose of AG014699. It is therefore referred to in 
the text, graphs and tables as D1 24h time-point. 
As explained in section 5.1.1, in cohort one of stage one, six patients (3 with BRCA1 
and 3 with BRCA2 mutations) received the first cycle of AG014699 at a daily dose of 4 
mg/m2.  All six patients subsequently received the second cycle at the higher dose of 
12 mg/m2 as no DLT was observed. PARP-1 activity results for this cohort, expressed as 
a % of the pre-treatment levels, are shown in figure 5.8. A single dose of 4 mg/m2 
AG014699 resulted in profound suppression of PARP-1 activity with mean activity 
levels at 30 min (end of infusion sample) of 2.2% of baseline.  However some recovery 
was seen at 24h with mean PARP-1 activity up to 31.5% of baseline levels.   
Data for the same six patients following a single dose of 12 mg/m2 AG014699 shows 
mean PARP activity levels of 1.3% at 30 min and less recovery of activity at 24 h (mean 
= 3.8%). These are the first examples of intra-patient dose escalation of a PARP-1 
inhibitor and show a dose dependent effect of PARP-1 enzyme inhibition at the 24 
hour time-point. 
In cohort two of stage one a further six patients (3 with BRCA1 and 3 with BRCA2 
mutations) were treated with AG014699 at a daily dose of 12 mg/m2 for cycle one and 
all (except patient 40-007 who withdrew from study due to early disease progression) 
were dose escalated to 18 mg/m2 for subsequent cycles as no DLT was observed. As 
patient 40-007 would not be assessable for response an additional patient was 
recruited to this cohort. Results for all seven patients are shown in figure 5.9. 
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Patient 
study no. 
Dose 
AG014699 
(mg/m
2
) 
 
Mean PARP-1 
activity (± SD) pmol 
PAR per 10
4 
PBL 
% PARP-1 activity of D1 pre-dose levels 
D1 pre-dose D1 EOI D1 4 hours D1 24 hours  
40-001 4 
12 
3.75 ± 0.20 
11.71 ± 0.29 
0.90 ± 0.40 
0.23 ± 0.21 
0.33 ± 0.58 
3.27 ± 0.55 
95.67 ± 4.19 
0.00 ± 0.00 
40-002 4 
12 
6.38 ± 1.92 
1.79 ± 0.14 
0.23 ± 0.21 
2.03 ± 0.55 
7.17 ± 0.76 
8.20 ± 0.30 
29.03 ± 2.20 
10.43 ± 0.98 
40-003 4 
12 
4.18 ± 0.20 
7.70 ± 0.23 
1.17 ± 0.12 
1.00 ± 0.20 
6.63 ± 0.75 
* 
11.00 ± 1.04 
6.17 ± 0.29 
40-004 4 
12 
1.69 ± 0.13 
18.16 ± 0.40 
10.23 ± 1.36 
3.17 ± 0.12 
5.23 ± 0.42 
5.83 ± 0.42 
38.40 ± 3.50 
0.00 ± 0.00 
40-005 4 
12 
1.19 ± 0.23 
0.40 ± 0.01 
0.30 ± 1.23 
0.00 ± 0.00 
0.00 ± 0.00 
0.00 ± 0.00 
7.91 ± 0.51 
0.00 ± 0.00 
40-006 4 
12 
3.22 ± 0.33 
13.01 ± 0.32 
1.13 ± 1.96 
* 
29.17 ± 5.31 
* 
6.80 ± 0.85 
6.17 ± 0.29 
40-007† 12 2.24 ± 0.12 1.46 ± 0.14 6.36 ± 1.51 3.22 ± 0.24 
40-008 12 
18 
1.50 ± 0.05 
2.48 ± 0.10 
1.18 ± 2.05 
10.97 ± 3.51 
20.61 ± 7.17 
17.09 ± 1.95 
147.89 ± 16.85 
30.58 ± 2.11 
20-009 12 
18 
21.13 ± 0.51 
21.94 ± 1.01 
12.22 ± 1.20 
3.87 ± 0.29 
10.70 ± 0.27 
* 
12.97 ± 0.58 
7.53 ± 0.38 
35-010 12 
18 
5.32 ± 0.49 
18.28 ± 1.38 
18.97 ± 3.07 
18.17 ± 1.57 
26.47 ± 0.49 
22.83 ± 0.90 
31.37 ± 3.19 
32.13 ± 0.15 
35-011 12 
18 
1.21 ± 0.17 
9.22 ± 1.47 
7.32 ± 1.07 
3.77 ± 0.51 
20.72 ± 0.09 
6.67 ± 0.42 
44.09 ± 3.50 
15.3 ± 0.10 
35-017 12 
18 
2.42 ± 0.08 
6.81 ± 0.14 
0.39 ± 0.21 
33.61 ± 0.93 
8.60 ± 0.52 
16.24 ± 0.75 
2.74 ± 0.20 
13.94 ± 0.22 
40-018 12 
18 
5.27 ± 0.28 
2.92 ± 0.16 
7.09 ± 1.06 
2.42 ± 0.06 
2.36 ± 0.12 
2.73 ± 0.10 
1.84 ± 0.12 
8.43 ± 1.34 
20-012 18 1.32 ± 0.12 4.37 ± 0.83 16.83 ± 1.36 4.73 ± 0.51 
35-013 18 0.43 ± 0.01 2.03 ± 1.04 0.00 ± 0.00 1.37 ± 1.31 
40-014 18 36.56 ± 10.90 11.13 ± 0.75 16.77 ± 1.27 56.13 ± 3.05 
35-015 18 2.34 ± 0.18 2.11 ± 0.13 1.23 ± 0.15 6.63 ± 0.06 
20-016 18 0.36 ± 0.04 0.22 ± 0.38 11.98 ± 1.32 1.16 ± 1.01 
20-019 18 2.71 ± 0.05 0.00 ± 0.00 * 1.90 ± 0.32 
35-020 18 3.04 ± 0.05 3.30 ± 0.35 * 14.80 ± 0.89 
35-021 18 0.56 ± 0.08 52.59 ± 1.77 42.74 ± 1.60 32.24 ± 3.21 
40-022 18 4.77 ± 0.25 11.90 ± 1.17 21.91 ± 3.00 34.63 ± 2.45 
36-023 18 9.05 ± 0.78 5.52 ± 0.37 5.02 ± 0.36 * 
35-024 18 0.70 ± 0.01 43.23 ± 5.89 42.93 ± 1.55 481.00 ± 83.96
◊
 
36-025 18 1.34 ± 0.03 31.90 ± 3.82 19.87 ± 1.10 39.20 ± 2.51 
06-027 18 20.00 ± 0.56 3.09 ± 0.28 4.72 ± 0.12 3.86 ± 0.20 
52-028 18 0.93 ± 0.11 17.77 ± 6.19 1.34 ± 1.74 0.00 ± 0.00 
40-029 18 5.93 ± 0.27 * 5.16 ± 0.56 3.85 ± 0.37 
35-030 18 40.26 ± 0.71 7.17 ± 0.48 21.09 ± 0.54 5.47 ± 0.45 
35-031 18 16.97 ± 3.38 49.81 ± 2.58 46.24 ± 10.22 43.69 ± 0.33 
06-033 18 1.19 ± 0.11 16.87 ± 1.67 33.09 ± 1.75 26.87 ± 0.42 
35-037 18 2.35 ± 0.42 3.46 ± 0.36 1.28 ± 0.27 2.79 ± 0.33 
35-038 18 14.05 ± 2.43 9.22 ± 1.05 12.20 ± 2.56 6.33 ± 0.24 
 
Table 5.4: PARP-1 activity in response to AG014699 expressed as % PARP-1 activity of the un-
treated control samples. * indicates that result unavailable due to sample not being taken or 
insufficient sample to do analysis. EOI = end of infusion, SD = standard deviati on, CV = 
coefficient of variation 
†Patient withdrew from study after C1 due to disease progression. 
◊ Result excluded from further analysis but reported 
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Dose level No. Patients Mean % PARP activity of baseline ± SD   (%CV) 
D1 EOI D1 4 hours D1 24 hours 
4 mg/m
2
  6 2.37  ±   3.89   
(167.31) 
8.09  ±  10.78    
(133.30) 
31.47  ±  33.94  
(107.84) 
12 mg/m
2
 13 4.59  ±  5.87    
(127.98) 
10.28   ±  8.59     
(83.53) 
20.53  ±  40.51  
(197.33) 
18 mg/m
2
 24 13.94  ±  
15.79(113.27) 
16.09  ±  14.04    
(87.28) 
16.40   ± 16.19    
(98.71) 
 
Table 5.5: PARP-1 activity in response to AG014699: summary statistics.  
 
 
As explained, all patients in stage one (with the exception of patient 40-007) 
underwent PD sampling for PARP-1 activity in cycle one and two of the study. It was 
therefore possible to investigate whether an individual’s baseline PARP-1 activity (D1 
pre-dose levels) varied between the first and second cycle of treatment. Figure 5.10 
shows the % change in baseline PARP-1 activity levels from the D1 pre-dose sample of 
cycle one to the D1 pre-dose time-point of cycle two for all 12 patients. In 75% of 
patients (9/12) there was an increase in the C2 D1 pre-dose PARP-1 activity compared 
to the C1 levels. The mean fold-change was for all patients a 2.12 increase over 
baseline. This could be consistent with known intra-subject variability of PARP-1 levels 
which has been reported as up to 1.9-fold over three blood samples during a period of 
72 hours (MD thesis data Chris Jones, Newcastle University, UK, 2006). However it may 
represent an induction of PARP-1 activity following recovery after inhibition by the 
AG014699. It would be interesting to investigate whether the same phenomenon 
occurred with PARP-1 protein expression levels. 
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Figure 5.8: PARP-1 activity in response to AG014699 cohort one, stage one patients. Grey lines and symbols represent the 4 mg/m2 dose and the 
green symbols and lines are the 12 mg/m2 dose level. 
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Figure 5.9: PARP-1 activity in response to AG014699 cohort two, stage one patients. Green lines and symbols represent the 12 mg/m2 dose and the 
blue symbols and lines the 18 mg/m2 dose level. 
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Figure 5.10: Intra-patient % change in PARP-1 activity after dose escalation (from C1 D1 pre-
dose to C2 D1 pre-dose levels). Patients who received 4mg/m2 for C1 are represented by the 
grey symbols and patients who received 12mg/m2 in cycle one are shown in green symbols. 
 
Patients in stage two of the study received 18 mg/m2 daily dosing of AG014699 for all 
cycles. PARP-1 activity data for these patients, in addition to those in cohort two, stage 
one, who were also treated at 18 mg/m2 in C2, are shown in figure 5.11A. Five patients 
had significantly less inhibition of PARP-1 activity at the EOI time-point than the rest of 
the group (mean % activity over baseline = 42.22 vs. 7.53; p < 0.001, un-paired t-test) 
and their individual results are plotted in figure 5.11B. In all five of these patients 
PARP-1 activity levels did fall further at the 4 h time-point (mean activity = 33.6 %) but 
in 3/4 patients (no sample received for patient 35-024) PARP-1 activity levels of > 30% 
of baseline were seen at the D2 pre-dose time-point.  
Overall for stage two patients dosed at 18 mg/m2, the D2 pre-dose sample shows a 
mean PARP-1 activity of 16.44% of baseline; demonstrating that AG014699 results in 
profound PARP-1 inhibition in PBL 24 h after the last dose. However, as figure 5.11A 
highlights in a number of patients recovery to > 30% of baseline is seen at this time-
point. The impact of this in terms of clinical response to AG014699 will be reviewed 
later. Interestingly no correlation between the degree of AG014699 induced inhibition 
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of PARP-1 activity and baseline (maximum stimulated) levels of PARP-1 activity was 
seen in these patients at any of the time-points, see figure 5.12. 
A wide inter-patient variation in inhibition of PARP-1 activity by AG014699 was seen at 
all time-points and dose levels with % CV shown in table 5.4.  
For all three dose cohorts the mean PARP activity ~ 24 h (D2 pre-dose sample) after a 
single dose of 4, 12 and 18 mg/m2 AG014699 was 31.47%, 20.53% and 16.40% 
respectively. Figure 5.13A shows a clear dose-response relationship between mean % 
PARP-1 enzyme inhibition at this time-point and increasing doses of AG014699. 
Interestingly this is not seen at the earlier time-points with the degree of inhibition at 
18 mg/m2 similar to or less than that at the other dose levels, even when you remove 
the data points for those patients identified in figure 5.11. This may suggest that higher 
AG014699 doses result in prolongation of PARP-1 inhibition rather than more 
profound inhibition. 
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Figure 5.11: PARP-1 activity in response to AG014699 stage two patients (A) Scatter-plot 
showing the effect of 18 mg/m2 dose of AG014699 on PARP-1 activity in PBL in 24 patients. 5 
Patients with the highest EOI activity levels are shown with study number next to the 
corresponding plots. (B) Data for the five patients identified in A 
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Figure 5.12: Relationship between patients baseline PARP activity and levels after AG014699 
exposure. Data shows no relationship between PARP-1 activity levels at the end of infusion (A), 
4 h (B) and 24 h (C) post dose of AG014699 and a patients’ baseline pre-treatment PARP-1 
activity levels. Correlation calculated using Pearsons coefficient. 
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Figure 5.13: (A) Mean % PARP-1 activity for each time-point of each dosing level (represented 
by the coloured bars). Data show a dose-response at the D2 pre-dose sample with reduction in 
PARP-1 activity with increasing dose of AG014699. Error bars represent the SEM. (B) The same 
data minus the five patients identified in figure 5.11. 
 
5.4.4 Pharmacokinetics of AG014699 
The pharmacokinetics of AG014447 (the free base of AG014699) was determined from 
plasma extracted from patient’s whole blood using LC/MS/MS, as described in chapter 
two, section 2.11.  The blood sampling schedule and preparation of plasma are 
described in section 5.3.2. A complete set of samples (9 time-points per cycle) was 
received for 28 patients. However, sufficient samples were received from 35 patients 
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and are included in this pharmacokinetic study. Results, expressed as concentration of 
AG014447 in ng/ml, for the individual sampling time-points for all 35 patients are 
shown in Table 5.6, with summary data presented in Table 5.7.   
As described in section 5.4.3 this is the first clinical trial to include intra-patient dose 
escalation of a PARP-1 inhibitor. Based on data from the previous phase I study of 
AG014699 in combination with temozolomide (Plummer et al., 2008) the maximum or 
peak concentration of AG014699 after administration (Cmax) occurred at the end of the 
30 minute infusion. Figure 5.14 shows the Cmax values on D1, 4 and 5 for each dose 
level and demonstrates a linear pharmacokinetics with increasing AG014699 dose, 
although there was considerable inter-patient variability.  
 
 
 
Figure 5.14: Box plot and whiskers plot showing the Cmax AG014447 (ng/ml) for each time-
point in each AG014699 doing cohort. Lines represent median values. 
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Separate graphs for D1, D4 and D5 Cmax AG014447 for each of the three dose levels are 
shown in Figure 5.15.  
Linear regression analysis demonstrates a significant relationship (P < 0.001) between 
increasing dose of AG014699 and Cmax for all three days tested. Mean Cmax AG014447 
on D1 were 246.1 ng/ml, 676.5 ng/ml and 859.7 ng/ml for the 4 mg/m2, 12 mg/m2 and 
18 mg/m2 dose levels respectively.  
This is comparable with the published phase I study data set with mean Cmax values on 
D1 of 134 ng/ml, 551 ng/ml and 837 ng/ml for the 4 mg/m2, 12 mg/m2 and 18 mg/m2 
cohorts respectively (Plummer et al., 2008). For the 18 mg/m2 dosing cohort Cmax was 
highest on D4 but this was not significantly different to the Cmax values for D1 and 5 (P 
= 0.22, one way analysis of variance). 
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Figure 5.15: Linear regression analysis showing the relationship of AG014699 dose and Cmax 
(ng/ml) on (A) D1, (B) D4 and (C) D5.  
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Patient study 
no. 
Dose 
AG014699 
(mg/m
2
) 
 
[AG014447] ng/ml 
D1 pre-dose D1 EOI D1 1-3 hrs D2 pre-dose D4 pre-
dose 
D4 EOI D4 1-3 hrs D5 pre-
dose 
D5 EOI 
40-001 4 
12 
 
0.00 
0.00 
168.00 
844.00 
7.98 
22.70 
0.25 
2.06 
2.60 
4.05 
91.90 
627.00 
29.90 
77.20 
1.52 
4.37 
161.00 
569.00 
40-002 4 
12 
 
0.00 
0.00 
311.00 
658.00 
21.20 
83.50 
4.32 
11.80 
5.77 
21.20 
305.00 
538.00 
58.10 
182.00 
6.95 
22.00 
280.00 
301.00 
40-003 4 
12 
 
0.00 
0.00 
222.60 
883.0 
37.90 
121.60 
9.75 
39.80 
17.70 
78.10 
370.00 
* 
97.40 
* 
19.90 
* 
334.00 
* 
40-004 4 
12 
 
0.00 
0.00 
89.30 
488.00 
20.00 
83.50 
6.09 
26.40 
10.60 
27.30 
242.00 
748.00 
63.10 
224.00 
10.90 
35.90 
176.00 
* 
40-005 4 
12 
 
0.00 
0.00 
335.00 
1356.00 
62.90 
275.00 
13.80 
37.30 
22.70 
38.10 
334.00 
893.00 
119.00 
320.00 
26.60 
38.50 
395.00 
699.00 
40-006 4 
12 
 
0.00 
* 
347.00 
* 
24.50 
* 
6.07 
* 
* 
* 
* 
* 
* 
* 
14.90 
* 
180.00 
* 
40-007* 12 
 
0.00 773.00 108.00 35.70 64.40 736.00 297.00 60.90 913.00 
40-008 12 
18 
 
0.00 
0.00 
348.00 
606.00 
55.70 
131.00 
7.90 
19.70 
6.80 
24.80 
292.00 
711.00 
96.90 
198.00 
 
9.93 
28.10 
194.00 
1655.00 
20-009 12 
18 
 
0.00 
0.00 
430.00 
708.00 
226.00 
368.00 
27.20 
25.80 
33.40 
60.40 
340.00 
886.00 
272.00 
328.00 
35.10 
45.90 
488.00 
1234.00 
 
35-010 12 
18 
 
0.00 
0.00 
538.00 
461.00 
137.00 
129.00 
18.40 
29.30 
35.00 
62.70 
3410.00† 
815.00 
97.60 
195.00 
31.80 
85.70 
348.00 
558.00 
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Patient study 
no. 
Dose 
AG014699 
(mg/m
2
) 
[AG014447] ng/ml 
D1 pre-dose D1 EOI D1 1-3 hrs D2 pre-dose D4 pre-
dose 
D4 EOI D4 1-3 hrs D5 pre-
dose 
D5 EOI 
35-011 12 
18 
0.00 
0.00 
754.00 
342.00 
86.20 
109.00 
24.50 
24.40 
33.80 
68.20 
325.00 
706.00 
83.50 
156.00 
38.80 
36.40 
549.00 
1000.00 
 
20-016 12 
18 
0.00 
0.00 
698.00 
979.00 
* 
387.00 
17.20 
76.80 
25.70 
46.50 
1110.00 
2010.00 
218.00 
418.00 
31.50 
66.10 
661.00 
877.00 
 
35-017 12 
18 
0.00 
0.00 
344.00 
431.00 
139.00 
170.00 
19.60 
31.80 
32.50 
74.10 
568.00 
445.00 
207.00 
280.00 
44.80 
64.80 
884.00 
589.00 
 
40-018 12 
18 
0.00 
0.00 
681.00 
811.00 
93.80 
120.00 
28.10 
42.30 
32.00 
84.60 
457.00 
490.00 
134.00 
298.00 
44.30 
76.10 
656.00 
885.00 
 
20-012 18 0.00 
 
622.00 259.00 18.30 27.30 920.00 302.00 29.00 1095.00 
35-013 18 0.00 
 
894.00 307.00 61.70 70.90 1180.00 464.00 94.20 745.00 
40-014 18 0.00 407.00 40.60 2.99 4.56 655.00 157.00 3.71 362.00 
35-015 18 0.00 679.00 203.00 369.00 395.00 1385.00 675.00 434.00 1600.00 
20-019 18 0.00 703.00 192.00 35.40 44.90 * * 42.80 784.00 
35-020 18 0.00 883.00 248.00 24.30 49.50 2400.00 441.00 69.80 967.00 
35-021 
 
 
 
18 0.00 985.00 158.00 27.40 65.70 455.00 222.00 56.10 653.00 
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Patient study 
no. 
Dose 
AG014699 
(mg/m
2
) 
[AG014447] ng/ml 
D1 pre-dose D1 EOI D1 1-3 hrs D2 pre-dose D4 pre-
dose 
D4 EOI D4 1-3 hrs D5 pre-
dose 
D5 EOI 
40-022 18 0.00 1460.00 173.00 53.30 85.90 1390.00 368.00 81.70 854.00 
36-023 18 0.00 1760.00 624.00 62.60 91.40 1680.00 747.00 1780.00
◊
 * 
35-024 18 0.00 444.00 102.00 5.55 3.96 300.00 100.00 3.18 276.00 
36-025 18 0.00 1770.00 121.00 6.46 12.20 423.00 131.00 11.30 620.00 
06-027 18 0.00 930.00 157.00 53.70 92.20 1360.00 348.00 81.00 538.00 
52-028 18 0.00 279.00 92.30 17.70 34.80 298.00 213.00 41.10 355.00 
40-029 18 0.00 1666.00 280.00 66.80 95.00 1600.00 645.00 108.00 1920.00 
35-030 18 0.00 740.00 103.00 18.70 82.80 812.00 128.00 47.30 280.00 
35-031 18 0.00 1050.00 273.00 88.10 118.00 2480.00 589.00 110.00 1260.00 
52-032 18 0.00 1350.00 270.00 118.00 162.00 808.00 * 209.00 691.00 
06-033 18 0.00 691.00 344.00 78.00 134.00 1140.00 586.00 74.30 837.00 
35-035 18 0.00 700.00 191.00 83.00 83.50 1120.00 386.00 112.00 1140.00 
35-037 18 0.00 1000.00 353.00 44.50 * 1620.00 48.30 143.00 877.00 
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Patient study 
no. 
Dose 
AG014699 
(mg/m
2
) 
[AG014447] ng/ml 
D1 pre-dose D1 EOI D1 1-3 hrs D2 pre-dose D4 pre-
dose 
D4 EOI D4 1-3 hrs D5 pre-
dose 
D5 EOI 
35-038 18 0.00 348.00 157.00 20.50 75.00 354.00 14.80 53.80 391.00 
 
Table 5.6: Concentration of AG014447 (ng/ml) for the 35 patients in both Stage 1 and 2. * indicates that result unavailable due to sampl e not being taken or 
insufficient sample to do analysis †◊ Spurious results were confirmed in repeated assays but removed from further PK analysis 
 
 
 
Dose level No. Patients Mean concentration AG014447 (ng/ml) ± SD   (%CV) 
D1 pre-dose D1 EOI D1 1-3h D2 pre-dose D4 pre-dose D4 EOI D4 1-3h D5 pre-dose D5 EOI 
4 mg/m
2
  6 0.00 246.10 
103.30 
(42) 
 
29.08 
19.14 
(66) 
6.71 
4.64 
(69) 
11.87 
8.31 
(70) 
268.60 
109.30 
(41) 
73.50 
34.96 
(48) 
13.46 
9.03 
(67) 
254.30 
97.12 
(38) 
 
12 mg/m
2
 14 0.00 676.50 
271.20 
(40) 
 
119.30 
70.16 
(59) 
22.77 
11.41 
(50) 
33.26 
20.00 
(60) 
837.00 
846.00 
(101) 
184.10 
86.00 
(47) 
33.16 
15.37 
(46) 
569.30 
227.80 
(40) 
 
18 mg/m
2
 28 0.00 846.40 
423.30 
(50) 
 
216.50 
122.80 
(57) 
53.79 
68.04 
(127) 
79.63 
73.19 
(92) 
1053.00 
614.20 
(58) 
324.50 
200.40 
(62) 
142.40 
331.10 
(232) 
853.40 
419.90 
(49) 
 
Table 5.7: Summary the PK AG014447 statistics for the three dose levels  
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5.4.5 Effects the of Pharmacokinetics of AG014699 on inhibition of PARP-1 activity 
To determine whether any relationship exists between the PK of AG014699 and extent 
of PARP-1 enzyme inhibition paired sample sets of PK and PD (where available) for 
each patient treated within each dose level were investigated.  
The results of PARP-1 enzyme inhibition at the D1 EOI and D1 24 hour time-points 
were analysed together with the D1 Cmax (EOI) and D2 pre-dose plasma levels of 
AG014447 using Pearson correlation coefficients. The D1 EOI and D2 pre-dose data 
sets for PARP-1 activity were not normally distributed (positive skew) and therefore a 
log transformation was performed prior to application of the correlation.   
In the 4 mg/m2 cohort an inverse relationship was observed between the 
concentration of AG014447 and the levels of PARP-1 enzyme activity; with a trend 
towards higher levels of plasma concentration AG014447 being associated with lower 
PARP-1 activity. The strongest association was with the D1 Cmax AG014447 and the D1 
EOI PARP-1 activity (R2 = 0.62, P = 0.06) and the D2 pre-dose concentration of 
AG014447 and the 24 hour PARP-1 activity levels (R2 = 0.63, P = 0.06). These results, 
presented in figure 5.16, did not reach statistical significance but this may have been 
secondary to the small sample size. Not unexpectedly, the relationship between PARP-
1 activity at D1 24 hours and the D1 Cmax AG014447 showed the lowest correlation (R
2 
= 0.50, P = 0.12). 
In the 12 mg/m2 cohort again a trend towards lower PARP-1 activity with higher 
plasma concentrations of AG014447 at the D2 pre-dose paired time-points was seen 
but any relationship was weak and not statistically significant (R2 = 0.34, P = 0.10), see 
figure 5.17.  
At the highest dose level 18 mg/m2 cohort no significant relationship was observed 
between the degree of PARP-1 activity and the plasma concentration of AG014447 in 
any of the data sets, see Figure 5.18.  
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Figure 5.16: Relationship between concentration of AG014447 and PARP-1 enzyme activity for 
the 4 mg/m2 cohort (A) log10 PARP-1 activity D1 vs. Cmax AG014447 D1. (B) log10 PARP-1 activity 
D2 pre-dose vs. Cmax AG014447 D1. (C) log10 PARP-1 activity D2 pre-dose vs. [AG014447] D2 
pre-dose. R2 and P values calculated using Pearson correlation coefficient. 
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Figure 5.17: Relationship between concentration of AG014447 and PARP-1 enzyme activity for 
the 12 mg/m2 cohort. (A) log10 PARP-1 activity D1 vs. Cmax AG014447 D1. (B) log10 PARP-1 
activity D2 pre-dose vs. Cmax AG014447 D1.(C) log10 PARP-1 activity D2 pre-dose vs. [AG014447] 
D2 pre-dose. R2 and P values calculated using Pearson correlation coefficient. 
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Figure 5.18: Relationship between concentration of AG014447 and PARP-1 enzyme activity for 
the 18 mg/m2 cohort.(A) log10 PARP-1 activity D1 vs. Cmax AG014447 D1.(B) log10 PARP-1 
activity D2 pre-dose vs. Cmax AG014447 D1.(C) log10 PARP-1 activity D2 pre-dose vs. [AG014447] 
D2 pre-dose. R2 and P values calculated using Pearson correlation coefficient. 
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5.4.6 Pharmacokinetics of AG014699 in a tumour biopsy  
As part of the Phase II PARP-BRCA study ethical approval to obtain single on-study 
tumour biopsies was obtained. Patient 40-014, with BRCA1 mutated ovarian cancer, 
had a vaginal vault recurrence at the time of study referral and consented to this 
additional biopsy. Patient 40-014 was treated within stage two of the trial and received 
all doses of AG014699 at a dose of 18 mg/m2. Unfortunately, due to the availability of 
the gynae-oncology surgical team the biopsy could not be taken until the patient’s 
second cycle of AG014699 treatment. The biopsy therefore did not coincide with the 
peripheral blood PK or PD sampling, which occurred, for this patient, in C1 only. The 
sample was taken 240 min following the start of the AG014699 infusion on C2 D4. The 
tumour was immediately snap frozen in liquid nitrogen and stored at -800 C until 
homogenisation and analysis using LC/MS/MS assay as described in chapter two, 
section 2.11. The concentrations of the analyte (AG014447) detected were multiplied 
by four to account for the dilution of the sample that occurred during the 
homogenisation step  Results are shown in figure 5.19 together with the patient’s 
plasma concentrations of AG014447 for C1. AG014447 was detectable in the tumour 
homogenate at a concentration of 692 ng/ml. This concentration compares to a 
plasma concentration of 157 ng/ml on the D4 + 92 min time-point in cycle 1 and 
demonstrates good tumour penetration and accumulation relative to plasma of 
AG014699 following intravenous administration. 
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Figure 5.19: Concentration of AG014447 (ng/ml) in Patient 40-014 plasma (P) and tumour (T) samples following 18 mg/m2 in cycle (C) one day (D) 1 and 4 for 
plasma and C2 D4 for the tumour homogenate. 
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5.4.7 Pharmacogenomics of AG014699 metabolism 
A single whole blood sample was scheduled to be taken for each patient prior to 
commencing the first cycle of AG014699 for use in genotyping assays. DNA was 
extracted as described in section 5.3.3 and subsequently analysed using TaqMan Real-
time PCR genotyping assay kits (Applied Biosystems, Warrington, UK) as described in 
chapter two, Materials and Methods, section 2.4.3. Whole blood samples for analysis 
of the CYP2D6 *2 and CYP2D6*4 SNP were received for 31 out of the 38 patients. The 
main reason for not obtaining a result for a given patient was that the blood sample 
was not taken at the treatment centre.  
5.4.7.1 CYP2D6*2 
Results for all 31 patients are shown in table 5.8 together with the corresponding PK 
results. The frequencies of the genotypes were as follows: major genotype (T/T) 12.9%, 
the heterozygote genotype (T/C) 38.7% and the minor variant genotype (C/C) 48.4%. 
The minor allele frequency of 68% is not in Hardy Weinberg Equilibrium (P = 0.52) and 
the frequency of the variant genotype higher than that reported in other Caucasian 
populations (20-35%), (Sistonen et al., 2007; Ramon y Cajal et al., 2010). However this 
result is difficult to interpret given the small sample size of this study. Figure 5.20 
shows the D1 Cmax (A) and D2 pre-dose concentrations of AG014447 (B) by CYP2D6*2 
genotype result.  
5.4.7.2 CYP2D6*4 
CYP2D6*4 is the most common inactivating mutation found in Caucasian populations. 
It is reported to occur at a frequency of between 12 – 23% in European populations 
(Sistonen et al., 2007; Ramon y Cajal et al., 2010). Results for all 31 patients are shown 
in table 5.8 together with the corresponding PK results. The frequencies of the 
genotypes were similar to that reported in previous population studies (see above) and 
as follows: major genotype (G/G) 77.4%, the heterozygote genotype (G/A) 12.9% and 
the minor variant genotype (A/A) 9.7%. The minor allele frequency is 16% and 
consistent with Hardy Weinberg Equilibrium (P = 0.004). Figure 5.20 shows the D1 Cmax 
(A) and D2 pre-dose concentrations of AG014447 (B) by CYP2D6*4 genotype result. 
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Patient no. CYP2D6*2 
 
CYP2D6*4 D1 Cmax [AG014447]  
ng/ml 
D2 pre-dose[AG014447] 
ng/ml 
40-001 C/C G/A 844.00 2.06 
40-002 T/T G/G 658.00 11.80 
40-003 T/C G/G 883.00 39.80 
40-004 C/C A/A 488.00 26.40 
40-005 T/C G/G 1356.00 37.30 
40-006 C/C G/G * * 
40-007 T/C G/G 773.00 35.70 
40-008 C/C G/G 606.00 19.70 
20-009 C/C G/G 708.00 25.80 
35-010 T/C G/G 461.00 29.30 
35-011 T/C G/G 342.00 24.40 
35-013 T/C G/G 894.00 61.70 
40-014 C/C A/A 407.00 2.99 
20-016 C/C G/A 979.00 76.80 
35-017 C/C G/G 431.00 31.80 
40-018 T/C G/G 811.00 42.30 
20-019 T/T G/G 703.00 35.40 
35-020 C/C G/A 883.00 24.30 
35-021 T/T G/G 985.00 27.40 
40-022 T/C G/G 1460.00 53.30 
36-023 T/C G/G 1760.00 62.60 
35-024 C/C G/G 444.00 5.55 
36-025 C/C G/A 1770.00 6.46 
52-028 T/T G/G 279.00 17.70 
40-029 C/C G/G 1666.00 66.80 
35-030 C/C A/A 740.00 18.70 
35-031 T/C G/G 1050.00 88.10 
52-032 T/C G/G 1350.00 118.00 
35-035 C/C G/G 700.00 83.00 
35-037 T/C G/G 1000.00 44.50 
35-038 C/C G/G 348.00 20.50 
 
Table 5.8: CYP2D6 genotyping results together with patients corresponding pharmacokinetic 
results.  
* Sample not taken. 
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Figure 5.20: Box and whiskers plots showing concentration of AG014447 at D1 Cmax (A) and D2 
pre-dose (B ) by CYP2D6 *2 and *4 genotype. P values are results of ANOVA comparing all 
three groups.  
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5.4.8 Clinical Outcomes of the Phase II trial 
Between January 2007 and September 2010 38 patients were enrolled into the study 
and results for these patients are evaluated here. Final results of the completed study 
will be reported at a later date. 
5.4.8.1 AG014699 administered 
All 38 patients received at least one complete 21 day cycle of AG014699. In stage one 
of the study six patients received one cycle of AG014699 at the 4 mg/m2 dose level and 
14 patients (including the previous six) received a cycle at the 12 mg/m2 level. In the 
second stage of the trial 31 patients (including seven from stage one cohort two) 
received at least one cycle of AG014699 at 18 mg/m2. To the end of September 2010 a 
total of 201 AG014699 cycles were administered within the study. The median number 
of treatment cycles per patient was five (range = 1-21). Six patients were dose-
escalated from 4 mg/m2 to 12 mg/m2 and seven patients were dose-escalated from 12 
mg/m2 to 18 mg/m2 as per study protocol. No patients received a dose reduction. No 
treatment cycles were delayed due to AG014699-related toxicity. 
5.4.8.2 Toxicity 
All 38 patients received at least one dose of AG014699 and were therefore assessable 
for toxicity. Toxicity was categorised and coded by the CTCAE version 3.0. Over-all 
AG014699 was well tolerated in this patient population with no dose-limiting toxicities 
observed in any stage of the study. This adds to the findings of the phase I study of 
AG014699 in combination with temozolomide, in which no toxicity from test doses of 
single-agent AG014699 were reported (Plummer et al., 2008).  
AG014699 had an acceptable safety profile with drug-related toxicity mainly grade 1 
and 2. The most commonly reported AG014699-related grade 1/2 non-haematological 
toxicities being: fatigue (16/38, 42.1% of patients), nausea (28.9%) and diarrhoea 
(21.1%). Haematological toxicities were not expected based on the previous studies of 
single doses of AG014699. However, possibly related grade 2 anaemia was reported in 
patient 40-007 during cycle one and possibly related grade 2 lymphopenia, grade 1 
neutropenia and grade 1 thrombocytopenia were seen in patient 40-001 during C18. 
No patient withdrew from the study due to toxicity.  
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Two patients died within 28 days of last study drug treatment and both deaths were 
deemed to be unrelated to AG014699. Patient 40-007 died of disease progression on 
study and patient 52-032, with heavily pre-treated metastatic breast cancer, died of 
hepatic failure. All recorded adverse events (AEs) to date are listed in Table 5.9. 
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Body system Adverse event CTCAE category Number of episodes  (Number of patients : % of total number of patients) 
All AEs Related AEs Grade 3/4/5 Related AEs 
Auditory/Ear Auditory/Ear (other) 
Tinnitus 
1   (1: 2.6%) 
1   (1: 2.6%) 
0   (0: 0%) 
1   (1: 2.6%) 
0   (0: 0%) 
0   (0: 0%) 
Blood/Bone marrow Anaemia 
Lymphopenia 
Neutropenia 
Thrombocytopenia 
1   (1: 2.6%) 
2   (2: 5.3%) 
2   (2: 5.3%) 
1   (1: 2.6%) 
1   (1: 2.6%) 
1   (1: 2.6%) 
1   (1: 2.6%) 
1   (1: 2.6%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
Cardiac arrhythmia Palpitations 
Sinus bradycardia 
Sinus tachycardia 
Vaso-vagal episode 
1   (1: 2.6%) 
1   (1: 2.6%) 
1   (1: 2.6%) 
1   (1: 2.6%) 
1   (1: 2.6%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
Cardiac General  Hypertension 2   (1: 2.6%) 2   (1: 2.6%) 0   (0: 0%) 
Constitutional Symptoms Fatigue 
Fever 
Insomnia 
Rigors/chills 
Weight gain 
Weight loss 
36   (20: 52.6%) 
6   (5: 13.2%) 
3   (3: 7.9%) 
1   (1: 2.6%) 
1   (1: 2.6%) 
4   (4: 10.5%) 
31   (18: 47.3%) 
2   (2: 5.3%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
3   (2: 5.3%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
Death Death-disease progression NOS 1   (1: 2.6%) 0   (0: 0%) 0   (0: 0%) 
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Body system Adverse event CTCAE category Number of episodes  (Number of patients : % of total number of patients) 
All AEs Related AEs Grade 3/4/5 Related AEs 
Dermatology/Skin Alopecia 
Bruising 
Dermatology-other 
Erythema multiforme 
Infection site reaction 
Pruritus 
Rash 
3   (2: 5.3%) 
3   (3: 7.9%) 
8   (5: 13.2%) 
2   (2: 5.3%) 
13   (6: 15.8%) 
12   (3: 7.9%) 
2   (2: 5.3%) 
3   (2: 5.3%) 
0   (0: 0%) 
3   (2: 5.3%) 
0   (0: 0%) 
8   (3: 7.9%) 
12   (3: 7.9%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
Endocrine Hot flashes 1   (1: 2.6%) 0   (0: 0%) 0   (0: 0%) 
Gastrointestinal  Anorexia 
Constipation 
Dehydration 
Diarrhoea 
Distension 
Dry mouth 
Dysphagia 
Flatulence 
GI-other 
Heartburn 
8   (8: 21.1%) 
16   (10: 26.3%) 
2   (1: 2.6%) 
25   (14: 36.8%) 
14   (11: 28.9%) 
3   (3: 7.9%) 
1   (1: 2.6%) 
1   (1: 2.6%) 
4   (3: 7.9%) 
4   (4: 10.5%)  
4   (4: 10.5%) 
2   (2: 5.3%) 
0   (0: 0%) 
15   (8: 21.1%) 
0   (0: 0%) 
1   (1: 2.6%) 
0   (0: 0%) 
0   (0: 0%) 
2   (1: 2.6%) 
1   (1: 2.6%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
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Body system Adverse event CTCAE category Number of episodes  (Number of patients : % of total number of patients) 
All AEs Related AEs Grade 3/4/5 Related AEs 
Gastrointestinal  Mucositits 
Nausea 
Obstruction GI-Colon 
Obstruction GI-Small bowel  
Taste alteration 
Teeth 
Ulceration-stoma 
Vomiting 
2   (1: 2.6%) 
31   (18: 47.4%) 
2   (1: 2.6%) 
1   (1: 2.6%) 
1   (1: 2.6%) 
1   (1: 2.6%) 
1   (1: 2.6%) 
30   (14: 36.8%) 
0   (0: 0%) 
14   (11: 28.9%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
6   (5: 13.2%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
Haemorrhage/Bleeding Haem GU-urinary 
Haem GU-vagina 
Haemorrhage-other 
1   (1: 2.6%) 
8   (3: 7.9%) 
2   (2: 5.3%) 
0   (0: 0%) 
1   (1: 2.6%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
Hepatobiliary/Pancreas Liver dysfunction 1   (1: 2.6%) 0   (0: 0%) 0   (0: 0%) 
Infection All systems 26   (19: 50.0%) 2   (2: 5.3%) 0   (0: 0%) 
Lymphatics Lymphatics-other 
Limb oedema 
1   (1: 2.6%) 
8   (6: 15.8%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
Metabolic/Laboratory ALT 
ALP 
Creatinine 
3   (3: 7.9%) 
3   (2: 5.3%) 
1   (1: 2.6%) 
1   (1: 2.6%) 
2   (1: 2.6%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
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Body system Adverse event CTCAE category Number of episodes  (Number of patients : % of total number of patients) 
All AEs Related AEs Grade 3/4/5 Related AEs 
Neurology Dizziness 
Mood-Anxiety 
Mood-Depression 
Sensory neuropathy 
16   (10: 26.3%) 
3   (3: 7.9%) 
1   (1: 2.6%) 
9   (6: 15.8%) 
13   (7: 18.4%) 
0   (0: 0%) 
1   (1: 2.6%) 
4   (3: 7.9%) 
0   (0: 0%) 
0   (0: 0%) 
1   (1: 2.6%) 
0   (0: 0%) 
Ocular/Visual Dry eye 
Vitreous haemorrhage 
1   (1: 2.6%) 
1   (1: 2.6%) 
1   (1: 2.6%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
Pain Pain-Abdomen 26   (15: 39.5%) 3   (2: 5.3%) 0   (0: 0%) 
Pulmonary/Upper 
respiratory 
Cough 
Dyspnoea 
Pleural effusion 
9   (8: 21.1%) 
8   (4: 10.5%) 
2   (2: 5.3%) 
1   (1: 2.6%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
Renal/Genitourinary Ureteric obstruction 
Urinary frequency 
3   (1: 2.6%) 
1   (1: 2.6%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
Syndromes Flu-like symptoms 1   (2.6%) 0   (0: 0%) 0   (0: 0%) 
Vascular Phlebitis 
Thromboembolism 
1   (1: 2.6%) 
3   (2: 5.3%) 
1   (1: 2.6%) 
0   (0: 0%) 
0   (0: 0%) 
0   (0: 0%) 
 
Table 5.9: Adverse events listings for the PARP-BRCA Phase II Trial 
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5.4.8.3 Response Rate 
The primary end-point of the clinical trial was best objective response rate (ORR) as 
measured by the RECIST. At the time of writing this thesis, 35 of the 38 patients 
recruited had received two complete cycles of AG014699 and were eligible for a 
response evaluation. The three non-evaluable patients were: patient 40-007 who had 
clinical evidence of disease progression after C1; patient 20-026 who required ureteric 
stenting after C1 and patient 52-032 who withdrew their consent on C2 D3 of 
treatment. Therefore, for these 35 patients the ORR was 6% (2/35; patient 40-005 and 
35-010). However, almost half the patients (49%, 17/35) achieved stable disease after 
two cycles, with 29% of all patients (10/35) achieving disease stabilisation for greater 
than four months and three patients remaining on study for over 54 weeks. This gives 
a clinical benefit response (CBR) rate of 34% (12/35). Interestingly this CBR rate was 
spread across all stages of the study and not limited to patients receiving the higher 18 
mg/m2 AG014699 doses. 16 patients had evidence of disease progression after two 
cycles of AG014699 and were withdrawn from the study. Data for the best overall 
response (expressed as % change in target lesions from pre-treatment values) was 
available in 33 of the 35 patients and is shown by waterfall plot in figure 5.21. 
 
 
Figure 5.21: Waterfall plot showing best RECIST response to AG014699 expressed as % change 
in target lesions over baseline measurements. The grey bars represent patients with 
progressive disease, the white bars patients with stable disease and the yellow bars patients 
with a partial response. Data shown are results for 33 patients.  
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The two patients who had partial responses to AG014699 were patients 40-005 
(BRCA2 breast) and 35-010 (BRCA1 ovary). Patient 40-005 had a partial response at C4 
and a time to progression (TTP) of 173 days. She remained on study until radiological 
evidence of disease progression occurred shortly after C8. Patient 35-010 had a partial 
response at C8, a TTP of 421 days with evidence of disease progression after C20.  The 
PD and PK data for these patients were subsequently reviewed and compared with the 
results for the rest of the study population. Patient 40-005 was found to have 
significantly higher endogenous PARP-1 activity (mean = 0.34 vs. 0.09 pmol PAR per 
104 PBL; P = 0.0001, un-paired t-test with Welch correction) but significantly lower 
levels of PARP-1 protein expression (mean = 0.11 vs. 0.21 ng per g total protein; P = 
0.008, un-paired t-test with Welch correction). These data are difficult to interpret 
given that no differences were seen in PARP-1 activity or expression levels in the other 
partial responder patient 35-010. 
To investigate whether the results of PD, PK end-points and baseline tumour 
characteristics differed between responders and non-responders in the whole study 
population, patients were divided into three outcome groups: those that had a partial 
response after 2 cycles and/or disease stabilisation for ≥ four months i.e. had a CBR 
(n=12); those who had SD after C2 but for less than four months (n=7) and finally those 
patients who developed PD after C2 i.e. at the first response assessment (n=16). Figure 
5.22 shows the patients divided into these three groups, colour coded by dose level 
cohort.  
5.4.8.4 Response to AG014699 and baseline PARP-1 characteristics 
Results for baseline PARP-1 characteristics (endogenous i.e. un-stimulated, PARP-1 
activity and baseline protein expression) by response to AG014699 are shown as box-
plots in figure 5.23. Patients in the CBR group had a significantly higher pre-treatment 
baseline PARP-1 activity than those who failed to respond to AG014699 (mean log10 
activity = 0.69 vs. 0.23 pmol PAR per 104 PBL, P = 0.03, un-paired t-test). However this 
difference was not seen with the endogenous PARP-1 activity levels (Figure 5.23B) 
PARP-1 protein levels were higher in the CBR group than the SD and PD groups (mean 
log10 expression = -0.66 vs. -0.74 vs. -0.89 ng per g total protein) but there was no 
significant statistical difference between the groups (P = 0.06, using one way ANOVA) 
(figure 5.23C). 
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Figure 5.22: Response to AG014699 by dose cohort. Grey bars denote patients in cohort 1, 
stage 1; green bars patients in cohort 2, stage 1 and the blue bars represent stage 2 patients. 
PD = progressive disease after two cycles, SD = stable disease after two cycles but for < four 
months and CBR = partial response after C2 and/or disease stabilisation for ≥ four months.  
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Figure 5.23: Box and whiskers plots showing (A) Pre-treatment PARP-1 levels, (B) Endogenous 
PARP-1 levels and (C) PARP-1 expression by clinical response to AG014699. 
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5.4.8.5 Clinical response to AG014699, PARP-1 inhibition and AG014699 PK  
Results for PARP-1 activity at the D1 EOI and D2 pre-dose time-points together with 
their corresponding PK samples were grouped into the same three response 
outcomes: CBR, SD and PD. Box plots for each data set are shown in figure 5.24.  
Although the best responders (CBR group) had the lowest mean D1 EOI PARP-1 activity 
levels (0.67 pmol PAR per 104 PBL) this did not differ significantly from the other two 
groups (SD = 1.03 pmol PAR, PD = 0.68 pmol PAR; P = 0.47 1 way ANOVA).  
A similar picture was seen at the D2 pre-dose PARP-1 activity levels (figure 5.24B) with 
no significant difference between the three groups. Analysis of the concentration of 
AG014699 at these time-points revealed no difference in the plasma concentrations 
between the clinical response groups (figure 5.24C+D). In fact the mean D1 C max values 
were almost identical with CBR = 813.3 ng/ml, SD = 858.6 ng/ml and PD = 831.4; P = 
0.97 1 way ANOVA).  
Interestingly mean D2 pre-dose levels of AG014447 were lowest in the CBR group 
(32.11 ng/ml) but not significantly different from the SD (41.93 ng/ml) and PD (61.96 
ng/ml) results. 
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Figure 5.24: Box and whiskers plots of results of pharmacodynamic and kinetic assays by clinical outcome group. A: D1 EOI PARP-1 activity, B: 
D2 pre-dose PARP-1 activity, C: [AG014447] D1 EOI and D: D2-pre-dose AG014447 levels. P values calculated using 1 way ANOVA. 
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5.5 Discussion 
The purpose of this study was to investigate the efficacy and toxicity of AG014699 in 
patients with advanced breast or ovarian cancer and known mutations within 
BRCA1/2. In addition, to evaluate pharmacodynamic, pharmacokinetic and 
pharmacogenomic endpoints and investigate their relationships, if any, to the clinical 
outcomes. And finally, to investigate whether using the data generated can more 
accurately predict which patients will respond to AG014699 and best apply this to 
future studies.  
At the time of writing the phase II PARP-BRCA PH2/052 trial is still on-going. Data 
presented and discussed in this chapter are for the first 38 patients recruited and 
treated up to the 30th September 2010. 
5.5.1. Patient recruitment and demographics 
It was initially envisaged that accrual of the 56 required patients would take 24 
months, with an average of 2-3 patients recruited per month. However recruitment 
has been slower than predicted; one possible reason for this is the restriction on the 
prior number of chemotherapies permitted in the metastatic breast cancer (MBC) 
patients. Oncologists treating MBC have an armamentarium of at least four systemic 
chemotherapies to use often before they will refer patients for early studies testing 
novel agents. This restriction on prior treatment has since been removed in a recent 
protocol amendment and hopefully will result in an increase in recruitment of MBC 
patients. Other possible reasons for the slow recruitment are: the presence of 
competing PARP inhibitor studies and the restriction of excluding non-UK residents, 
which of course reduces the pool of BRCA1/2 carrier patients. In contrast, the olaparib 
early phase studies recruited quickly and were conducted internationally including 
cancer centres specialising in the treatment of patients with familial cancers (Fong et 
al., 2009; Audeh et al., 2010; Tutt et al., 2010).  
For the 38 patients discussed in this chapter all were female with 16 (42%) having 
breast cancer and 22 (58%) ovarian cancer. 21 (55%) of the patients had a BRCA1 
mutation and 17 (45%) carried a BRCA2 mutation. The low number of BRCA2 ovarian 
cancer patients (n=6) may reflect the lower risk of developing ovarian cancer in BRCA2 
mutation carriers (Ford et al., 2004). Patients mean age was 51.4 years with a range of 
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28 to 72 years. This mean age is at least ten years lower than the reported average age 
at diagnosis of breast (61 years) and ovarian cancer (63 years) 
(www.cancerresearchuk.org/cancerstats) and not unexpected given that BRCA 
mutation carriers present at an earlier age with cancer (King et al., 2003). 
Patients were all of a good performance status (WHO 0-1) and had received a mean 
number of two prior chemotherapies. All the ovarian cancer patients had received 
prior platinum therapy, either as carboplatin or cisplatin. The study excluded platinum 
refractory ovarian cancer patients at design because the investigators surmised that 
cancers resistant to the platinums may also be insensitive to PARP inhibitors. Since the 
study was designed this theory has been confirmed by reports of cisplatin therapy 
inducing secondary mutations in known BRCA2 mutation carriers resulting in 
restoration of BRCA2 protein function and platinum resistance (Sakai et al., 2009). In 
addition Fong et al. reported that there was a positive correlation between greatest 
response to the PARP inhibitor olaparib and the longer the patient’s platinum-free 
interval (PFI) (Fong et al., 2010). Unfortunately information on the PFI of the 22 
ovarian cancer patients in this study is not available but would be useful when 
discussing the individual’s response to AG014699.  
5.5.2. Baseline PARP-1 characteristics 
The baseline PARP-1 activity was determined in the C1D1 pre-dose blood sample 
(obtained for 35 (92%) of patients) and enabled assessment of both endogenous PARP 
activity i.e. that which was not stimulated in the PARP activity assay by the addition of 
oligonucleotide and the substrate NAD+ and the maximum stimulated PARP-1 activity 
in the PBL prior to addition of the PARP inhibitor.  
Results for all 35 patients show low levels of endogenous PARP activity, with a mean 
value = 0.097 pmol PAR per 104 PBL and a large variation between patients (CV = 
146.5%). The majority of results are read from the lower end of the standard curve 
which questions the accuracy of measuring such low LAU values. Loading more than 
10,000 PBL into each well would result in a higher LAU signal and this could be 
considered for future work. As yet no published data are available for comparison of 
endogenous PBL PARP-1 activity in similar populations or even in non-BRCA cancer 
population or healthy volunteers using these methods.   
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For all patients the mean baseline maximum stimulated PARP activity was 6.80 pmol 
PAR per 104 PBL. Again a large variation in activity was seen between individuals; range 
0.38 – 40.26 pmol PAR per 104 PBL and % CV = 145%.  
Two other studies have measured baseline maximum stimulated PARP activity in 
cancer patients and healthy volunteers using the same PD assay (Jones, MD thesis 
2006; Zaremba et al., 2011). Both these studies showed a large variation in baseline 
PARP activity levels between subjects. This may be because a true inter individual 
variation in PARP activity exists but the limitation of the immunoblot assay must also 
be considered. As discussed in chapter two: section 2.9, samples from individual 
patients were all analysed on the same blot to eliminate  the known inter-assay 
variability and enable accurate comparisons of PARP activity levels in response to 
AG014699.  However it was only possible to load a maximum of two patients’ samples 
on any given blot. Therefore in comparing the PARP activity results for the whole study 
population multiple blots are being compared and although the inter-assay variability 
was well within the range (20-30%) considered acceptable for biological assays it may 
have contributed the large variation seen.  
In addition data from Chris Jones (MD thesis, Newcastle University, UK) shows that 
activity levels vary up to 1.9-fold within the same subject in any given 72 hour period 
and this also has implications for this study where patients PARP activity in respons e to 
AG014699 is measured over a 24 hour period. Interestingly, a mean PARP activity in 
this PARP-BRCA PH2/052 study population of 6.80 pmol is almost double that reported 
in Zaremba’s study of 118 cancer patients with unknown BRCA status (mean = 3.60 
pmol). One could argue that this is simply a result of the inter-assay variability. 
However one possible explanation for this finding is that PARP is hyper-activated in 
patients with BRCA mutations, suggesting an up-regulation of the BER pathway to 
compensate for defective HR. This theory has also been proposed by Gottipati et al 
who demonstrated that PARP activity is increased in BRCA2-defective hamster cell 
lines (V-C8) compared to their BRCA2-complimented counter-parts (V-C8 + B2) 
(Gottipati et al., 2010). In addition, they showed that PAR was over-expressed in the 
BRCA- deficient human pancreatic cancer cell line, CAPAN-1, when compared to the 
BRCA2-proficient human pancreatic cancer cell line BXPC3. No increase in DNA single 
strand breaks were seen in these BRCA2-defective cell lines to account for this increase 
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in PARP activity. The authors speculated that this up-regulation of or over-dependence 
on PARP-1 could be the underlying mechanism behind the sensitivity of BRCA-
defective cells to PARP inhibitors. But there are differences between the current study 
and that undertaken by Gottipati et al. For example, they measured un-stimulated 
activity as opposed to maximally stimulated PARP activity; they used BRCA defective 
cell lines instead of the surrogate tissues (PBL) and finally activity was determined 
through a different pharmacodynamic assay; therefore extrapolation to results 
presented here for this study is difficult.  
Interestingly though in Gottipati’s study increased levels of PARP activity (defined by  
PAR polymer quantification) correlated well with increased sensitivity to PARP-1 
inhibition by 4 amino-1.8-naphthalimide (ANI) and they suggested that PAR levels 
could potentially be used as a biomarker to select out patients that might benefit from 
PARP inhibitor therapy. In a recent review of clinical biomarkers Redon et al also 
suggested as endogenous PARP activity levels vary between patients they may prove a 
useful biomarker to determine which patients will be sensitive to PARP inhibitors 
(Redon et al., 2010).  
Review of the data presented in this chapter failed to show a link between endogenous 
PARP activity levels and clinical response to AG014699 (Figure 5.22A). However, the 
baseline mean maximum stimulated PARP-1 activity levels were significantly higher in 
those patients who responded to AG014699, defined by CBR, than those patients who 
had PD after two cycles (mean log10 activity = 0.69 vs. 0.23 pmol PAR per 10
4 PBL, P = 
0.03, un-paired t-test). This might suggest that PARP enzyme dynamic function in 
response to DNA damage can be used as a predictor of PARP inhibitor response. 
However, this will, of course, require further investigation in larger studies. In addition 
the use of PARP activity as a marker of potential PARP inhibitor sensitivity in patients 
might be problematic given that it is reported that baseline PARP activity can vary 
within the same individual in any 72 hour period up to two-fold (Chris Jones, MD 
thesis, Newcastle University, UK, 2006). 
Results for baseline PARP-1 protein expression were obtained for 30 (79%) patients 
and presented in section 5.4.2. Again as for PARP activity levels a large inter-patient 
variation was seen (% CV = 93%). Mean protein expression for the whole study 
population = 0.21 ng per g and this was the same as that reported by Zaremba (mean 
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PARP-1 expression 0.21 ng per g) suggesting that PARP-1 expression is not increased 
in BRCA defective populations.  
One might speculate that higher PARP-1 protein expression would correlate with 
increased PARP-1 enzyme activity. The data in this chapter show a trend towards 
higher activity with increased protein expression but the correlation is weak and not 
statistically significant using Pearsons correlation coefficient (R2 = 0.14, P = 0.06) (see 
figure 5.5).  
The data from this study also failed to demonstrate a relationship between age and 
either PARP-1 activity or expression. This may be due to the small numbers of patients 
sampled in the clinical trial population. Other studies investigating this have reported 
conflicting results about the link between PARP-1 activity and age (Grube and Burkle, 
1992; Muiras et al., 1998). More recently a negative correlation between increasing 
PARP activity and age in cancer patients was observed in Zaremba’s study (Zaremba et 
al., 2011). 
As discussed in section 5.1.2 lower PARP-1 activity is associated with the T2444C single 
nucleotide polymorphism within the PARP-1 gene. The amino acid substitution of 
valine to alanine in the catalytic domain of PARP-1 protein can result in an up to 40% 
reduction in PARP-1 activity (Lockett et al., 2004; Wang et al., 2007). Genotyping was 
performed on DNA extracted from 31 of the 38 study patients and only 1 patient (35-
013) was homozygous for the variant SNP (C/C). This patient had the second lowest 
baseline PARP activity and as this was a single result further statistical analysis was not 
possible. The pooled data for the T/C and the C/C patients had a lower mean activity 
than that of the T/T group but this did not reach statistical significance. Again the small 
sample size may be impeding the statistical analysis of the results.  
Interestingly, in terms of clinical response, patient 35-013 did not respond to 
AG014699 with disease progression after only two cycles. 
5.5.3 PARP activity in response to AG014699 
PARP activity following treatment with AG014699 was investigated in 33 of the 38 
study patients. Six patients received a cycle of AG014699 at a dose of 4 mg/m2; 13 
received at least one cycle at 12 mg/m2 and 24 patients were given at least one cycle 
of AG014699 at the 18 mg/m2 dose level. 12 patients were dose-escalated either from 
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4 mg to 12 mg/m2 or from 12 mg to 18 mg/m2. This enabled assessment of the degree 
of PARP inhibition to different doses of AG014699 and the effect of intra-patient dose-
escalation in BRCA patients to be investigated. Results, presented in section 5.4.3, 
show that AG014699 is a potent clinical inhibitor of PARP with a mean % inhibition 
over pre-treatment values at the end of the infusion being 97.6, 95.4 and 86.1% for the 
4 mg/m2, 12 mg/m2 and 18 mg/m2 dose levels respectively. The data also shows that 
24 hours following a single dose of AG014699 PARP-1 activity remains well below 50% 
of baseline levels, even at the lowest dose cohort of 4 mg/m2 with a mean inhibition of 
69% seen. 
However the most striking PD observation from these studies is that increasing the 
dose of AG014699 does not always result in a greater degree of PARP-1 enzyme 
inhibition. Reviewing the individual patient plots in Figures 5.8, 5.9, 5.11 and the 
summary data presented in Figure 5.13 it is clear that increasing the dose of AG014699 
results in not greater but prolonged duration of PARP-1 inhibition. A clear dose-
response is seen in the D2 pre-dose (24 hour) sample where the 18 mg/m2 schedule 
results in lower recovery of PARP-1 activity than the lower dose levels. Given that the 
current schedule of AG014699 within this study is five days of treatment every 21 days 
the prolongation of inhibition may be as important as the degree of inhibition in order 
to illicit a clinical response.  
Of note no correlation was seen between the degree of PARP-1 enzyme inhibition 
achieved at all three time-points post AG014699 and the baseline pre-treatment 
levels. 
5.5.4 Pharmacokinetics of AG014699 
Plasma samples to determine the PK of AG014447, the free base of AG014699, were 
received in 35 of the 38 patients. The results, presented in section 5.4.4, show that 
AG014699 displays linear pharmacokinetics with increasing dose. There was 
considerable inter-patient variability for each time-point, but the data set is 
comparable with the published results for the phase I study (Plummer et al., 2008). 
Interestingly, no statistically significant correlations were observed between the 
plasma concentration of AG014699 and the degree of PARP-1 enzyme inhibition and 
any dose level or time-point. A trend towards higher AG014699 concentration and 
lower PARP-1 activity was seen at the 4 mg/m2 and 12 mg/m2 dose levels, but not at 
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the highest dose 18 mg/m2. This may suggest that above a certain concentration of 
AG014699 no further PARP-1 inhibition can be achieved and the dose dependent 
effect is lost.  
The study protocol included the option of patients volunteering for an on-study 
tumour biopsy. This would enable the assessment of PARP-1 activity in the actual 
tumour as opposed to surrogate PBL and to measure the accumulation, if any, of 
AG014699 in tumour tissues. The common sites of metastatic disease in this cancer 
patient group potentially would mean biopsies of liver/lung or peritoneal deposits 
which are invasive and not without risk therefore the up-take for additional biopsy was 
low. In fact only one patient (40-014) who presented with a vaginal vault recurrence 
consented to biopsy, which was taken 240 minutes from the start of the AG014699 
infusion on D2 of C2. PD analysis of PARP-1 activity levels was not performed as no 
pre-treatment sample was available to compare the result with. However, a high 
concentration of drug was measured within the tumour (692 ng/ml), demonstrating 
that AG014699 penetrates and accumulates in tumour cells following intravenous 
administration. 
5.5.5 CYP2D6 genotyping 
Results for the CYP2D6*2 and CYP2D6*4 are presented in section 5.4.7. At this stage in 
the trial it is difficult to draw firm conclusions about the effects of the SNPs on the 
pharmacokinetics of AG014699 given the small study population of 31 patients. 
Further analysis will need to be performed with the results of the whole study 
population. 
5.5.6 Clinical outcomes 
AG014699 was well tolerated in this patient population with no dose-limiting toxicities 
seen. At the time of study design it was not known whether inhibiting PARP-1 in 
BRCA1/2 mutation carriers would be toxic to normal tissues and these results are 
reassuring.  
Perhaps the most disappointing finding of this study is the low objective response rate 
(6%) to AG014699. This is considerably lower than that reported in the phase II studies 
of olaparib in similar patient populations, where response rates of between 13 -41% 
were seen (Audeh et al., 2010; Tutt et al., 2010).  
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There are a number of possible explanations for this low response rate. Firstly, recent 
studies in cancer cell lines have demonstrated that second mutations in BRCA1 or 
BRCA2 genes can lead to resistance to PARP inhibitors (Edwards et al., 2008; Sakai et 
al., 2008; Sakai et al., 2009). Secondary mutations restoring BRCA function and HR DNA 
repair in the face of PARP inhibition may arise in order to maintain genomic integrity. 
In one study, a model for drug resistance was first developed by producing cells from 
the BRCA2-deficient human pancreatic cancer cell line, CAPAN-1, that were insensitive 
to PARP inhibitors (Edwards et al., 2008). The PARP inhibitor–resistant (PIR) clones 
developed following exposure to the PARP inhibitor KU0058948 (Farmer et al., 2005) 
are highly resistant (>1,000-fold). PIR clones are also cross-resistant to the DNA cross-
linking agent cisplatin, but not to the microtubule stabilizing drug docetaxel. 
KU0058948 and cisplatin both exert their effects on BRCA-deficient cells by increasing 
the frequency of un-repaired DSBs in the absence of effective HR, suggesting that the 
resistance of PIR clones to KU0058948 might be because of restored HR. cDNA and 
genomic DNA sequencing from PIR clones revealed the presence of novel BRCA2 alleles 
with deletions surrounding and incorporating the c.6174delT mutation, leading to the 
restoration of an open reading frame and sufficient functional BRC repeats and C -
terminal domains to restore HR repair functions.  
Platinum chemotherapy is a well-established strategy in the treatment of ovarian 
cancer, including patients bearing BRCA1 or BRCA2 mutations. Clinical observations 
suggest that BRCA1/2 mutation carriers with ovarian cancer tend to respond better to 
platinum therapy, in contrast to patients with no family history of the disease (Tan et 
al., 2008). Systemic chemotherapy with the platinum agents may exert BRCA1/2-
selective effects through similar mechanisms to PARP inhibitors. To investigate this 
further, the BRCA2 gene was sequenced in tumours from patients bearing the BRCA2 
c.6174delT mutation whose ovarian carcinomas had become resistant to carboplatin 
chemotherapy. These studies revealed deletions in the BRCA2 gene, which restored 
the open reading frame; implying that a specific mutation (c.6174delT) in BRCA2 and 
sensitivity to platinums  in both cell lines and patients could potentially be reversed by 
an intragenic deletion (Edwards et al., 2008; Sakai et al., 2009). A similar phenomenon 
has also been reported in BRCA1 mutated, cisplatin resistant ovarian cancers (Swisher 
et al., 2008). 
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In the current study population, 16 patients developed disease progression at the first 
assessment of response (after C2); suggesting primary PARP inhibitor resistance. Of 
these patients, 11 (69%) had platinum pre-treated ovarian cancer. Unfortunately, data 
is not available for their PFI and whether any of these patients would be defined as 
platinum resistant. However it is not yet clear if BRCA1/2 mutations, other than those 
reported in the studies mentioned above, can be reverted by secondary intragenic 
mutation and whether secondary mutations resulting in PARP inhibitor resistance will 
be something we see in clinical practice. But it could explain why some patients failed 
to respond to AG014699 in this study. 
Another possible explanation for the poor ORR is that these patients had unfavourable 
PARP-1 baseline characteristics or that the dose regimen did not result in optimum 
plasma levels of AG014699 or inhibition of PARP. Review of patients PARP baseline 
activity shows that patients who failed to respond i.e. the PD group had significantly 
lower PARP activity levels than those in the CBR group (0.23 vs. 0.69 pmol PAR per 104 
PBL, P = 0.03).This may imply that these patients are less reliant on the BER pathway 
and less sensitive to PARP inhibitors. Of note, PARP-1 protein expression levels were 
not significantly different between the three response groups. There was also no 
significant difference between the degree of PARP-1 enzyme inhibition and the peak 
plasma or trough concentrations of AG014699 regardless of whether or not patients 
benefited from treatment. In fact, most patients had excellent inhibition of PARP 
activity as measured by the PD assay. However it is important to note again that these 
baseline PARP characteristics were determined from PBL and not BRCA-defective 
tumour samples. 
The most likely explanation for the lack of clinical response to AG014699 seen in this 
study is the scheduling used. The drug is administered on days one to five of a 21 day 
cycle potentially  allowing over two weeks for PARP-1 activity levels to be restored or 
even up-regulated as suggested in Figure 5.10. The in vivo data presented in chapter 
four adds weight to this this theory. In the UACC3199 xenografts experiment one, the 
anti-tumour effect of AG014699 was lost after ten days once the treatment was 
stopped, whereas greater tumour growth delay occurred in experiment two with a five 
day treatment repeated every seven days for six weeks. These data also fit with the 
more favourable response rates seen in olaparib studies where the drug is 
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administered on a continuous, oral basis (Fong et al., 2009; Audeh et al., 2010; Tutt et 
al., 2010). Informed by the preliminary trial data and the in vivo results, the PARP-BRCA 
clinical trial was amended to permit an additional PD PARP activity sampling time-point 
on D15.  This additional sample would assess PARP activity during the non-treatment 
period (10 days after the last dose of AG014699). To date, four recently recruited 
patients (data not included in this thesis) have had this D15 sample taken. Results for 
these four patients’ PARP activity, expressed as % of baseline levels, are shown in 
figure 5.25 (personal communication from James Murray, Newcastle University, UK). 
As the figure shows, in the majority of patients, by D15 PARP activity levels have 
almost fully recovered with the mean % activity of 77%. This suggests that once the 
five days of AG014699 treatment is complete, the PARP enzyme activity recovers and 
so any potential for synthetic lethality is lost; emphasising the point that for single 
agent activity, duration of PARP inhibition may be equally as important as the degree 
of inhibition. 
The administration of an intravenous drug like AG014699 on a continuous basis to 
patients would be difficult, requiring the insertion of central venous catheters and a 
treatment commitment that may be unacceptable to many patients.   
 
 
Figure 5.25: Mean % PARP activity in response to AG014699 over time for four patients. EOI = 
end of infusion, H = hours, D = day 
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However the recent development by Pfizer GRD of an oral formulation of AG014699 
has allowed the protocol for the current study to be amended to test the safety and 
efficacy of a continuous dosing schedule. This will hopefully result in increased 
response rates and clinical benefit to patients. 
5.5.7 Conclusions 
In summary, this study has shown that AG014699 is a potent inhibitor of PARP-1 that is 
well tolerated in BRCA-mutation carriers with minimal normal tissue toxicity. Despite 
the poor ORR a considerable number of patients (34%) have derived a CBR from 
AG014699 even in its current intermittent schedule; with three patients remaining on 
treatment for greater than 12 months. Given the low reported toxicity rate of single 
agent AG014699 this could be considered an acceptable outcome in patients whose 
only alternative is likely to be systemic cytotoxic chemotherapy. Higher baseline PARP-
1 activity levels were seen in the CBR group and this requires confirmation by testing 
the whole study population. Finally, results of the amended PARP-BRCA study, 
investigating the continuous scheduling of oral AG014699, are eagerly awaited. 
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Chapter Six 
6. Summary and future directions 
These studies represent the first comprehensive in vitro, in vivo and clinical 
investigation into the effects of the PARP-1 inhibitor, AG014699, in human cancers 
defective in homologous recombination DNA double strand break repair. The major 
findings of the preclinical experiments and the phase II clinical trial are summarised 
below. 
6.1 Summary 
Cell survival data presented in chapter three demonstrate that BRCA mutated human 
cancer cells are significantly more sensitive to AG014699 than human cell lines with 
wild type or heterozygote BRCA (mean LC50 = 3.96 ± 2.90 vs. mean LC50 = 25.09 ± 9.17; 
P < 0.0001). These results support the theory of PARP- BRCA synthetic lethality and 
confirm that AG014699 is active in BRCA deficient human cancer models. Interestingly, 
BRCA1 mutant human cells (MDA-MB-436) were more sensitive than the BRCA2 
mutant (CAPAN-1) human cancer cell line (mean LC50 = 1.33 ± 0.59 vs. mean LC50 = 5.54 
± 2.51; P = 0.03). This difference is not explained by higher levels of PARP enzyme 
inhibition in the MDA-MB-436 cells following exposure to 10 M AG014699. The MDA-
MB-436 cells however did form the lowest numbers of Rad51 foci after AG014699 and 
were the most sensitive cell line to AG014699 of the whole panel; suggesting they 
harbour the most defective HR pathway. However, this observation is based on the 
comparison of only two human cell lines and it should be noted that the HCC1937 
BRCA1 deficient breast cancer line, although not assessed by the same assay appear 
less sensitive than the CAPAN-1 cells. Furthermore, differences in patients’ response to 
AG014699 by BRCA mutation have not been observed in the clinical trial data (see 
chapter five, section 5.4.8.3) and no difference in response rate by mutation status has 
been reported in any of the olaparib clinical trials (Fong et al., 2009; Audeh et al., 2010; 
Tutt et al., 2010).  However, it is likely that a spectrum of HRD deficiency exists 
between BRCA mutant cancers; simply reflecting their genetic diversity. 
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The proposed mechanism for the synthetic lethality of PARP inhibitors in BRCA 
deficient cells is that PARP inhibition leads to the accumulation of DNA single-strand 
breaks which result in stalled replication forks and ultimately double-strand breaks. As 
DNA DSBs are normally repaired by the HR pathway, in HR-defective cells, these DSBs 
are left un-repaired or are repaired in an error-prone way by NHEJ. Both outcomes can 
result in genomic instability and ultimately cell death. To test this theory, 
immunofluoresence assays of H2AX and Rad51 foci formation were undertaken in the 
panel of 11 cell lines. Results of these experiments support this hypothesis showing 
that following AG014699-induced PARP inhibition, all cell lines regardless of HR status 
accumulate DNA damage (H2AX foci). But only the HR proficient cell lines are able to 
significantly increase nuclear Rad51 foci over baseline levels. The change in Rad51 
numbers which discriminated the HR proficient cells from the HR deficient ones was 
found to be a ≥ 2-fold increase.  
Both the in vitro and in vivo experiments described in chapters three and four 
respectively have shown that the BRCA1 methylated UACC3199 human breast cancer 
cell line is sensitive to PARP inhibition. The mean LC50 of 7.60 M was significantly 
lower than in the HR proficient cell lines (mean LC50 = 29.68 M; P < 0.0001). 
UACC3199 cells also failed to increase the number of Rad51 foci by ≥ 2-fold following 
AG014699. Furthermore, the UACC3199 xenografts responded to the prolonged i.p. 
AG014699 regimen, which delayed tumour growth by 9 days over un-treated controls. 
These data, together with the in vitro studies in XRCC3 deficient IRS-1SF cells 
presented in chapter thee, reinforce the theory proposed in other studies (McCabe et 
al., 2006) that it is HRD that confers sensitivity to PARP inhibition not simply germline 
BRCA mutation. The sensitivity of UACC3199 cells and xenografts to AG014699 is a 
major finding of this work as dysfunction of BRCA1, e.g. through epigenetic silencing, is 
known to occur commonly in high grade serous ovarian cancers (HGSOC) (Press et al., 
2008) and triple negative breast cancers (Turner et al., 2007). Recently reported phase 
II clinical trial data have shown that single agent olaparib has activity (24% response 
rate) in advanced non-germline BRCA mutated HGSOC (Gelmon et al., 2011). This 
together with the preliminary data, reported at ASCO 2011, showing that maintenance 
olaparib can delay disease progression in HGSOC with unknown BRCA mutation status 
(Ledermann et al., 2011) suggests that future studies of AG014699 should investigate 
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its activity in the HGSOC population. Interestingly, in the Gelmon study, no responses 
were seen in the triple negative breast cancer arm. This may be simply due to the small 
sample size (only 15 patients) or it could be that the degree of HRD in triple 
negative/basal-like breast cancers is not profound enough to result in PARP inhibitor-
induced synthetic lethality. This highlights the need for biomarkers of HR function so 
that each cancer can be tested to see if the HRD is enough to warrant treatment with 
PARP inhibitors. 
One such potential biomarker of HR function is the ability to form Rad51 foci following 
DNA damage. Data presented in chapter three, section 3.4.4 demonstrate that cells 
known to be HR deficient through BRCA1, BRCA2 or XRCC3 deficiency do not 
significantly increase the number of nuclear Rad51 foci over baseline control values in 
response to AG014699-induced DNA damage. A major strength of this work was to 
propose that this method could be used to identify cancer cells with HRD and 
subsequent candidates for PARP inhibitor therapy. This idea was subsequently tested 
in ascitic fluid-derived primary ovarian cancer cell lines with unknown HR status 
(Mukhopadhyay et al., 2010). The results showed that a ≥ 2-fold increase in the 
number of Rad51 foci following ex-vivo treatment with AG014699 predicted with a 100% 
positive predictive value subsequent PARP inhibitor sensitivity. It is clear that this assay 
warrants further investigation. However, there are obvious weaknesses in using such 
approaches. Firstly, the difficulties in obtaining replicating viable cancer cells from 
patient sources such as ascites or pleural fluid. Also, many patients do not present with 
malignant effusions during the history of their cancer. In addition, there is a risk that in 
developing primary cultures one might exhibit selection pressure on the cell 
population which may result in a HR phenotype not reflective of the patients’ primary 
tumour burden. There are also the technical difficulties of developing and establishing 
primary cultures and damaging DNA ex vivo. Another problem lies in the complexity of 
the HR pathway and that the lack of induction of Rad51 foci may not mean that HR is 
non-functional as other proteins may exist that may be able to perform similar 
functions as yet unknown. There may be no future in this assay outside of translational 
studies due to its technical difficulties. However, even if genome wide sequencing of all 
the HR genes was currently practical and affordable in normal clinical practice for 
every cancer patient, it would not be able to assess the actual function of the HR 
pathway.   
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Another challenge for the development of HRD biomarkers is the recent proposal that 
HRD can be ‘contextual’ (Chan et al., 2010). An example of this is seen hypoxia, which 
is a common feature of the tumour microenvironment. Chan and colleagues 
demonstrated that chronic hypoxia results in reduced synthesis of essential HR 
proteins with a three-fold reduction in HR capacity and increased sensitivity to DNA 
damaging chemotherapy agents and, in the more recent paper, sensitivity to PARP 
inhibition (Chan et al., 2008; Chan et al., 2010). Another potential problem is the 
reported evolution of HRD tumours to HR proficient ones through, for example, 
secondary inter-genic mutations restoring BRCA function; which has been seen in both 
BRCA1 and 2 mutant cancers (discussed in detail in section 1.9 of chapter one). It has 
also recently been reported that inactivation of NHEJ either through genetic loss or 
pharmacologic inhibition (Patel et al., 2011) and loss of 53BP1 (Bunting et al., 2010) 
can restore PARP inhibitor resistance in previously sensitive BRCA1 mutant models. 
53BP1 is a human ortholog of the yeast DNA checkpoint proteins Rad9p/Crb2) which 
has a role in DNA damage response and checkpoint control (reviewed in Aly and 
Ganesan, 2011).  In short, such phenomena would not necessarily be picked up by 
functional assays and therefore more research is needed to better select patients for 
PARP inhibitors in order to avoid non-responders and, pertinent to the current climate, 
to better allocate cancer drug resources. 
There was a large variation in both the cell line and patient populations in the levels of 
baseline PARP activity. In the cell lines mean endogenous baseline PARP activity was 
1.57 pmol PAR per 104 cells. This ranged from as low as 0.28 up to 5.95 pmol PAR per 
per 104 cells, with a CV of 101%. As expected the baseline (maximum stimulated) PARP 
activity levels were higher but there was less inter-cell variation with a mean of 45.07 
pmol PAR per per 104 cells, range 8.82 to 87.60 pmol and CV of 42%. There was a trend 
towards higher baseline PARP activity (in both endogenous and maximum stimulated 
samples) in the HR deficient cell lines but the results did not meet statistical 
significance.  For the clinical trial patient population the mean baseline (maximum 
stimulated) PARP activity was 6.80 pmol PAR per 104 PBL. This ranged from 0.38 up to 
40.26 pmol PAR per 104 PBL with a CV of 145%. Comparing these findings to data from 
Zaremba et al using the same immunoblot technique in a cohort of 118 cancer patients 
with unknown BRCA status (Zaremba et al., 2011), PARP activity appears to be higher 
in BRCA mutation carriers. Although differences in these studies may be gender related 
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as 100% of this study subjects were women. Redon and colleagues also recently 
proposed that baseline PARP activity levels in patients could help predict which 
patients would respond to PARP inhibitors (Redon et al., 2010).  
Reviewing the clinical PD data in chapter five, section 5.4.8.4, patients who responded 
to AG014699, i.e. had a clinical benefit response, had a significantly higher levels of 
mean pre-treatment (maximum stimulated) baseline PARP activity than the group of 
patients who failed to respond to AG014699 (evidence of disease progression after C2). 
This finding may be clinically as well as statistically significant; suggesting that a 
patient’s baseline PARP activity level could determine whether or not they would 
respond to AG014699.  
However, a weakness of this observation is that it represents the results of less than 40 
patients and this analysis will need to be repeated with the larger complete study 
population. In addition, it should be noted that the results of both the cell lines and 
patients data suggesting that higher baseline levels of PARP activity is seen in the 
presence of HRD is influenced by the inter-assay variability of the PARP activity assay 
as these results are derived from the analysis and comparison of multiple immunoblots 
over several months of work. 
Interestingly there was also a trend towards higher baseline PARP-1 protein expression 
in the clinical benefit responders (CBR) group compared to the non-responders but this 
did not reach levels of statistical significance.  
Analysis of the PARP-1 T2444C SNP did show a significantly lower baseline PARP 
activity with the homozygous variant but as this genotype (C/C) was only found in one 
patient (35-013) no further analysis as to whether this affected subsequent response 
to AG014699 could be made. 
During the design of the phase II clinical trial, one of the major concerns of inhibiting 
PARP-1 in BRCA mutant carriers was the potential toxicity to normal tissues. This 
concern was not unwarranted given the results presented in chapter three 
demonstrating that DNA DSBs (represented by H2AX foci) accumulated in cells lines 
continuously exposed to AG014699. This occurred in not just the BRCA mutant lines 
but in the heterozygote and wild type cells  too. In fact, in most cell lines the numbers 
of H2AX foci induced by AG014699 were similar to that seen after 2 Gy IR (see figure 
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3.13). The phase I study of olaparib also reported significant induction of γH2AX foci in 
normal tissue (eyebrow hair follicles), following PARP inhibition (Fong et al., 2009). The 
question then was if this DNA damage occurs continuously over time in patients’ 
normal tissues, could it result in genomic instability and even secondary carcinomas? 
In vivo experiments by Tong et al. reported that deficiency of PARP-1 resulted in the 
development of mammary carcinoma in female mice, suggesting that PARP-1 
dysfunction in humans may, in fact, be a risk factor for breast cancer (Tong et al., 2007). 
Reassuringly, the results of the xenograft studies, reported in chapter four, did not 
show that single agent AG014699 was toxic to mice with minimal weight loss seen and 
no evidence of secondary carcinomas.  In addition, treating BRCA2 heterozygote and 
BRCA2 wild type mice with either AG014699 25 mg/kg D1-5 i.p. every 21 days for six 
cycles or saline control was shown to make no difference in the groups in terms of the 
animals weight loss or survival after a follow-up of 365 days (Drew et al., 2011b) This 
again suggests that intermittent scheduling of AG014699 is safe.  
As patient safety is paramount in any clinical study the trial design included two safety 
cohorts (as discussed in chapter five, section 5.1.1.2) of 4 mg/m2 and 12 mg/m2 
AG014699. The results show the intermittent schedule of AG014699 18 mg/m2 (the 
highest dose level tested) to be safe and tolerable, at least in the short-term, in BRCA 
mutation carriers. Toxicity results for all 38 patients are presented in chapter five, 
section 5.4.8.2. To summarise, AG014699 had an acceptable safety profile with drug-
related toxicity mainly grade 1 and 2. The most common being fatigue, nausea and 
diarrhoea. There were no DLTs at any dose level and no patients withdrew from the 
study due to drug-related toxicity.  Whist these data are encouraging, it should be 
noted that to date no long term safety data about the use of PARP inhibitors in this 
cancer patient population are available; although three patients have so far received 
AG014699 within this study for over 54 weeks. More toxicity may manifest as the trial 
is amended and a more prolonged dosing schedule of the oral compound of AG014699 
is investigated (discussed below). 
The most disappointing result of the clinical study has been the low objective response 
rate (6%) to AG014699. This does not however down-play the CBR rate seen in 34% of 
patients; which for many patients is an acceptable outcome in the setting of minimal 
toxicity and limited treatment options. But it cannot be denied the response rate was 
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low and needs to be addressed. This low ORR is now less unexpected given the in vivo 
data presented in chapter four showing that a prolonged schedule of AG014699 
resulted in greater anti-tumour activity. Although other reasons are postulated in the 
discussion of chapter five, the in vivo data suggest that the most likely explanation for 
the lack of responders in the clinical trial is the intermittent dosing schedule of 
AG014699. PD data from the patients show that the D1-5 dosing schedule results in 
profound PARP enzyme inhibition with very little recovery seen at 24 hours post dose. 
However once dosing has stopped after D5 it is likely that PARP activity will eventually 
recover. Additional data provided recently from the new D15 PD sampling time-point 
shows (figure 5.25) that PARP activity recovers on average to 77% over baseline pre-
treatment levels by day 15.  One of two conclusions can be drawn from this clinical 
response data: one that AG014699 in this patient population is inactive or two that it is 
active but anti-tumour effect through the mechanism of synthetic lethality is reduced 
or even lost during the non-treatment period. Given the PD data showing > 90 % PARP 
enzyme inhibition during the treatment period and the results of other classes of true 
PARP inhbitors (Fong et al., 2009; Audeh et al., 2010; Tutt et al., 2010) the second 
conclusion is most likely and continuous scheduling of AG014699 needs to be 
investigated. 
In summary the major findings of these studies are: 
1. AG014699 is selectively toxic to BRCA mutated human cancers. 
2. AG014699 has anti-tumour activity in BRCA1 methylated models. 
3. The ability of cells to increase nuclear Rad51 levels by ≥ 2-fold following 
AG014699 exposure was seen only in HR proficient cell lines. 
4. There is a large variation in baseline PARP-1 activity levels in both cell lines and 
patients and activity appears to be higher in the presence of HRD. 
5. AG014699 as a single agent in BRCA mutant cancer patients is well tolerated 
and appears to be safe in the short-term. 
6. In in vivo experiments the more prolonged the exposure to AG014699-induced 
PARP inhibition the greater the anti-tumour activity suggesting that schedule 
matters in addition to the degree of PARP inhibition. 
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6.2 Future directions 
One of the major strengths of this work is that it has influenced clinical practice. The in 
vivo data and the clinical response results presented and discussed in this thesis have 
recently led to a major amendment in the PARP-BRCA CRUK phase II clinical trial to 
investigate a more prolonged schedule of AG014699. Furthermore, continuous dosing 
of AG014699 is now theoretically possible and practical in patients with the recent 
development of an oral formulation of the compound. The amended trial will 
investigate continuous AG014699 in the same patient population as the original study 
(BRCA1/2 mutated advanced breast and ovarian cancer) with dosing cohorts of 7 days, 
14 days and finally 21 days out of a 21 day cycle. The hope is that this will lead to 
increased response rates and meaningful clinical benefit to greater numbers of 
patients. Although it is almost certain that for single agent AG014699 use the more 
profound and the longer the duration of PARP enzyme inhibition the better, it is still 
not yet known to what extent and exactly for how long PARP-1 needs to be inhibited 
to achieve optimal activity. For these reasons the amended study must include more 
PD and PK sampling time-points following AG014699 dosing.  
As already summarised data presented in this thesis suggest that AG014699 may have 
therapeutic potential in patients with non-BRCA germline mutated cancers such as 
those with epigenetically silenced BRCA1. In addition, data discussed in section 1.6.4 
suggest that future target populations of single agent AG014699 should include: triple 
negative/basal-like breast cancers, high grade serous ovarian cancers and PTEN mutant 
endometrial cancers. Any such studies must include exploratory biomarkers of HRD 
and results of these assays should be correlated with clinical response in order to 
better select future patients for PARP inhibitor studies. Further investigation 
/development of the Rad51 assay should perhaps include looking for alternative 
sources of tumour cells such as that contained in FFPE tissue (something which almost 
all diagnosed cancer patients will have) and circulating tumour cells.  
In early 2011 AG014699 was acquired by Clovis Oncology from Pfizer GRD. This 
sparked the end of AG014699 as we know it and the beginning of ‘CO-338’. 
Fortunately the commitment to current AG014699 studies continues and the future 
development of the drug has been maintained. 
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The amended study is now open to recruitment with the first patient dosed on 25th 
October 2011. Whether patients can tolerate continuous dosing and whether it will 
result in greater efficacy will soon become apparent. 
Finally, in 2003 when the first patient received the first ever dose of AG014699, a new 
class of drugs entered the stage of cancer treatment. Eight years on, there are at least 
eight other PARP inhibitors in clinical trial development. The demonstration of single-
agent PARP inhibitor activity in BRCA-mutated ovarian and breast cancers, with a wider 
role being proposed in HR-defective sporadic tumours is probably the most exciting 
discovery to come of these studies. This selective targeting of cancer cells defective in 
one DNA repair pathway by inhibiting another is a major breakthrough in the 
treatment of cancer. As the clinical data mature and continuing clinical trials are 
reported, it is likely that PARP inhibitors, including CO-338, will become key players in 
the targeted treatment of cancer. 
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